Washington University in St. Louis

Washington University Open Scholarship
Arts & Sciences Electronic Theses and
Dissertations

Arts & Sciences

Spring 5-15-2021

Mechanisms of Natural Killer Cell Anti-Tumor Function and
Homeostasis
Julia Alexandra Wagner
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons,
Medical Immunology Commons, Molecular Biology Commons, and the Oncology Commons

Recommended Citation
Wagner, Julia Alexandra, "Mechanisms of Natural Killer Cell Anti-Tumor Function and Homeostasis"
(2021). Arts & Sciences Electronic Theses and Dissertations. 2468.
https://openscholarship.wustl.edu/art_sci_etds/2468

This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an
authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Immunology

Dissertation Examination Committee:
Todd Fehniger, Chair
Megan Cooper
Timothy Ley
Daniel Link
Wayne Yokoyama

Mechanisms of Natural Killer Cell Anti-Tumor Function and Homeostasis
by
Julia Alexandra Wagner

A dissertation presented to
The Graduate School
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2021
St. Louis, Missouri

© 2021, Julia Alexandra Wagner

Table of Contents
List of Figures……………………………………………………………………………………..v
List of Tables…………………………………………………………….……………………...viii
Acknowledgments………………………………………………………….………………….....ix
Abstract………………………………………………………………………………………….xiii
Chapter 1: Introduction to Natural Killer Cells……………………………………………….…..1
1.1

NK Cell Overview……………………………………………………..………….1

1.2

NK Cell Functions………………………………………………………………...2

1.2.1

NK Cell Cytotoxicity………………………………………………………..2

1.2.2

NK Cell Cytokine Production……………………………………………….5

1.2.3

Functional Immune Cross-Talk……………………………………………..5

1.3

Receptors on NK Cells: Target Cell Recognition and Cytokine Signaling……….6

1.3.1

NK Cell Inhibitory Receptors……………………………………………….8

1.3.2

NK Cell Activating Receptors……………………………………………..11

1.3.3

NK Cell Cytokine Receptors………………………………………………14

1.4

NK/ILC Development……………………………………………………………14

1.5

NK Cells vs. ILC1s…..…………………………………………………………..18

1.6

IL-15: Biology and Role in NK Cell Homeostasis………………………………19

1.6.1

The IL-15 Receptor………………………………………………………...20

1.6.2

IL-15 and IL-15R Tissue Expression……….……………………………...20

1.6.3

IL-15 Trans-Presentation…………………………………………………..21

1.6.4

IL-15 Signaling…………………………………………………………….23

1.6.5

IL-15 & NK Cell Development, Homeostasis, and Function………...……24

1.7

NK Cell Self-Tolerance………………………………………………………….26

1.8

NK Cell Memory………………………………………………………………...27
ii

1.9

Clinical Applications of NK Cells……………………………………………….29

1.10

References………………………………………………………………………..31

Chapter 2: Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed NK Cell AntiLeukemia and FcRIIIa-Triggered Responses…………………….......……………..39
2.1 Summary……………………………………………………………………………..39
2.2 Introduction…………………………………………………………………………..40
2.3 Results………………………………………………………………………………..42
2.4 Discussion……………………………………………………………………………46
2.5 Methods……………………………………………………………………….……...47
2.6 Acknowledgments……………………………………………………………………49
2.7 References……………………………………………………………………………50
Chapter 3: CD56bright NK Cells Exhibit Potent Anti-Tumor Responses Following IL-15
Priming………………………..…….......…………………………….…………..….52
3.1 Summary……………………………………………………………………………..52
3.2 Introduction…………………………………………………………………………..53
3.3 Results………………………………………………………………………………..55
3.4 Discussion……………………………………………………………………………89
3.5 Methods………………………………………………………………………………95
3.6 Acknowledgments…………………………………………………………………..102
3.7 References…………………………………………………………………...……...103
Chapter 4: Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and.
Cytotoxicity……………………………………………………………………........110
4.1 Summary……………………………………………………………………………110
4.2 Introduction…………………………………………………………………………110
4.3 Results……………………………………………………...……………………….113
4.4 Discussion…………………………………………………………………………..136
iii

4.5 Methods……………………………………………………………………………..140
4.6 Acknowledgments…………………………………………………………………..147
4.6 References…………………………………………………………………………..147
Chapter 5: Concluding Remarks & Future Directions……………………………………….....152
5.1 NK Cells and Cancer Therapy ………………………………………………......…152
5.1.1

Cytokine-Induced Memory-Like NK Cells…………………………….152

5.1.2

IL-15-Primed CD56bright NK Cells……………………………………...154

5.2 Eomes and NK Cell Homeostasis & Function……………………………………...157
5.3 References…………………………………………………………………………..160

iv

List of Figures
Figure 1.1: NK cell and tumor target cell cytotoxic synapse……………………………………...3
Figure 1.2: The outcome of NK/target cell interactions depends on signal integration………......9
Figure 1.3: Schematic of NK vs. ILC development……………………………………..……….15
Figure 1.4: IL-15 receptor signaling……………………………………………………………..22
Figure 1.5: Types of human NK cell memory………………………………………………..….28
Figure 2.1: Memory-like NK cells display enhanced IFN- production and
cytotoxicity in response to FcRIIIa-based triggering…………....…………………..43
Figure 2.2: Intracellular signaling downstream of FcRIIIa is similar between
memory-like and control NK cells…………………………………....……………...45
Figure 3.1: IL-15-primed human CD56bright NK cells have enhanced responses
to tumor target cells……………………….....………………………………………57
Figure 3.2: IL-15 priming occurs rapidly and at low concentrations of IL-15…………………….58
Figure 3.3: IL-15 primes human CD56bright NK cells for broad and polyfunctional
responses to myeloid leukemia target cells……………………………...….....……..59
Figure 3.4: IL-15 priming selectively enhances CD56bright NK cell survival
under cytokine-starved conditions………………………………………………..….61
Figure 3.5: IL-15 priming does not result in robust CD56bright or CD56dim NK cell proliferation....62
Figure 3.6: Responses of IL-15-primed CD56dim NK cells were influenced by maturity status…..64
Figure 3.7: IL-15-primed CD56bright NK cells have enhanced cytotoxicity………………………66
Figure 3.8: TRAIL contributes to IL-15-primed CD56bright NK cell killing of
TRAIL-sensitive targets……………………………………………………….….....68
Figure 3.9: IL-15 priming enhances CD56bright NK cell granularity……………………………..69
Figure 3.10: IL-15-primed CD56bright NK cells more effectively formed
conjugates with K562 leukemia targets………………………......…………………70

v

Figure 3.11: IL-15-primed CD56bright NK cells displayed increased expression of
co-activating and adhesion molecules as well as enhanced
integrin signaling upon tumor target engagement…………………………………...72
Figure 3.12: IL-15-primed CD56bright NK cells have increased NKp30,
NKp44 and CD69 expression……………………………………….……………...73
Figure 3.13: IL-15 priming enhanced CD56bright NK cell anti-tumor responses against
primary AML blasts in vitro and K562 leukemia in vivo in NSG mice………..........76
Figure 3.14: IL-15 primes CD56bright NK cells of patients with hematologic
malignancies for enhanced functional responses to tumor cell lines………………..78
Figure 3.15: Multiple myeloma patient CD56bright NK cells are primed in vitro
by IL-15 and in vivo by ALT-803 for enhanced functional responses
against autologous myeloma cells and multiple myeloma cell lines……………….80
Figure 3.16: ALT-803 primes CD56bright NK cells for enhanced anti-tumor responses in vitro…83
Figure 3.17: IL-15 more robustly activates the PI3K/Akt/mTOR and
Ras/Raf/MEK/ERK pathways in CD56bright NK cells………………………………85
Figure 3.18: The Ras/Raf/MEK/ERK pathway is required for IL-15 priming of CD56bright
and CD56dim NK cell anti-tumor responses whereas the PI3K/Akt/mTOR
pathway is selectively required for CD56bright NK cell priming................................87
Figure 3.19: Selective mTOR blockade does not impede IL-15 priming
of CD56bright or CD56dim NK cell anti-tumor responses…………………….………88
Figure 3.20: Combined PI3K/Akt/mTOR and Ras/Raf/MEK/ERK pathway
blockade impairs flow-sorted, IL-15-primed CD56dim NK
cell anti-tumor responses and cytotoxicity……………………………………..…..90
Figure 4.1: Tamoxifen induces robust and type 1 ILC-specific cre activity in mice harboring the
Ncr1-iCreERT2 knock-in locus.………………………………………...…………..114
Figure 4.2: Background cre expression in Ncr1-iCreERT2 mice.…………………………..…...116
Figure 4.3: Induced Eomes deletion results in a significant decrease in global NK cell numbers,
with a particularly profound loss of stage III NK cells.……………………….……118

vi

Figure 4.4: Induced Eomes deletion results in increased stage III NK cell apoptosis…..………120
Figure 4.5: RNA sequencing reveals stage-specific changes in ILC-EomesΔ/Δ vs. Eomes WT
splenic NK cells……………………………………………………………………121
Figure 4.6: Induced Eomes deletion alters stage III but not bulk, stage II, or stage IV NK cell
cycling dynamics.………………………………………………………………….122
Figure 4.7: Ncr1-iCreERT2 mice have delayed homeostatic proliferation kinetics that are not
altered by induced Eomes deletion……………………………………………...…124
Figure 4.8: Induced Eomes deletion results in modest differences in IL-15 signaling………....126
Figure 4.9: Bcl-2 protein levels are not altered by induced Eomes deletion and high-dose IL-15
does not rescue ILC-EomesΔ/Δ stage III NK cells………………………….……….127
Figure 4.10: Eomes is required for normal NK cell maturation………………………………...129
Figure 4.11: Eomes is required for normal NK cell maturation in vivo…………………………130
Figure 4.12: Induced Eomes deletion does not significantly alter NK cell functional responses, but
impairs ex vivo cytotoxicity………………………………………………………132
Figure 4.13: Inducible Eomes deletion results in global decreases in the NK cell cytotoxic
program………………………………………………………………………….133
Figure 4.14: Inducible Eomes deletion impairs in vivo NK cell rejection of 2m-/- splenocytes...135

vii

List of Tables
Table 1.1: Major NK cell activating, inhibitory, and cytokine receptors and their ligands…….....7
Table 3.1: NK cell mass cytometry panel design, reagents, and clustering usage………………...63
Table 3.2: AML patient characteristics for figures where primary AML blasts were utilized…….77
Table 3.3: In vitro multiple myeloma patient characteristics……………………………….……81
Table 3.4: In vivo multiple myeloma patient characteristics………………………………….....84
Table 3.5: List of anti-human mAbs……………………………………………………………..96

viii

Acknowledgments
This work was supported by the Howard Hughes Medical Institute Medical Research Fellowship
and the National Institutes of Health (NIH) T32 HL007088, R01 AI102924, R01 CA205239, and
P50 CA171963.
I have been fortunate enough to have a great number of people help and support me throughout
my graduate school training. First, I would like to thank the Washington University MSTP
admissions committee for allowing me to transfer into the MSTP program and giving me the
opportunity to pursue a PhD. I began my studies at Washington University as a MD student, but
took time off after second year to do a research project as part of the MA/MD program. This
experience ignited my passion for scientific research and I feel so privileged to have been able to
pursue it to the fullest extent.
None of this work would have been possible without my thesis advisor, Todd Fehniger. Thank
you for letting me come into your lab as a medical student with virtually no wet lab experience,
and for encouraging me to stay on as a PhD candidate. I have learned so much from you over the
past four and a half years, not only in terms of how to conduct thoughtful and rigorous scientific
research, but also with regards to grantsmanship, presentation skills, and career development.
Thank you for always having time to talk to me about data, research ideas, experiment plans,
career goals, or really anything else going on in my life. I’m looking forward to many more years
of mentorship to come. I would also like to thank the members of my dissertation examination
committee, Megan Cooper, Timothy Ley, Daniel Link, and Wayne Yokoyama, for their
insightful scientific discussion and thoughtful critique over the course of my thesis work.

ix

I cannot imagine a better lab to have trained in than the Fehniger Lab. Todd’s values are evident
in the hardworking and collaborative lab environment he has fostered. In particular, I want to
thank Melissa Berrien-Elliott for being an amazing friend and mentor over the years. We joined
the Fehniger Lab around the same time, her as a post-doc and me as a graduate student, and I
cannot picture my time in the lab without her. Thank you for teaching me about science and
work-life balance, for all of your unsolicited advice, and for always being a listening ear. In
addition, I would like to thank Tim Schappe, our lab manager, for always knowing exactly where
everything is kept and if not where to order it, and for doing all the gavaging in Chapter 4 (even
on weekends sometimes). Finally, I would like to thank all the members of the 6th and 7th floors
of the Southwest Tower for being such a great group of people to come to work with every day. I
learned so much about hematopoietic development and malignancy at our journal clubs and
retreats, and through random discussions in the break room, and I am a better scientist for it. A
special thank you to Bill Eades and the Siteman Cancer Center Flow Cytometry Core as well for
teaching me the ins and outs of flow cytometry and cell sorting.
My love of science was fostered at an early age, in part by the wonderful teachers I had in high
school, CEGEP, and university. I would like to thank Marguerite Comley, Chris Olive, JeanFrançois Deslandes, and Charlie Di Flumeri, in particular, for being amazing scientific educators
and mentors and for all of their continued support over the years. In addition, thank you to James
Brophy and Alain Dagher at McGill University for letting me begin my scientific research career
in their labs as an undergrad.
Thanks to all of the amazing friends I have made in St. Louis over the past nine years, both in
medical and graduate school. You made coming to a new city (and country!) a lot less scary and
a lot more fun than I could possibly have imagined - I feel so lucky to have all of you in my life.
x

Ellie Wilson, Lucy Bollinger, Miranda Lindburg, Johanna Kaufman, Zev Greenberg, and Celia
Bangert: your friendship has truly been invaluable over the years. To my fellow MSTP ladies –
thank you for all of the fun Girls’ Nights and for being such an incredibly brilliant and caring
group of people to go through MD/PhD training with. To my wonderful family, thank you Mom
and Dad for your continued love and support, and Dad thank you for making me do so many
math problems and science experiments with you as a kid. To my St. Louis parents, Eric and
Vita Lepchenske, thanks for all the delicious food and great company. Finally, to my siblings
Caroline and David, you are my best friends and biggest cheer-leaders. I love you more than I
could ever say.
Julia Wagner
Washington University in St. Louis
May 2021

xi

Dedicated to the unsung female scientists of history.

xii

ABSTRACT OF THE DISSERTATION
Mechanisms of Natural Killer Cell Anti-Tumor Function and Homeostasis
by
Julia Alexandra Wagner
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2021
Professor Todd Fehniger, Chair

Natural killer (NK) cells are innate lymphoid cells (ILCs) that mediate anti-tumor and anti-viral
immune responses. They do so via two primary effector functions: cytokine production and
direct cytotoxicity. Unlike adaptive T and B lymphocytes, NK cells do not rearrange their DNA
to express a predominant antigen-specific receptor, and instead express a variety of
stochastically-expressed, germline DNA-encoded activating and inhibitory receptors whose
signals integrate to govern their functional responses. What results is a diverse repertoire of NK
cells capable of recognizing a variety of malignantly-transformed or virally-infected cells.
Studies from several groups have established the anti-tumor potential of NK cells, most notably
in the setting of allogeneic hematopoietic cell transfer (HCT) or adoptive NK cell therapy,
spurring substantial interest in NK cell-based immunotherapies for cancer. While clinical trial
results to date have highlighted the favorable safety profile of NK cells, clinical responses to NK
cell therapy have been limited in both number and duration. Mechanisms of enhancing the antitumor potential of endogenous or adoptively-transferred NK cells are necessary.
It is well-established that NK cell function is tuned by immunomodulatory cytokines. Our group
has previously demonstrated that short-term pre-activation of NK cells with the cytokines
xiii

interleukin (IL)-12, 15, and 18 results in the generation of long-lived memory-like NK cells with
robust anti-leukemic properties in vitro and in vivo. These memory-like NK cells display
enhanced cytokine production and cytotoxicity compared to conventional NK cells and have
proven to be safe in a phase I clinical trial (NCT01898793). While complete responses were
observed in this study, not all patients responded to NK cell therapy. We hypothesized that the
clinical efficacy of memory-like NK cells could be further enhanced by combining them with
monoclonal antibody therapy. To lend evidence to support this hypothesis, we characterized the
response profile of memory-like NK cells to FcRIIIa (CD16)-based stimulation. We
demonstrated that, indeed, both interferon (IFN)- production and killing in response to CD16
ligation are enhanced in memory-like NK cells compared to controls.
In addition, studies of NK cell immunotherapy to date have focused on CD56dim NK cells; the
subset that predominates in the peripheral blood and is classically associated with NK cell
cytotoxicity. Thus, the anti-tumor potential of immunomodulatory CD56bright NK cells, which
predominate in secondary lymphoid tissues and in number overall, has remained relatively
unexplored. To this end, we investigated the impact of priming CD56bright NK cells with IL-15
on their anti-tumor function. We demonstrated that IL-15 priming markedly enhanced CD56bright
NK cell degranulation, cytotoxicity, and cytokine production in vitro in response to tumor cell
lines as well as primary myeloma and acute myeloid leukemia (AML) targets. Furthermore, IL15 priming augmented the anti-tumor responses of cancer patient CD56bright NK cells to their
autologous tumor cells. IL-15 priming of CD56bright NK cells also occurred in vivo, since
treatment of multiple myeloma patients with the IL-15 super-agonist ALT-803 resulted in
enhanced ex vivo responses of patient CD56bright NK cells to a myeloma cell line. Finally, IL-15primed CD56bright NK cells were capable of controlling AML in a NOD-SCID-c (NSG) mouse
xiv

model. The mechanisms for IL-15 priming involved increased cytotoxic protein and activating
receptor expression, integrin activation, and stimulation of the PI3K and MAPK pathways. These
results identified CD56bright NK cells as potent anti-tumor effectors that warrant further
investigation as a cancer immunotherapy.
Along with activating NK cells, IL-15 is critical for NK cell development and homeostasis. One
result of IL-15 signaling is increased expression of Eomesodermin (Eomes), a transcription
factor that defines the NK cell vs. ILC1 lineages. Eomes is required for early NK cell
development, but its role in mature NK cell homeostasis and function is unknown. To study this,
we utilized a novel NK cell-specific inducible Cre mouse model. An inducible model was
required since excision of Eomes early in NK cell development precludes normal NK cell
generation. We demonstrated that Eomes expression in mature NK cells is required for their
homeostasis and function since inducible Eomes deletion resulted in a significant decrease in NK
cells across the NK compartment, with a particularly profound effect on the penultimatelymature Stage III population. Stage III NK cells demonstrated increased apoptosis upon Eomes
deletion as well as an impaired ability to differentiate from precursor Stage II cells. Inducible
Eomes deletion also negatively impacted NK cell function, impairing NK cell anti-tumor
cytotoxicity ex vivo and abrogating rejection of 2m-/- splenocytes in vivo. However, in vitro
functional responses to a variety of stimuli were largely preserved. These data reveal a
previously unappreciated role for Eomes in mature NK cell homeostasis and function, and
suggest that an alternate means of classifying NK cell developmental stage may be based on
Eomes dependence. In sum, this thesis highlights two potential mechanisms for improving NK
cell-based immunotherapy and utilizes a novel NK cell-specific mouse model to demonstrate a
previously unappreciated role for Eomes in mature NK cell function and homeostasis.
xv

Chapter 1: Introduction to Natural Killer Cells
This chapter is adapted from a manuscript published in Wintrobe’s Clinical Hematology:
Freud AG, Wagner JA, Scoville S, and Fehniger TA. Chapter 14: Natural killer cells and innate
lymphoid cells. Wintrobe’s Clinical Hematology, 14th Edition.

1.1 NK Cell Overview
NK cells are cytotoxic lymphocytes of the innate immune system that play a critical role in the
control of viral infection and malignancy, and represent the founding member of an expanding
family of innate lymphoid cells (ILCs). Human NK cells are identified via non-NK restricted
surface antigens: CD56 (neural cell adhesion molecule) or NKp46 (activating receptor)
expression, and a lack of CD3 (a marker of T cells). Murine NK cells also express NKp46 and
lack CD3, and some strains express additional markers such as NK1.1 (C57BL/6J) or Klrb1c.
They are also commonly recognized via expression of the integrin CD49b (DX5). NK cells are
readily identifiable in the peripheral blood, where they comprise approximately 10% of
circulating lymphocytes. In addition, NK cells are found in secondary lymphoid tissues, bone
marrow, the liver, and the pregnant uterus, among other locations. NK cells are heterogeneous
and exist within a range of maturation and functional states, delineated by the expression of
distinct surface markers. In addition, the precise complement of activating and inhibitory
receptors expressed on NK cells, which permit the discrimination of target cells from normal
tissue, varies from NK cell to NK cell. This results in a diverse population of effector cells, even
in the absence of germline DNA-rearranged antigen-specific receptors.
NK cells were originally described based on their function: they are large granular lymphocytes
that kill target cells “naturally”, i.e. without prior exposure and in a non-major histocompatibility
1

complex (MHC)-restricted fashion. As our knowledge of NK cells has expanded, however, it has
become clear that NK cells function in far more than spontaneous cytotoxicity. NK cells are
robust cytokine and chemokine producers, and thus capable of modulating the function of other
immune cells. In addition, despite being originally classified as members of the innate immune
system, recent work has shown that NK cells can display “adaptive” or memory-like properties
in response to numerous stimuli, including specific haptens, viruses, and combined cytokine preactivation. Thus, NK cells are unique cytotoxic and immunomodulatory “first line of defense”
cells that can both form a bridge to the adaptive immune response, or participate in it directly.

1.2 NK Cell Functions
NK cells are critical for host defense against viral infection, malignant transformation, and
certain intracellular bacteria and fungi.1,2 For example, NK cells play a central role in immunity
against herpes viruses, and impaired NK cell function has been associated with an increased
likelihood of developing cancer.3 As members of the innate immune system, NK cells are
involved in the first wave of defense against pathogens and tumor initiation, and can recruit
additional innate and adaptive immune cells as required. NK cells mediate these important
functions through two primary effector mechanisms: cytotoxicity and cytokine production.

1.2.1 NK Cell Cytotoxicity
As implied by their name, NK cells kill targets ‘naturally’, or without prior sensitization. NK
cells kill via the release of cytotoxic granules or by expressing ligands for death receptors,
though the granule exocytosis pathway predominates. NK cell degranulation is a multi-step,
highly-regulated process that results in directed granule release towards the target (Figure 1.1).4
Completion of the first stage, initiation, depends on the balance of activating and inhibitory
2

Figure 1.1: NK cell and tumor target cell cytotoxic synapse.
Immunofluorescence photomicrograph of the cytotoxic synapse formed between a primary
human NK cell (above) and a tumor target (K562 leukemia, bottom). After target recognition,
conjugation, and NK cell triggering, granules with perforin (blue) and granzymes mobilize
towards the cytotoxic synapse and converge on the microtubule-organizing center (MTOC,
red), prior to directed release towards the target cell. This is followed by apoptotic-like target
cell death. F-actin: green.
Photo credit: Emily M. Mace, Ph.D.

3

receptor signals transmitted to the NK cell upon “sampling” a target. A small percentage of NK
cells express open (activated)-conformation lymphocyte function associated antigen-1 (LFA-1)
at rest, an integrin that likely facilitates short-term engagement with target cells during this
sampling phase before additional activating receptor signals are delivered. Secondary signals
from activating receptors like NKG2D, DNAM-1, or the co-stimulatory CD2 likely further
activate LFA-1, promoting tight adhesion with the target cell and immune synapse formation.
Upon ligand binding, LFA-1 delivers signals that activate protein kinases, promote F-actin
polymerization and reorganization, and arrest migration. These signals, in addition to those from
activating receptors, promote lytic granule convergence upon the microtubule organizing center
(MTOC) and granule polarization to the immune synapse. Importantly, the initiation phase of
lytic granule release can be reversed by signals from inhibitory receptors. 4
During the next effector stage, the NK cell is committed to degranulation. Here, the de novo Factin polymerization that began in the initiation stage brings about significant cytoskeletal
rearrangements as well as firm adhesion to the target cell. NK cells at the effector stage take on a
characteristic flattened shape that extends the diameter of the immune synapse, where a lytic
cleft forms. Lytic granules are then delivered to the synapse, and a subset is released across the
cleft toward the target. The final stage, termination, involves detachment from the target cell, and
either the return to a resting state or engagement with a new target cell. Interestingly, NK cell
cytotoxic kinetics are such that when an NK cell chooses to engage with additional targets rather
than retuning to rest, subsequent kills occur more rapidly.
NK cell degranulation onto a target results in death by apoptosis. NK cell granules contain
cytotoxic proteins such as perforin and Granzyme B that act in concert to kill target cells.
4

Perforin forms holes in target cell membranes that permit entry of granzyme proteins, serine
proteases that cleave caspases to trigger apoptosis.5 Expression of death receptor ligands such as
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and Fas-L also results in
caspase-dependent apoptosis of cells that express the cognate receptors.

1.2.2 NK Cell Cytokine Production
In addition to degranulation, NK cells produce cytokines that modulate other members of the
immune system.6 While robust NK cell degranulation typically occurs in the setting of activating
receptor ligation (whether by antibody binding or target cell engagement), cytokine production
occurs in response to both cytokines and activating receptor stimulation. NK cells constitutively
express receptors for cytokines such as interferon (IFN)- and interleukins (IL)-2, 12, 15, 18,
and 21. In response to these cytokines, NK cells produce cytokines such as IFN−, TNF, and
GM-CSF (granulocyte macrophage colony-stimulating factor) and chemokines such as
macrophage inflammatory protein (MIP)-1, MIP-1 and CCL5 (RANTES). Stimulation with
individual cytokines typically does not suffice to induce robust cytokine production by NK cells.
However, stimulation with combinations of cytokines (e.g. IL-12 and IL-18 or IL-12 and IL-15)
does.7–9 Release of chemokines (MIP-1/, RANTES) in response to activating receptor
engagement typically occurs more rapidly than IFN- or TNF production. In addition,
engagement of individual receptors can suffice for chemokine release, whereas the engagement
of multiple receptors is required for IFN- and TNF production.10

1.2.3 Functional Immune Cross-Talk
NK cells interact with other members of the immune system either indirectly via the release of
cytokines and chemokines or directly via cell-cell interactions.11 NK cells interact directly with
5

dendritic cells (DCs), macrophages, and T cells. NK cells are activated by mature DC-derived
cytokines and cellular contact in the paracortical areas of lymphoid tissue. In addition, NK cells
appear to have a role in DC editing and can selectively kill immature DCs, likely as a result of
their lower MHC class I expression.12 Similarly, macrophages secrete pro-inflammatory
cytokines that stimulate NK cells and activated NK cells can edit the macrophage pool,
selectively killing M0 and M2 macrophages, but sparing M1.13 In addition to interacting with
other innate immune cells, there is also cross-talk between NK and T cells. NK cells contribute
to the resolution of adaptive immune responses by killing activated T cells that upregulate
NKG2D ligands.14 In addition, NK cells are principal producers of IFN-, which promotes TH1
polarization, along with other important immune functions like MHC class II upregulation and
macrophage activation. Other NK cell-derived cytokines and chemokines that modulate the
immune system are MIP-1 and  which activate and recruit granulocytes along with promoting
the synthesis of pro-inflammatory cytokines, RANTES, which is chemotactic for T cells,
basophils and eosinophils, and TNF, which participates in multiple antitumor and antiviral
functions along with mediating systemic inflammatory responses.11

1.3 Receptors on NK Cells: Target Cell Recognition and Cytokine
Signaling
NK cell target recognition is a tightly regulated process that integrates activating and inhibitory
receptor signals with the activation state of the NK cell to determine the functional response.
Unlike adaptive T and B lymphocytes, the diversity and specificity of NK cell responses do not
arise from the rearrangement of DNA sequences that encode a predominant, antigen-specific
receptor. Instead, NK cells express a variety of germline DNA-encoded, invariant activating and
inhibitory receptors whose signals integrate to govern NK cell functional responses (Table1.1).15
6

Table 1.1: Major NK cell activating, inhibitory, and cytokine receptors and their
ligands.

Cytokine

Activating

Inhibitory

Italic = Activating receptor that does not signal via ITAMs. * = Induced expression.
Receptor Name

Ligand

KIR

HLA Class I

CD94/NKG2A

HLA-E

LIR-1

HLA Class I & Non-Classical HLA Class I

FcRIIIa (CD16)

IgG Fc Region

NKp46

Viral Hemagglutinins, Unknown

NKp30

Viral Hemagglutinins, B7-H6, BAG6, Unknown

NKp44*

Viral Hemagglutinins, Unknown

NKp80

Activation-Induced C-Type Lectin (AICL)

CD94/NKG2C

HLA-E

KIR

HLA Class I

NKG2D

MICA/B, ULBP1-6

DNAM-1

CD155 (Necl5), CD112 (Nectin-2)

IL-2R

IL-2

IL-12R

IL-12

IL-15R

IL-15

IL-18R

IL-18

IL-21R

IL-21

IFNAR

IFN-

TGFRI/II

TGF-

IL-10R

IL-10

7

As a general rule, NK cell inhibitory receptors recognize MHC class I molecules, immunologic
markers of “self”. Reduced or absent MHC class I expression, which may be seen on an infected
or malignantly-transformed cell, does not on its own result in NK cell activation. NK cell
triggering does not classically occur without signals from activating receptors, which typically
recognize cell stress-induced ligands, or antibody constant regions that may be found on an
opsonized target. In addition, through the constitutive expression of cytokine receptors, the
surrounding milieu can further tune the signals arising from activating and inhibitory receptor
engagement by altering the NK cell’s activation state (Figure 1.2).

1.3.1 NK Cell Inhibitory Receptors
In humans, the predominant NK cell inhibitory receptors are CD94/NKG2A and a family of
killer cell immunoglobulin-like receptors (KIR).15 The evolutionarily older CD94/NKG2A is the
principal inhibitory receptor of CD56bright NK cells and relatively immature CD56dim cells, while
KIR acquisition is a property of the more mature CD56dim population. NK cell inhibitory
receptors share a common signaling motif in their cytoplasmic domains, the immunoreceptor
tyrosine-based inhibitory motif (ITIM), defined by the amino acid sequence (I/L/V/S) XYXX
(L/V). Upon ligand engagement by an inhibitory receptor, the tyrosine in this motif is
phosphorylated by a Src family kinase, and recruits SHP-1 or 2 (tyrosine phosphatases). These
recruited enzymes dephosphorylate local activating receptor-associated tyrosine kinases,
terminating Ca2+ influx, functional responses, and proliferation.15 Thus, engagement of any
inhibitory receptor reduces the potential of most activating receptors to stimulate a response.
CD94/NKG2A is a heterodimeric, type II transmembrane C-type lectin receptor expressed on
both human and murine NK cells. CD94 also associates with other NKG2 receptors, including
8
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Figure 1.2: The outcome of NK/target cell interactions depends on signal
integration.
(A) In the healthy state, non-cytokine-primed NK cells encounter self-tissue expressing MHC
class I, which delivers inhibitory signals to NK cells via KIR (or Ly49 receptors) and
CD94/NKG2A, preventing NK cell activation. (B) Under inflammatory conditions, proinflammatory cytokines bind NK cells via constitutively-expressed receptors. These cytokine
signals promote cytokine production by the NK cells, up-regulation of activating and adhesion
receptors, further arming with cytotoxic granules, etc. that together prime the NK cell for an
encounter with a target cell. (C) Virally-infected or malignantly-transformed cells typically
down-regulate MHC class I and up-regulate cell stress ligands. Thus, when an NK cell
encounters such a target, activating receptor signals outweigh inhibitory ones, tipping the
balance in favor of NK cell activation and promoting enhanced cytokine production and
focused degranulation towards the target cell.
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the activating NKG2C, and itself has no cytoplasmic domain. Instead, inhibitory signals are
transmitted by the two ITIMs contained within the cytoplasmic tail of NKG2A. CD94/NKG2A
recognizes the non-classical MHC class I molecule HLA-E, which is widely expressed on
normal tissue and presents the leader sequences of other class I molecules (HLA-A, B, C). In
contrast, KIR are a family of monomeric type I transmembrane proteins encoded by 14 different
genes (KIR 2DL1-5, 3DL1-3, 2DS1-5, 3DS1) that are only expressed on human NK cells.16 The
first number in KIR nomenclature represents the number of extracellular immunoglobulin-like
domains (2 or 3), while L or S represent the length of the cytoplasmic tail (L for long, S for
short). KIR can be either activating or inhibitory, and all inhibitory receptors have long (L),
ITIM-containing cytoplasmic tails. KIR recognize MHC class I molecules, and different KIR
recognize distinct MHC subsets. KIR2DL1 recognizes HLA-C2 molecules, KIR2DL2/3
recognizes HLA-C1, and KIR3DL1 recognizes HLA-Bw4. KIR sequences and expression
patterns generate a pool of NK cells with unique inhibitory properties. This is achieved in several
different ways. First, a given NK cell expresses only a subset of available KIR genes. As well,
KIR are inherited as haplotypes which vary in their proportion of activating and inhibitory KIR
(Haplotype A = more inhibitory, B = more activating). Finally, several alleles exist for each KIR,
which modulate surface expression density and MHC affinity. Specific KIR alleles have been
linked to susceptibility to certain autoimmune disease, viruses, and cancer, as well as to
allogeneic hematopoietic cell transfer outcomes, highlighting the biological importance of
KIR/KIR-ligand interactions and NK cell functional modulation. Finally, NK cells also express
the inhibitory leukocyte immunoglobulin-like receptor 1 (LIR1), which recognizes both classical
and non-classical MHC class I molecules.
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Murine NK cells also express CD94/NKG2A, however they do not express KIR. The murine
counterpart to KIR are the Ly49 receptors - a diverse family of homodimeric type II C-type
lectin proteins that contains both activating and inhibitory subtypes.17 These receptors show
stochastic NK cell expression, and furthermore are differentially expressed in specific mouse
strains. Like KIR, inhibitory Ly49s (ex: Ly49A, C, and I) recognize MHC class I molecules and
suppress NK cell function via ITIM motifs in their cytoplasmic tails.
In addition to constitutively-expressed inhibitory receptors, NK cells, like other immune cells,
upregulate inhibitory receptors upon activation as a means of controlling the magnitude and
duration of an immune response. These induced inhibitory checkpoint molecules, which include
T cell immunoglobulin and ITIM domain (TIGIT), programmed death (PD)-1, and lymphocyte
activation gene (LAG)-3, typically bind ligands expressed on target cells such as tumors.18 Thus,
one strategy to improve NK cell immunotherapy outcomes involves blockade of these induced
checkpoints, tipping the signaling balance towards activation.

1.3.2 NK Cell Activating Receptors
The pool of NK cell activating receptors is more diverse than the inhibitory one.15 Most NK cell
activating receptors are associated with immunoreceptor tyrosine-based activation motif
(ITAM)-bearing signaling adapters. Different signaling adapters possess different numbers of
ITAMs (3 in CD3, 2 in DAP12, and 1 in FcR), and ITAMs are defined by YXXL/I motifs
separated by 6-8 amino acids. The binding of an activating receptor to its ligand results in the
phosphorylation of ITAM tyrosine residues by Src family kinases. These phosphorylated
tyrosines recruit additional tyrosine kinases and scaffolding proteins that activate a variety of
different signaling pathways.15 Some of the most notable NK cell activating receptors that
11

associate with ITAM-bearing signaling adapters are FcRIIIa (CD16), the natural cytotoxicity
(NCR) receptors, CD94/NKG2C, and activating KIR. CD94/NKG2C and activating KIR
recognize the same ligands as their inhibitory counterparts. While CD94/NKG2C is usually
expressed on only a minor subset of NK cells, this subset has been shown to expand
preferentially in the setting of human cytomegalovirus (HCMV) infection (see below).19
FcRIIIa is one of several Fc receptors that bind antibody constant domains. Fc receptors are
sub-classified based on the type of antibody that they recognize.20 FcRIIIa is one of several
IgG-recognizing Fc receptors. Fc receptors are expressed on monocytes, macrophages, and
dendritic cells, amongst others, where they are important mediators of phagocytosis. FcRIIIa is
a low-affinity receptor primarily expressed on NK cells that signals via CD3 or FcR. While
signals from several activating receptors are usually required to activate an NK cell, signals from
FcRIIIa alone are potent enough to result in antibody-dependent cytokine release and
cytotoxicity.21 FcRIIIa, then, allows for specific NK cell targeting to cells expressing an antigen
of interest. This is relevant physiologically in the context of a mixed immune response, but also
therapeutically. Indeed, combination therapy involving NK cells and monoclonal antibodies
directed against tumor antigens is under active investigation.
NK cell NCRs include NKp30, NKp44, NKp46, and NKp80.15 With the exception of NKp80, a
C-type lectin, NCRs are type I transmembrane proteins with extracellular immunoglobulin
domains responsible for ligand binding, and a transmembrane portion bearing a positively
charged amino acid that mediates association with signaling adaptors. NKp30, NKp46, and
NKp80 show constitutive NK cell expression, whereas NKp44 is induced upon NK activation.
NKp30 and NKp46 associate with CD3 and FcR, and NKp44 with DAP12. NKp80 signals
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through a hemi-ITAM sequence that is part of its cytoplasmic domain. The identities of all NCR
ligands have not been elucidated. NKp30, 44, and 46 have been shown to bind viral
hemagglutinins. With regards to tumor ligands, NKp30 binds B7-H6 and BAG6, present on
multiple different tumor cell lines, but specific tumor ligands for the other NCRs remain
unknown. NKp80 is genetically linked to its ligand, activation-induced C-type lectin, expressed
on a variety of malignant cells as well as activated, non-malignant tissues.
Two important NK cell activating receptors that do not signal via ITAMs are NKG2D and
DNAX accessory molecule (DNAM-1).15 Unlike other NKG2-family receptors, NKG2D exists
as a homodimer and signals via the adaptor DAP10. DAP10 does not have ITAMs and instead
has a YXXM motif in its cytoplasmic tail that recruits PI3K. NKG2D binds a variety of different
ligands that, for the most part, are induced by cellular stress and resemble MHC class I, such as
MIC-A/B, and ULBP1-6. DNAM-1 is an Ig-like adhesion molecule whose cytoplasmic domain
has three sites that can be phosphorylated upon binding to its ligands, the nectin proteins Necl5
and Nectin-2. These ligands are expressed on a wide variety of tumor cells, and DNAM-1 plays
an important role in tumor immunosurveillance. Indeed, activating signals from DNAM-1
synergize with those from other NK receptors to promote IFN- production and cytotoxicity.22
Like activating KIR, activating Ly49 (ex: Ly49D, H) lack signaling motifs in their cytoplasmic
tails, but associate with ITAM-bearing adaptor proteins. A particularly important role for
activating murine Ly49 receptors has been described in the response to murine cytomegalovirus
(MCMV) infection.23,24 Strains of mice that lack Ly49H are susceptible to MCMV infection,
whereas those that express it are resistant.25,26 Early (<2 days) into MCMV infection, NK cells
become activated and proliferate in response to inflammatory signals. However, later in the
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course of infection, Ly49H+ NK cells preferentially proliferate and expand as a result of Ly49H
engagement of the viral protein m157 and promote viral control.27,28

1.3.3 NK Cell Cytokine Receptors
NK cell cytotoxicity and cytokine production in response to a target cell is modulated by
cytokines present in the local environment as a result of constitutive NK cell expression of
cytokine receptors. Cytokines such as interferon IFN- and IL-2, 12, 15, 18, and 21, produced by
early innate immune responders like dendritic cells and macrophages, are potent inducers of NK
cell activation and cytotoxicity.29 For instance, IL-15, the central cytokine in NK cell
development and homeostasis (see below), enhances NK cell cytotoxicity along with promoting
survival and proliferation. Part of the IL-15 receptor ( subunit) is also utilized by IL-2, and as
a result, IL-2 exerts similar biologic effects. IL-12 stimulates both NK cell cytokine production
and cytotoxicity, and IL-18 synergizes with IL-12 and IL-15 to promote IFN- production. The
effects of IL-21 on NK cells are not fully understood and may depend on synergistic signals from
other cytokines like IL-15, in the presence of which IL-21 appears to promote NK cell
cytotoxicity and maturation. NK cell functional responses and cytotoxicity can also be
diminished by immunosuppressive cytokines like IL-10 and TGF-.

1.4 NK/ILC Development
NK cells develop from the bone marrow-resident common lymphoid progenitor (CLP), which
has the potential to generate all lymphocyte subsets (ILCs, T cells, and B cells). Similar to T and
B cell development, the CLP gives rise to developmental intermediates that show progressive
commitment towards individual ILC subsets (Figure 1.3). Namely, the CLP gives rise to the
common ILC progenitor (CILCP) from which either the common helper ILC progenitor (CHILP)
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Figure 1.3: Schematic of NK vs. ILC development.
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or the NK precursor (NKP) arise.30 Transcription factors that promote or inhibit specific gene
programs have been shown to play a critical role in promoting the development of unique
lymphocyte subsets. For instance, GATA-3, TCF-1, and ID2 promote CHILP cell fate, whereas
TOX, ETS1, and RUNX3 promote CILCP commitment to the NKP.30
The CHILP and NKP give rise to fully mature effector cells. This differentiation occurs both in
the bone marrow as well as in peripheral tissues, however the precise location and full
complement of requisite signals remain incompletely characterized. The NKP passes through
several developmental intermediates before giving rise to fully mature NK cells, and these
intermediates can be delineated via the expression of specific surface markers, namely CD27 (a
receptor in the TNF superfamily) and the integrin CD11b.31 NKp46, a near NK cell-restricted
activating receptor, is induced as NKPs transition towards the most immature NK cell stage
(CD27- CD11b-: Stage I).32 Stage I cells then develop into Stage II (CD27+ CD11b-), Stage III
(CD27+ CD11b+) and finally terminally mature Stage IV (CD27- CD11b+) NK cells.31
Additional surface markers are gained or lost as NK cells mature, including acquisition of Ly49
receptors, loss of TRAIL, and acquisition of DX5.32
The T-box transcription factors T-bet and Eomesodermin (Eomes) are known master regulators
of T cell development and function, and similar roles for these transcription factors in ILCs have
more recently been described.33 NK cell development is dependent upon both T-bet and Eomes,
as hematopoietic-specific deletion of both T-bet and Eomes results in a total loss of NK cells,34
however only T-bet is required for the development of the ILC1 subset.35 Eomes expression is
highest at immature stages of NK cell development, whereas T-bet is expressed more robustly as
NK cells mature.36 In addition, loss of Eomes in the hematopoietic compartment results in a
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drastic loss of NK cells of all stages,34 however T-bet deletion results in a more modest NK cell
reduction with cells biased towards an immature phenotype.37 These observations have prompted
a model whereby Eomes instructs early NK cell development and T-bet functions more in
terminal maturation. T-bet and Eomes are also robustly expressed in human NK cells and show a
similar pattern to that seen in mice, with T-bet more highly expressed in relatively mature
CD56dim NK cells and Eomes in the less mature CD56bright population.38 Similar to its role in T
cells, T-bet has been shown to positively regulate NK cell IFN- and Granzyme B production,
thus promoting NK cell effector functions.37 Consistent with this, robust NK cell effector
functions are acquired later in maturation.31 The role for Eomes in NK cell function is less clear.
While its expression correlates with IFN- production in vitro and Eomes downregulation has
been proposed to be a marker for NK cell exhaustion,39 a conclusive role for Eomes in NK cell
functional responsiveness has yet to be shown.
Like murine NK cells, human NK cells arise from the CLP and pass through several intermediate
developmental stages on their way to terminal maturation.32 Two NK cell developmental subsets
are readily detectable in the peripheral blood: the relatively immature Stage IV CD56 bright
population, and terminally mature stage V CD56dim NK cells. While CD56bright NK cells
represent a minority of peripheral blood NK cells (<10%), they predominate in secondary
lymphoid tissue and are the most numerous NK cell subset overall.40,41 In addition to CD56
staining intensity, CD56bright and CD56dim NK cells can be phenotypically distinguished in
several ways. For example, CD56bright NK cells express low levels of cytotoxic proteins
(perforin, Granzyme B) at rest, rely on CD94/NKG2A for self-tolerance and express little KIR,
and possess distinct chemokine and homing receptors. Conversely, CD56dim NK cells show
cytotoxic protein expression at rest, express KIR (and CD94/NKG2A to a lesser extent), and
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express high levels of FcRIIIa, which is largely absent on the CD56bright subset.6 With regards to
function, CD56dim NK cells are cytotoxic at rest and are also capable of cytokine production. In
contrast, CD56bright NK cells are minimally cytotoxic at rest, but are robust cytokine and
chemokine producers in response to inflammatory signals.6

1.5 NK Cells vs. ILC1s
NK cells are the founding members of the ILC lineage, however several other ILC subsets have
been identified in recent years. Broadly speaking, ILCs can be divided into cytotoxic (NK cell)
or helper (ILC1, 2, and 3) lineages. Parallels to T cell development (cytotoxic CD8 T cells vs.
helper CD4 lineages) have not gone unnoticed. Indeed, T cell receptor aside, remarkable
functional parallels exist between ILCs and their T cell counterparts, in addition to sharing
lineage-defining transcription factors.30 Like NK cells, CD8 T cells express T-bet and Eomes and
display perforin and Granzyme B-dependent cytotoxicity as well as IFN- production. Helper
ILCs primarily contribute to immune responses via cytokine production. ILC1s, like the CD4
TH1 subset, express T-bet and produce IFN-. ILC2s, like TH2 cells, express GATA3 and
produce IL-5 and IL-13. ILC3s, like TH17 cells, express RORt and produce IL-17 and IL-22.30
NK cells are most similar to ILC1s. At least 3 ILC1 subsets have been described in mice, in the
epithelium, intestine, and liver, with an additional salivary gland subset that shares features of
both ILC1s and NK cells.42 Indeed, an important distinguishing feature of NK cells is that they
recirculate, whereas ILCs are largely tissue-resident. A clear definition of what constitutes an
ILC1 vs an NK cell has been elusive, however, given that the phenotype and function of ILC1s
varies from tissue to tissue.42 One of the best-characterized groups of ILC1s is found in the liver.
It has been known for over a decade that the liver is home to a sizeable population of TRAIL+
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DX5- NK1.1+ cells,43 however, these were originally thought to be a pool of immature NK cells.
These TRAIL+ DX5- cells were later shown to lack Eomes expression34 and to be unable to
differentiate into mature DX5+ NK cells,36,44 suggesting that they represented a unique cell
lineage. Since then, several studies have established that these are hepatic ILC1s with unique
phenotypic and functional characteristics compared to NK cells. With regards to phenotype,
hepatic ILC1s lack DX5 and Eomes expression and express much lower levels of CD11b and
most Ly49 receptors.34,44 However, these ILC1s express the integrin 1 (CD49a), a marker of
tissue residency, TRAIL, and the inhibitory receptor CD94/NKG2A.44 Liver ILC1s are robust
cytokine producers, making IFN- at comparable levels to conventional NK cells and TNF and
GM-CSF at even higher levels.44 Finally, liver ILC1s have the potential for robust cytotoxicity as
they can express high levels of perforin and Granzyme B upon phorbol myristate acetate
(PMA)/ionomycin activation, degranulate in response to tumor targets, and can mediate TRAILdependent killing.45 Interestingly, ILC1s of different tissues appear to vary in their potential for
perforin and Granzyme B-dependent cytotoxicity.45

1.6 IL-15: Biology and Role in NK Cell Homeostasis
IL-15 is an immunomodulatory, four alpha-helix bundle cytokine that plays a critical role in
promoting both innate and adaptive immunity. IL-15 was initially discovered based on its ability
to stimulate T cell proliferation in the presence of neutralizing antibodies against IL-2. IL-2 and
IL-15 share relatively little sequence homology, yet possess highly analogous tertiary structures
that allow them to interact with a shared intermediate-affinity receptor. This receptor is a
heterodimer consisting of a  subunit (CD122), expressed primarily on subsets of T and NK
cells, and the common gamma chain (c) (CD132), which is expressed on most lymphocytes and
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also mediates IL-4, 7, 9, and 21-based signaling.46 While IL-2 and IL-15 share some in vivo
effects, such as promoting the survival, activation, and proliferation of cytotoxic T and NK cells,
some important differences exist. For instance, IL-2, but not IL-15, is critical for maintaining the
regulatory T (Treg) cell population and this distinction has helped spark interest in using IL-15 in
the clinical setting to augment immune responses, particularly against cancer, without inhibition
by Tregs. Furthermore, the biological effects of IL-2 are concentrated on T and NK cells, whereas
IL-15 acts in a much broader fashion.47 Important aspects of IL-15 biology and its role in NK
cell development, homeostasis, and function are discussed below.

1.6.1 The IL-15 Receptor
The divergent physiologic effects of IL-2 and IL-15 can be explained in part by unique receptor
 subunits. These  subunits themselves do not signal, but they decrease energy barriers for
cytokine binding to the intermediate-affinity (10-9 M) c receptor.46,47 IL-2R (CD25)
possesses relatively low IL-2 affinity (10-8 M), yet can complex with IL-2/15Rc to bind IL-2
with high affinity (10-11 M). Thus, IL-2 likely binds the IL-2/15Rc and then recruits IL-2R on
the same cell (cis).48 In contrast, the IL-15R alone binds IL-15 with high affinity (10-11 M) and
functions primarily to trans-present IL-15 to cells expressing the c receptor. The IL-2 and IL15 quaternary complexes (i.e. IL-2/15 with IL-2/15Rc) assemble nearly identically.49 Indeed,
saturating levels of IL-2 and IL-15 induce similar phosphorylation of signaling intermediates and
gene expression, suggesting that it is cytokine/receptor affinity in different contexts that explains
many of the cytokines’ unique physiologic effects.49

1.6.2 IL-15 and IL-15R Tissue Expression
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IL-2 and IL-15, as well as their alpha receptors, show distinct patterns of tissue expression. IL-2
expression is relatively restricted: it is secreted primarily by activated CD4 T cells, but can also
be produced by naïve CD8 T cells, dendritic cells, and certain cells of the thymus.50 Accordingly,
IL-2R is chiefly expressed on lymphocytes like activated T, B, and NK cells and Tregs. On the
other hand, many tissues produce IL-15 mRNA, including placenta, kidney, lung, heart, muscle,
monocytes/macrophages, dendritic cells (DCs), and thymic epithelium.51 IL-15R mRNA
expression overlaps with that of IL-15. IL-15 is regulated at transcriptional, translational, and
secretory levels, with post-transcriptional regulation appearing to predominate.51

1.6.3 IL-15 Trans-Presentation
IL-15 is unique in that most of its physiologic effects are mediated via trans-presentation.48 Rather
than being secreted, IL-15 binds IL-15R intracellularly and the complex is transported to the cell
surface.52 IL-15R then presents IL-15 to cells expressing IL-15Rc (Figure 1.4). Accordingly,
several studies have demonstrated that memory CD8 T cell, NK cell, and intraepithelial
lymphocyte (IEL) development requires IL-15R expression on cells of the surrounding
environment, but not on the lymphocytes themselves.53–55 Such a mechanism permits more
controlled and directed IL-15 delivery, which may be important since transgenic IL-15 can induce
fatal NK and CD8 T cell leukemia.56 Indeed, trans-presentation by DCs, activated monocytes, and
parenchymal cells underlies normal CD8 T cell, NK cell, and IEL development and activation.55,57–
61

A role for IL-15 trans-presentation in humans has also been shown using a mouse xenograft

system in which transplanted human hematopoietic stem cells showed more robust NK cell
differentiation when supported by complexed IL-15/IL-15R than by IL-15 alone.62
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Figure 1.4: IL-15 receptor signaling.
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While there is little doubt that trans-presentation is the predominant mechanism through which IL15 signaling occurs, it may be by-passed in certain physiologic settings. Both IL-15 and IL-15R
are upregulated by a number of pathogens. Primary CD8 T cell expansion after vesicular stomatitis
virus (VSV) infection is impaired in the setting of IL-15 but not IL-15R deficiency, suggesting
that infection alone can induce sufficient IL-15 to over-ride the requirement for trans-presentation
and directly bind the IL-15Rc.63 However, VSV and lymphocytic choriomeningitis virus
(LCMV)-specific memory CD8 T cell development and persistence is impaired in mice lacking
IL-15R.63,64 In addition, IL-15-responsive lymphocytes such as CD8 T and NK cells can express
IL-15R. Therefore, it is possible that IL-15R can cis-present IL-15 to IL-15Rc, on these cells,
though CD8 T and NK cells are not known to be sources of IL-15. Thus, the exact role of IL-15R
in this context remains to be determined. Studies in human NK cells implicated IL-15R in
promoting survival in response to IL-15.65 Furthermore, murine CD8 T cells transfected with IL15R display enhanced survival and proliferative responses,66 suggesting that IL-15 cispresentation can play a role in T and NK cell homeostasis.

1.6.4 IL-15 Signaling
With regards to signal transduction in lymphocytes, IL-15R itself does not signal, but IL-15R
and c activate three downstream signaling pathways: the Janus-associated kinase (JAK)/signal
transducer and activator of transcription (STAT) pathway, the mitogen-activated protein (MAP)
kinase pathway, and the phosphatidylinositol 3-kinase (PI3K) pathway, which activates Akt and
mammalian target of rapamycin (mTOR) signaling (Figure 1.4).67 The JAK/STAT pathway is
activated directly by the IL-15Rc heterodimer: the  chain activates JAK1, which
phosphorylates and activates STAT3, and the c chain activates JAK3, which exerts similar
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effects on STAT5. pSTAT5 functions in both a dimeric and tetrameric form, inducing expression
of genes important for such things as survival (bcl-2, Mcl-1, Bcl-xl), function (IFNG, Prf1,
GzmB), differentiation, and proliferation.68,69 IL-15 is endogenously regulated by suppressor of
cytokine signaling (SOCS) family members that function by targeting JAKs for proteasomal
degradation. CIS70 and SOCS171 in particular have been implicated in negative regulation of IL15 signaling. PI3K and MAPK pathway activation occur via an adaptor protein, Shc, which
binds a phosphotyrosine residue on IL-15R.72,73 The MAPK pathway promotes phosphorylation
and activation of various transcription factors that promote cellular proliferation, along with NK
cell cytotoxicity.74,75 For its part, mTORC1 activation by PI3K promotes protein translation via
activation of S6K1/S6 and inhibition of E4BP1 and has been shown to promote NK cell
proliferation, migration, effector functions, and metabolism.76–78

1.6.5 IL-15 & NK Cell Development, Homeostasis, and Function
IL-15 is the central cytokine involved in NK cell development, homeostasis, and function. One
of the earliest signs of commitment to the NK cell lineage is induction of CD122 (IL-15R) on
NKPs. NK cell development is critically dependent on IL-15, as evidenced by studies in mice
lacking IL-15 or components of the IL-15 signaling machinery. The first such report came from
IL-15R knockout mice, which were markedly lymphopenic despite relatively normal T and B
cell development.79 This lymphopenia was due to a drastic decrease in NK, NK T, and CD8 T
cell, as well as intraepithial lymphocyte numbers. In addition, lymphocytes displayed impaired
lymph node homing and proliferation. Similar results were observed in IL-15 knockout mice
(and these immune deficits could be reversed by exogenous IL-15 administration),80 as well as in
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studies of mice lacking IL-15R or  subunits81,82 and downstream signaling proteins.83–85
Interestingly, IL-2 or IL-2R deficiency does not result in such an immune cell deficit, but rather
these mice show massive peripheral lymphoid organ expansion and autoimmune disease, in large
part due to defective Treg development and function.86,87 In humans, IL-15 alone can support
CD56+ NK cell development in vitro from bone marrow progenitors,88 and IL-15 transpresentation promotes NK cell differentiation from HSCs in vivo,62 highlighting that IL-15 is
also critical for human NK cell development. The p110 and  catalytic subunits of PI3K in
particular, along with STAT5 have been shown to promote NK cell maturation.68,89,90 Along with
promoting NK cell development, IL-15 is required for peripheral NK cell survival. IL-15 induces
the expression of anti-apoptotic molecules like Bcl-291 and Mcl-192 and suppresses pro-apoptotic
molecules like Bim.92 In the absence of IL-15 signaling, peripheral NK cells are rapidly lost.91
In addition to its roles in NK cell development and survival, IL-15 regulates NK cell
proliferation and activation. IL-15 is a potent inducer of NK cell proliferation, whether
homeostatic91 or in response to activation or inflammation.93 Nanomolar concentrations of IL-15
can induce robust human CD56bright NK cell proliferation in vitro, but minimal CD56dim
proliferation.93 However, CD56dim NK cells can proliferate upon longer-term culture in high
doses of IL-15. Along with proliferation, IL-15 promotes NK cell activation and cytotoxicity. In
mice, this is achieved by promoting the translation of pre-existing perforin and granzyme
mRNA, arming NK cells with functional cytotoxic granules.94 Freshly-isolated human CD56dim
NK cells already express perforin and Granzyme B protein, however culture in IL-15 does
augment NK cell cytotoxicity.29,75,93 In addition to increasing cytotoxic protein expression, IL-15
has also been shown to upregulate certain NK cell activating receptors on both normal donor and
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cancer patient NK cells.75,95,96 Finally, NK cells constitutively express cytokine receptors and
produce cytokines such as IFN- in response to stimulation with cytokines like IL-12, 15, 18, and
type I IFNs.6 Signals from the IL-15 and other cytokine receptors synergize to drive cytokine
production. Of note, short-term stimulation with a particular combination of cytokines, IL-12,
15, and 18, results in the differentiation of cytokine-induced memory-like NK cells which
display enhanced cytotoxicity as well as IFN- responses to a variety of stimuli.97–100

1.7 NK Cell Self-Tolerance
In light of their potent cytotoxicity, a critical feature of NK cells is self-tolerance. A major
mechanism for T and B cell tolerance is the deletion, during development, of cells with receptors
specific for self-antigens. Since NK cells lack a predominant antigen-specific receptor, they must
distinguish healthy self-cells from target cells via alternative mechanisms. KIR (or Ly49) and
MHC class I allele inheritance are not linked and a given NK cell expresses only a fraction of the
KIR alleles it possesses. As a result, a small proportion of human NK cells exist that lack
CD94/NKG2A and express only KIR without cognate ligands present, yet autoimmunity does
not occur. This is the result of NK cell “licensing” or education, whereby NK cells that fail to
signal through an inhibitory receptor during development are functionally anergic.101 Thus,
inhibitory receptors have a paradoxical role in that they also enable NK cell functional responses.
Furthermore, it is becoming clear that licensing is not purely a developmental process. In
transplant scenarios, populations of previously-licensed NK cells without a cognate ligand in the
recipient lose their capacity for functional responses, whereas previously-unlicensed NK cells
can acquire functional competence.102 Licensing, then, appears to be a dynamic process, with
inhibitory receptor signals continually tuning the ability of an NK cell to respond to a target.
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While both KIR (or Ly49) and CD94/NKG2A can license NK cells, licensing through KIR has
been demonstrated to confer enhanced function compared to licensing through CD94/NKG2A. 103
The mechanism for NK cell licensing has not been fully elucidated. It is not clear whether
licensing is the result of NK cell “arming” or “disarming”. In the arming hypothesis, inhibitory
receptor signals themselves confer the ability to respond to activating receptors. However, the
disarming model posits that unlicensed NK cells are hyporesponsive as a result of continuous
signaling through a self-specific activating receptor. Here, inhibitory signals provide a
counterbalance to this activation-induced anergy. The molecular mechanisms that underlie the
licensing process are as yet unknown, but may involve increasing basal mTOR/Akt activation.104

1.8 NK Cell Memory
Immunologic memory, or the ability to respond more quickly and robustly upon antigen reexposure, is typically not a property attributed to innate immune cells. However, recent
paradigm-shifting evidence has demonstrated that NK cells can indeed display memory-like
properties in response to certain stimuli.105 First, murine NK cells were shown to display antigenspecific memory-like responses following stimulation with specific haptens106 or viruses107 and
non-antigen-specific responses following combined cytokine pre-activation.97 Similar properties
have more recently been described in humans (Figure 1.5).
Human cytokine-induced memory-like NK cells differentiate following short-term pre-activation
with the cytokines IL-12, 15, and 18. These memory-like NK cells are long-lived and display
enhanced cytokine (IFN-) production in response to tumor target or cytokine re-stimulation as
well as enhanced cytotoxicity against tumor cells in vitro and in vivo.98,99 The enhanced
responsiveness of these memory-like cells is furthermore preserved with cell division. Cytokine27
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Figure 1.5: Types of human NK cell memory.
Human NK cells have been shown to display memory-type responses following infection with
HCMV or combined cytokine pre-activation. HCMV infection expands mature, NKG2C+ NK
cells with a restricted KIR repertoire. These cells show increased expression of CD2 but
decreased expression of natural cytotoxicity receptors (NKp30, NKp46), and down-regulate the
intracellular adaptor FcR. Functionally, HCMV adaptive NK cells appear specialized towards
IFN- production in response to antibody-dependent stimulation. In contrast, IL-12/15/18 preactivation results in the differentiation of memory-like NK cells, which show increased
CD94/NKG2A expression, along with increased levels of numerous different activating
receptors. Memory-like NK cells produce enhanced IFN- in response to cytokine or activating
receptor stimulation compared to naïve NK cells, and are more robustly cytotoxic.
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induced memory-like NK cells appear to be less sensitive to KIR-based inhibitory signaling, but
show increased levels of the inhibitory receptor NKG2A. Memory-like NK cells also upregulate
certain activating receptors, including NKG2D, NKp46, and NKp30.99
A different type of NK cell memory has been described in response to human cytomegalovirus
(HCMV) infection.19 These HCMV-adaptive NK cells are phenotypically mature, KIR-restricted,
and usually express the activating receptor NKG2C. Adaptive NK cells also express higher
levels of the co-stimulatory molecule CD2, but lower levels of activating receptors like NK46
and NKp30. In addition, adaptive NK cells display altered levels of intracellular signaling
adaptors downstream of FcRIIIa (ex: FcR), which appear to heighten their responsiveness to
this activating receptor. The function, developmental biology, and molecular regulation of both
types of human memory-like NK cells are subjects of ongoing investigation.

1.9 Clinical Applications of NK Cells
The inherent anti-tumor function of NK cells has been actively utilized clinically, first in the
setting of allogeneic hematopoietic cell transplantation (HCT), and more recently in the form of
adoptive cellular therapy. While T cells are also critical mediators of graft vs. leukemia
responses, they can also cause graft vs. host disease (GVHD), wherein allogeneic T cells attack
normal host tissues. Importantly, NK cells have never been shown to directly cause GVHD and
may even protect against this immune reaction.108 Initial evidence for NK cell graft vs. leukemia
responses in vivo arose from MHC-haploidentical, T cell-depleted HCT for AML therapy. Here,
NK cell alloreaction against AML blasts was associated with improved long-term disease-free
survival.109,110 Since then, several studies have conclusively demonstrated that donor KIR
haplotype influences long-term HCT outcomes in AML patients.111–113 Specifically, the KIR B
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haplotype, which contains a predominance of activating KIR, contributes to relapse protection
and improved survival compared to the largely inhibitory A haplotype.111 Subsequent studies
identified specific activating KIR (KIR2DS1) that are protective against AML relapse. 113
In addition to administering NK cells in the form of HCT, several groups are investigating the
clinical potential of adoptive NK cell therapy. Early studies, which consisted of allogeneic NK
cell infusions supported by exogenous IL-2 administration, demonstrated the feasibility and
safety of such an approach.114,115 Furthermore, positive clinical responses were observed,
although these occurred in a subset of patients and were limited in duration. Thus, many groups
are actively investigating means of enhancing the in vivo anti-tumor response of adoptively
transferred NK cells. One approach involves combined cytokine pre-activation of NK cells prior
to infusion, leading to the generation of memory-like NK cells with enhanced anti-tumor
responses in vivo.99 Alternately, other groups are seeking to expand adaptive NK cells, akin to
those that expand in response to CMV, for infusion into patients. Clinical outcomes from these
and other studies are eagerly awaited.
Besides modifying an adoptively-transferred NK cell’s inherent threshold for tumor
responsiveness, anti-tumor responses can also be enhanced by modulating activating and
inhibitory receptor signals received in vivo. Ongoing clinical trials are investigating the use of
antibodies against NK cell inhibitory receptors (KIR and NKG2A). With reduced inhibitory
signals, NK cells would be biased towards activation upon encountering a target cell expressing
activating receptor ligands. With regards to activating receptors, FcRIIIa is highly useful
clinically since ligation of it alone can activate NK cell effector functions, and it can also be used
to target NK cells towards antibody-opsonized targets. The combination of NK cells and tumor
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antigen-targeting antibodies is also being actively investigated in the clinical setting. Finally, like
T cells, NK cells can be engineered to express chimeric antigen receptors (CARs), another way
to specifically target them to a cell of interest.116 CARs consist of an extracellular region
recognizing a particular antigen, a transmembrane domain, and an intracellular activating
domain. In sum, NK cell cancer immunotherapy is a rapidly-expanding and highly-promising
field, fueled by the intricate and flexible nature of the NK cell anti-cancer program.
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Chapter 2: Cytokine-Induced Memory-Like Differentiation
Enhances Unlicensed Natural Killer Cell Antileukemia and
FcRIIIa-Triggered Responses
This chapter is adapted from a manuscript published in Biology of Blood and Marrow
Transplantation:
Wagner JA, Berrien-Elliott MM, Rosario M, Leong JW, Jewell BA, Schappe T, Abdel-Latif S,
and Fehniger TA. Cytokine-induced memory-like differentiation enhances unlicensed NK cell
anti-leukemia and FcRIIIa-triggered responses. Biology of Blood and Marrow Transplantation,
2017. PMCID: PMC5408734 (DOI 10.1016/j.bbmt.2016.11.018.)
J.A.W, T.A.F conceived of the project, designed experiments, and wrote the manuscript with input
from all other authors; J.A.W., M.M.B-E., M.R., J.W.L, B.A.J. T.S., S. A-L. performed
experiments; J.A.W., T.A.F. analyzed data. All authors reviewed data and approved of the final
manuscript.

2.1 Summary
Human cytokine-induced memory-like natural killer (NK) cells differentiate following shortterm pre-activation with interleukin (IL)-12, IL-15, and IL-18 and display enhanced effector
function in response to cytokines or tumor targets for weeks following the initial pre-activation.
We investigated whether memory-like differentiation also enhanced NK cell responsiveness to
FcRIIIa (CD16)-based triggering. Indeed, IFN- production by memory-like NK cells in
response to CD16 cross-linking or antibody-coated targets, as well as killing of antibody-coated
targets, were both enhanced compared to control NK cells. Mechanistically, the differential
responsiveness of memory-like vs. control NK cells to FcRIIIa-based triggering was not
explained by alterations in key downstream signaling intermediates, indicating that the biology
of memory-like NK cells is distinct from that of adaptive NK cells in human cytomegalovirus
(HCMV)+ individuals. These results demonstrate that the broadly enhanced functionality of
cytokine-induced memory-like NK cells extends to stimulation via FcRIIIa, and suggests that
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these cells could demonstrate clinical efficacy in combination with therapeutic monoclonal
antibodies.

2.2 Introduction
NK cells are innate lymphoid cells that mediate anti-tumor immune responses, particularly against
hematologic malignancies.1,2 Distinct from adaptive T and B lymphocytes, NK cells express a
variety of germline DNA-encoded, stochastically-expressed activating and inhibitory receptors
that govern functional responses to target cells.3 NK cell activating receptors (e.g. NKG2D, natural
cytotoxicity receptors) generally recognize cell stress ligands expressed on virally-infected or
malignantly-transformed cells. Usually, NK cell activation requires signals from several activating
receptors. One exception, however, is FcRIIIa, a low-affinity receptor for the Fc region of IgG
antibodies expressed on NK cells. Signals from FcRIIIa alone are sufficient to induce NK cell
degranulation and target cell killing (antibody-dependent cellular cytotoxicity, ADCC) and NK
cell cytokine production.4 In contrast to activating receptors, inhibitory receptors [e.g.
CD94/NKG2A

and

killer

immunoglobulin-like

receptors

(KIR)]

recognize

major

histocompatibility complex (MHC) class I-type molecules.
Recent reports have demonstrated that NK cell function is also shaped by prior experience.5
Exposure to specific haptens, viral infection, or combined cytokine pre-activation elicits innate
memory or memory-like responses from murine NK cells.6–8 Paralleling findings in model
organisms, brief combined pre-activation with IL-12, IL-15, and IL-18 results in human memorylike NK cell differentiation.9,10 While this initial cytokine stimulus potently activates NK cells,
within days they return to their basal activation state, and memory-like differentiation is detectable
after 1 week in vitro with survival supported by low-dose IL-15.9 Memory-like NK cells show
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enhanced cytotoxicity and IFN- production upon re-stimulation with cytokines, tumor targets, or
via activating receptor ligation for weeks to months following the initial pre-activation event when
compared to control NK cells that were only exposed to low-dose IL-15.
Human memory-like NK cell recognition of, and functional response against, leukemia targets is
also enhanced in vivo.11,12 As a result, cytokine-induced memory has been translated to the
clinic in several ongoing clinical trials for patients with relapsed or refractory acute myeloid
leukemia (AML, NCT01898793, NCT02782546, NCT03068819).12,13 Preliminary results from
these trials have demonstrated significant donor memory-like NK cell engraftment of recipient
bone marrow, and retention of enhanced memory-like functionality upon ex vivo re-stimulation
with tumor targets. In addition, AML clearance and complete responses were observed in a
subset of patients, demonstrating the immunotherapeutic potential of memory-like NK cells in
the setting of hematologic malignancies.12 However, the clinical responses that occurred were of
limited duration, and some patients failed to respond at all. Thus, methods of further augmenting
memory-like NK cell anti-tumor function are necessary.
One therapeutic strategy that has been successful for several types of malignancies, including
solid tumors, is monoclonal antibody therapy.14 Here, patients are treated with antibodies
recognizing tumor antigens that induce clearance of tumor cells via several mechanisms,
including ADCC. NK cells are known mediators of ADCC, which is triggered by FcRIIIa
crosslinking. IL-15 has been shown to enhance NK cell ADCC in vitro as well as in vivo in
preclinical murine models of B cell lymphoma.15 However, whether cytokine-induced memorylike differentiation results in enhanced responsiveness to FcRIIIa-based stimulation is unknown.
Interestingly, adaptive NK cells that differentiate in response to HCMV infection have been
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shown to display enhanced responsiveness to antibodies as a result of altered signaling
downstream of FcRIIIa. FcRIIIa is known to signal via two immunoreceptor tyrosine-based
activation motif (ITAM)-containing adaptors: CD3 and FcR.16 CD3 has 3 ITAMs, and
FcR has one. HCMV-adaptive NK cells have been shown to express reduced levels of FcR
but more CD3 , likely resulting in greater activation of signaling cascades downstream of
FcRIIIa.17–19 Whether these molecular changes are also observed in cytokine-induced memorylike NK cells is unknown. Here, we demonstrate that memory-like differentiation does indeed
enhance responsiveness to FcRIIIa ligation, however it does so via mechanisms distinct from
HCMV-adaptive NK cells.

2.3 Results
Memory-like NK cell differentiation augments IFN- and cytotoxicity responses to FcRIIIabased triggering
The ability of memory-like NK cells to respond via FcRIIIa has not yet been reported. We used
peripheral blood mononuclear cells (PBMC) from healthy donors to differentiate control and
memory-like NK cells and assessed their ability to produce IFN- in response to FcRIIIa ligation.
A significantly greater percentage of memory-like NK cells produced IFN− in response to
stimulation with plate-bound anti-FcRIIIa (Figure 2.1A) or rituximab-coated Raji lymphoma
targets (Figure 2.1B) than control NK cells. Consistent with K562 re-stimulation,9 degranulation
responses to plate-bound anti-FcRIIIa or rituximab-coated Raji lymphoma targets were similar
between memory-like and control NK cells (not shown). To further support these findings, we
performed ADCC experiments. Memory-like NK cells also displayed enhanced killing of
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Figure 2.1: Memory-like NK cells display enhanced IFN- production and
cytotoxicity in response to FcRIIIa-based triggering.
Memory-like and control NK cells were stimulated with plate-bound anti-FcRIIIa antibody
(A) or rituximab-coated Raji lymphoma target cells (B) in a 6 hour functional assay, or
rituximab-coated Raji lymphoma targets in a 4 hour FLoKA (C). (A,B) Representative flow
cytometry data is shown, as well as summary data of mean ± SEM IFN- positive memory-like
vs. control NK cells from n=8-10 normal donors, n ≥ 4 independent experiments. (C) Memorylike vs. control NK cell ADCC at different effector to target ratios. Con = control, mem =
memory-like, Ritux = rituximab-coated. Raji cells alone are relatively NK cell-resistant, and
killing without rituximab did not differ between control and memory-like NK cells. N = 4
normal donors, 2 independent experiments. Data were compared using t-tests with multiple
comparisons correction where appropriate.
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rituximab-coating Raji lymphoma targets compared to control NK cells at all E:T ratios examined
(Figure 2.1C). Thus, NK cell IFN- and killing responses to FcRIIIa-based triggering are
enhanced by memory-like differentiation.
Intracellular signaling and adaptor molecule expression downstream of FcRIIIa are similar
between memory-like and control NK cells
Currently, the molecular mechanisms responsible for enhanced IFN- production by cytokineinduced memory-like NK cells are unknown. We utilized the well-characterized signaling cascade
triggered as a result of FcRIIIa ligation to study potential mechanisms leading to the enhanced
IFN- response of memory-like NK cells.16 Adaptive NK cells that arise in HCMV-infected
individuals are specialized to respond to FcRIIIa-based triggering via modification of intracellular
signaling proteins, including reduced expression of FcR17–19 We therefore first examined the
expression levels of CD3 and FcR the two ITAM-bearing signaling adaptors that couple with
FcRIIIa.16 FcR expression was unchanged between memory-like and control NK cells (Figure
2.2A). Similarly, CD3 expression was comparable between memory-like and control NK cells,
with a slight, but statistically significant, decrease in memory-like NK cells (Figure 2.2A).
Reduced expression of Syk was also observed in adaptive NK cells,17,18 and we therefore examined
expression of Syk and ZAP-70, related tyrosine kinases that participate in the signaling cascade
downstream of CD3 and FcR Memory-like and control NK cells expressed similar levels of
Syk protein, but ZAP70 expression was modestly decreased in memory-like NK cells (Figure
2.2B). Finally, we assessed key proximal and distal phosphorylation-based signaling intermediates
downstream of FcRIIIa in CD56dim NK cells. We observed no difference in proximal (SYK/ZAP-
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Figure 2.2: Intracellular signaling downstream of FcRIIIa is similar between
memory-like and control NK cells.
FcR (A), CD3 (A), ZAP70 (B) and Syk (B) expression in memory-like vs. control NK cells
assayed via intracellular flow cytometry. Histograms display representative data, bar graphs
display summary data from n = 7 normal donors, n ≥ 2 independent experiments. Grey = no
antibody staining, green = memory-like, blue = control. (C) Phosphorylation of SYK/ZAP70,
dim
ERK, and Akt following ligation of FcRIIIa in CD56
NK cells. Phosphorylation in
bright
CD56
NK cells (which express low to no FcRIIIa) is shown as a negative control.
Histograms display representative data, bar graphs display summary data from n = 5-7 normal
donors, n ≥ 3 independent experiments. Open dashed lines represent unstimulated
phosphorylation values, shaded lines represent stimulated values. Green = memory-like, blue =
control. Data were compared using t-tests.
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70) or distal (ERK, Akt) signaling molecule phosphorylation following FcRIIIa ligation in
memory-like vs. control NK cells (Fig 2.2C). Thus, in contrast to HCMV- adaptive NK cells, the
enhanced FcRIIIa-triggered IFN- and killing responses of memory-like NK cells do not appear
to be the result of differential intracellular signaling. Future studies will examine additional
mechanisms, including epigenetic differences between control and memory-like NK cells, to
explain the enhanced capacity for killing and IFN- production.

2.4 Discussion
We show here for the first time that cytokine-induced memory-like NK cells have enhanced IFN responses to FcRIIIa triggering, as well as enhanced ADCC in vitro. In addition, few reports
have examined the molecular mechanisms underlying cytokine-induced memory-like NK cell
differentiation and function. We decided to test the hypothesis that signaling downstream of
activating receptors, specifically FcRIIIa, was enhanced in memory-like NK cells. However, we
observed only modest differences in the expression levels of key intracellular proteins (CD3,
Syk) that signal downstream of FcRIIIa, and a comprehensive analysis of proximal and distal
phospho-signaling downstream of this receptor also revealed no differences between control and
memory-like NK cells. Thus, enhanced memory-like NK cell responses to ligation of FcRIIIa
likely arise from alternate mechanisms, not a difference in secondary signals. The enhanced
cytotoxicity, for instance, might be explained by the fact that memory-like NK cells possess higher
levels of cytotoxic proteins than controls.12 In addition, memory-like NK cells might possess
higher levels of IFNG mRNA transcript, or be more rapidly able to engage translational machinery,
though these hypotheses have yet to be tested. This is distinct from HCMV-induced adaptive NK
cells, which have a number of intracellular adapter alterations that impact FcRIIIa signaling like
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lower FcR and Syk expression.20 FcRIIIa associates with the ITAM-bearing adaptors FcR
and CD3, either together as heterodimers or separately as homodimers. Given that CD3 bears
more activating ITAM motifs than FcR this could underlie the enhanced responsiveness of
HCMV-adaptive NK cells to FcRIIIa stimulation.
These results suggest that memory-like NK cells will be effective responders to antibodyopsonized targets. Thus, therapeutic monoclonal antibodies or other approaches to activate via
FcRIIIa may represent a strategy to further enhance the anti-leukemic targeting and triggering of
memory-like NK cells. Such an approach could also provide the rationale to extend memory-like
NK cell therapy beyond AML, to other hematologic malignancies like non-Hodgkin’s lymphoma
and solid tumors with a known targetable antigen. While compelling, these in vitro results will
require further study using appropriate in vivo models in order to elucidate memory-like NK cell
response patterns in an adoptive immunotherapy setting.

2.5 Methods
Reagents
The following anti-human monoclonal antibodies (mAbs) were used: CD56(N901),
CD3(UCHT1), and CD45(J.33; all Beckman Coulter); CD16(3G8), IFN(B27), CD107a(H4A3),
Syk(4D10),

ZAP-70(1E7.2),

pZAP70(pY319)/pSYK(pY352),

pERK1/2(pT202/pY204),

pAkt(pS473; all BD); CD3z(6B10.2; eBioscience); CD107a(H4A3), goat anti-mouse
IgG(Poly4053; all Biolegend); FcR1 (Milli-Mark); and rituximab (Genentech). The following
endotoxin-free recombinant human (rh) cytokines were used: rhIL-12, rhIL-18 (Peprotech), rhIL15 (CellGenix and Miltenyi). The following cell lines were used: Raji (ATCC, CCL-86). Cells
were obtained from ATCC in 2008, viably cryopreserved and stored in LN2, thawed for use in
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these studies, and maintained for <2 months at a time in continuous culture as per ATCC
instructions. Raji cells were authenticated in 2015 by confirming cell growth morphology
(lymphoblast), short tandem repeat profile, growth characteristics, phenotype of uniform
expression of human CD20, and functionally as anti-CD20 mAb opsonized targets for ADCC.
NK cell culture
Healthy anonymous human PBMC were obtained by Ficoll centrifugation of cells from
leukoreduction filters following platelet apheresis with or without NK cell purification (RosetteSep
enrichment, StemCell Technologies, Vancouver, Canada).9 Purified NK cells were used in Figures
2.1C and 2.2C. PBMC and purified NK cells were pre-activated with rhIL-12 (10ng/mL), rhIL15 (50ng/mL), and rhIL-18 (50ng/mL) (to generate memory-like NK cells) or low-dose (1ng/mL)
rhIL-15 (to generate control NK cells) for 16 hours, then harvested, washed, and differentiated for
6 days with low-dose rhIL-15 support as described.9 Cells were cultured at 3-5x106/mL.
NK cell functional assays
Control, and memory-like NK cells were stimulated with plate-bound anti-FcRIIIa, or rituximabcoated Raji cells (E:T 5:1) for 6 hours with brefeldin A and monensin (BD Biosciences) added for
the final 5 hours. Cells were then surface stained for NK cell markers, fixed/permeabilized and
intracellularly stained for IFN- (Cytofix/Cytoperm; BD Biosciences).9 For degranulation assays,
anti-CD107a mAb was added at the start of the functional assay. During functional assays
involving memory-like and control NK cells, 0.5ng/mL rhIL-15 was included in the medium to
support NK cell survival.
NK cell signaling assays
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For phosphorylation assays, purified anti-FcRIIIa antibody was added at 10ug/mL to control or
memory-like NK cells and allowed to bind for 20 minutes at 4oC. Following a wash, purified antiIgG antibody was added at 20ug/mL and cells were briefly spun down then placed at 37C for 5
minutes. The reaction was stopped by fixation in 1.7% paraformaldehyde followed by
permeabilization in 100% methanol. Cells were stained overnight for NK cell surface markers and
phospho-signaling molecules. For signaling molecule expression levels, unstimulated control or
memory-like NK cells were surface stained for NK cell markers then fixed/permeabilized
(Fixation/Permeabilization Concentrate; eBioscience) and intracellularly stained for FcR, CD3,
Syk, and ZAP-70.
Flow-based killing assay (FLoKA)
Control or memory-like NK cells were incubated for 4 hours with carboxyfluorescein succinimidyl
ester (CFSE)-labelled Raji lymphoma targets or rituximab-coated CFSE-labeled Raji lymphoma
targets. After incubation, cells were stained with a 7-AAD viability dye and analyzed immediately
using flow cytometry. Percent specific killing was calculated as the percentage of dead (7-AAD
positive) target cells, minus background death (less than 5% in all cases).
Statistical analysis
Statistical comparisons (student paired t-test, with multiple comparison’s testing where
appropriate) were performed using GraphPad Prism 5 software (* = p<0.05, ** = p<0.01, *** =
p<0.001).
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3.1 Summary
NK cells are innate lymphocytes important for defense against infectious pathogens and cancer.
Classically, NK cell anti-tumor responses are attributed to the CD56dim subset, whereas the
CD56bright population is thought to function primarily in immunomodulation. Here, we challenge
this paradigm by demonstrating that brief priming with IL-15 markedly enhanced the ability of
CD56bright NK cells to respond to cancer. Priming improved multiple CD56bright NK cell functions:
degranulation, cytotoxicity, and cytokine production. Primed CD56bright NK cells from leukemia
patients demonstrated enhanced responses to autologous blasts in vitro, and primed CD56 bright NK
cells controlled K562-leukemia in vivo in a murine xenograft model. Multiple myeloma (MM)
patients’ primed CD56bright NK cells also had superior responses to autologous targets.
Furthermore, CD56bright NK cells from MM patients primed with the IL-15R agonist ALT-803 in
vivo displayed enhanced functional responses to MM targets. Effector mechanisms contributing
to IL-15-based priming included improved cytotoxic protein expression, target cell conjugation,
and LFA-1-, CD2-, and NKG2D-dependent activation. Finally, IL-15 more robustly stimulated the
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PI3K/Akt/mTOR and MEK/ERK pathways in CD56bright, compared to CD56dim NK cells, and
blockade of these pathways attenuated anti-tumor responses. These findings identify CD56bright
NK cells as potent anti-tumor effectors that warrant further investigation as a cancer
immunotherapy.

3.2 Introduction
NK cells are innate lymphoid cells important for host defense against infectious pathogens and
cancer.1 The NK cell response to a potential target relies on the integration of activating and
inhibitory receptor signals induced by interaction with the target cell,2,3 memory of prior
exposures,4 the cytokine milieu,5 and education during development.6 Human NK cells are
identified via surface expression of CD56 and lack of CD3, and can be categorized into two
developmentally-related, but functionally-distinct, subsets based on relative CD56 expression:
CD56bright and CD56dim. 1,7,8 The CD56dim subset comprises 80-95% of peripheral blood NK cells.
CD56dim NK cells represent the final stage of NK cell maturation (stage V), and as a result express
maturity-related inhibitory receptors (killer cell immunoglobulin-like receptors; KIR), cytotoxic
effector proteins (including perforin and Granzyme B) at rest, and high surface levels of CD16
(FcγRIIIa), permitting responses to antibody-opsonized targets. The less mature (stage IV)
CD56bright NK cells are a minor subset in the peripheral blood, but predominate in secondary
lymphoid tissues. Indeed, CD56bright NK cells are estimated to outnumber CD56dim NK cells
overall.9–11 CD56bright NK cells express lower levels of cytotoxic effector proteins at rest, partially
express CD16, rely on CD94/NKG2A receptors rather than KIR for self-tolerance, and possess
distinct chemokine and homing receptor repertoires compared to the CD56 dim subset. CD56bright
NK cells are potent cytokine producers (IFN-γ, TNF, GM-CSF) following combined cytokine
receptor stimulation,7,12,13 but unlike CD56dim NK cells, display minimal anti-tumor
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responsiveness at rest. As a result of these properties, CD56 bright NK cells are traditionally
considered

ineffective

anti-tumor

responders

that

instead

function

primarily

in

immunomodulation.
Studies from a number of laboratories have established the anti-tumor potential of NK cells, chiefly
in the setting of allogeneic hematopoietic cell transplantation (HCT)14 or adoptive NK cell
transfer,15,16 inspiring substantial interest in NK cell-based immunotherapy.17,18 In addition,
reports that donor KIR haplotype can influence allogeneic HCT outcomes provides correlative
evidence that NK cells mediate a graft versus leukemia effect in vivo.19–21 However, these studies
typically do not investigate which NK cell subset is responsible for mediating anti-tumor
responses, and functional analyses have focused on KIR+ NK cells, leaving the anti-tumor potential
of CD56bright NK cells relatively unexplored.
IL-15 is a central cytokine in NK cell development, homeostasis, and function.1,22 There are three
IL-15 receptor subunits: IL-15R, , and . The IL-15 receptor shares its  subunit with IL-2, and
its  subunit (common  chain) with IL-2, 4, 7, 9, 15, and 21. The IL-15R heterodimer is an
intermediate (nanomolar)-affinity IL-15 receptor constitutively expressed by both CD56bright and
CD56dim NK cells that functions in ligand binding and signal transduction. IL-15R binds IL-15
with high (picomolar) affinity. IL15/IL-15R can associate with IL-15R either on the same cell
(cis-presentation) or on a different cell (trans-presentation) to initiate signaling, although transpresentation is thought to be the major IL-15R trigger in vivo.22,23 Three primary pathways are
activated downstream of the IL-15 receptor: JAK1/3/STAT3/5, PI3K/Akt/mTOR, and
Ras/Raf/MEK/ERK.23,24 Through these pathways, IL-15 has been shown to promote the survival
and proliferation of CD56bright and CD56dim NK cells, and to enhance the cytotoxicity of the
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CD56dim subset.25 Prolonged exposure to IL-2, which also acts through the intermediate-affinity
IL-2/15Rβγ, has similarly been shown to increase NK cell cytotoxicity.25 However, IL-2 also
promotes regulatory T cell responses, and may thereby limit anti-tumor immunity.

26,27

Thus,

while IL-15 supports the survival and proliferation of CD56bright NK cells,22 its impact on the antitumor responses of this human NK cell subset has not been well-examined.
In a model organism, we and others have previously demonstrated that brief priming of murine
NK cells with IL-15 optimizes functional responses to tumor or virus-infected targets, including
cytokine production and killing.28,29 Since in some ways the CD56bright NK cell cytotoxic program
resembles that of specific pathogen-free murine NK cells,28 we reasoned that IL-15 may globally
enhance CD56bright NK cell anti-tumor responses. Here, we demonstrate that brief priming of
CD56bright NK cells with IL-15 results in markedly increased degranulation, cytotoxicity, and
effector cytokine production in response to tumor targets in vitro and in vivo. This priming effect
was seen for normal donor CD56bright NK cells, as well as CD56bright NK cells of patients with
hematologic malignancies triggered by autologous tumor cells. Several mechanisms were
identified that underlie the enhanced anti-tumor responsiveness of these polyfunctional IL-15primed CD56bright NK cells. Moreover, we link preferential induction of PI3K/Akt/mTOR and
MEK/ERK signaling by IL-15 in CD56bright, compared to CD56dim, NK cells with enhanced
function.

Blockade of these pathways attenuated IL-15 priming, identifying a molecular

mechanism responsible for this priming event. Our findings suggest that in clinical settings of
increased IL-15, CD56bright NK cells may exhibit potent multifunctional anti-tumor responses, and
that this NK cell subset could be harnessed for cancer immunotherapy.

3.3 Results
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IL-15 primes human CD56bright NK cells for enhanced anti-tumor responses
Purified NK cells from normal donors were cultured for 12-16 hours with (primed) or without
(control) recombinant human (rh) IL-15 at 5 ng/mL (a concentration that induces signaling via the
IL-2/15Rβγ).22 Cells were then washed and triggered with tumor targets for 6 hours, after which
degranulation (CD107a surface expression) and cytokine production (intracellular IFN-γ and TNF
expression) were assessed (Figure 3.1A). IL-15 priming robustly enhanced degranulation and
cytokine production by CD56bright NK cells in response to K562 acute myeloid leukemia (AML)
target cells (Figure 3.1B). Indeed, while IL-15 priming also modestly enhanced CD56dim NK cell
anti-tumor responses, these were surpassed by those of IL-15-primed CD56bright NK cells (Figure
1B). Similar responses to K562 target cells were observed with flow-sorted, control or IL-15primed CD56bright and CD56dim NK cells (Figure 3.1C), indicating that IL-15 priming of CD56bright
NK cell anti-tumor responses was not a result of competition for IL-15 or differential effector-totarget (E:T) ratios. IL-15 priming of CD56bright NK cells could be observed after as little as 1 hour
of stimulation (Figure 3.2A), and with IL−15 concentrations as low as 1 ng/mL (Figure 3.2B). In
addition, a large proportion of IL-15-primed CD56bright NK cells exhibited polyfunctional
responses, with simultaneous degranulation, IFN-γ, and TNF production in response to K562
target cells (Figure 3.3A, B). Enhanced responses of IL-15-primed CD56bright NK cells were also
confirmed against the MHC class I-expressing HL-60 AML cell line (Figure 3.3C).
Since IL-15 is critical for NK cell homeostasis as well as function, we also established that
CD56bright NK cell responses immediately following purification were equivalent to those after
overnight culture in media alone (control NK cells) from the same donor (data not shown).
Additionally, after 16 hours there was no difference in NK cell viability between control and
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(A) Purified NK cells from normal donors underwent short-term (12-16 hour) culture in media
alone (control) or media with 5ng/mL IL-15 (primed). Cells were then washed and triggered
with tumor targets. (B) Control or primed purified NK cells were incubated with K562 AML
target cells for 6 hours at a 5:1 E:T ratio. Bivariate flow cytometry plots from a representative
normal donor show surface CD107a as well as intracellular IFN- and TNF following tumor
target triggering. Summary data show mean ± SEM percentage of CD107a, IFN- and TNF
positive NK cells. N=14 normal donors, 7 independent experiments. (C) Flow-sorted, control
or primed CD56bright and CD56dim NK cells were triggered with K562 tumor targets for 6 hours
at a 5:1 E:T ratio. Summary data show mean ± SEM percentage of CD107a, IFN- and TNF
positive NK cells. N=9 normal donors, 6 independent experiments. Data were compared using
a one-way repeated measures ANOVA, with Bonferonni’s multiple comparisons testing of
indicated groups.
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Figure 3.3: IL-15 primes human CD56bright NK cells for broad and polyfunctional
responses to myeloid leukemia target cells.
Control (c) or IL-15-primed (p) purified NK cells were triggered with K562 tumor targets for
6 hours at a 5:1 E:T ratio and assessed for response polyfunctionality. (A) Representative flow
cytometry plots show IFN- and TNF expression in CD107a-positive control or primed
CD56bright NK cells following triggering with K562 target cells. (B) Summary data show mean
± SEM CD107a and/or IFN- and/or TNF percent positive control or primed CD56bright NK
cells. N=14 normal donors, 7 independent experiments. (C) Summary data show mean ± SEM
CD107a, IFN-, or TNF positive control or primed CD56bright and CD56dim NK cells triggered
with HL-60 AML targets. Data were compared using a one-way repeated measures ANOVA
with Bonferroni’s multiple comparisons testing of indicated groups.
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primed conditions. However, IL-15 priming selectively enhanced CD56bright NK cell survival in
the setting of cytokine withdrawal (Figure 3.4). Brief IL-15 priming was not sufficient to induce
substantial proliferation of CD56bright or CD56dim NK cells (Figure 3.5), suggesting that NK cell
proliferation pathways require prolonged IL-15R signals to promote cell division in CD56bright and
CD56dim NK cells.
IL-15 priming of CD56dim NK cells is in part maturity-dependent
While CD56dim NK cells are considered more differentiated than the CD56bright subset, they still
exist within a range of maturity states. NK cell maturity can be delineated by the presence or
absence of specific surface markers such as KIR, NKG2A, CD57, CDllb, and CD27.30,31 We
hypothesized that IL-15 priming of CD56dim NK cells produced variable responses because
immature NK cells were preferentially being primed. We tested this hypothesis using mass
cytometry, which permitted simultaneous analysis of >30 parameters on each NK cell (Table 3.1).
Using viSNE,32 we clustered control or IL-15-primed NK cells stimulated with K562 tumor targets
into CD56bright, CD56dim, immature CD56dim, and mature CD56dim subsets based on the expression
of maturity markers that were unaffected by priming (KIR, NKG2A, CD57) as well as CD56
(Figure 3.6A, B). Immature CD56dim NK cells had a NKG2A+KIR-CD57- profile, whereas
mature CD56dim NK cells were primarily NKG2A±KIR+CD57+. The proportions of control or
primed NK cells belonging to each CD56dim subset were similar (Figure 3.6A). Using mass
cytometry to assess functional responses against K562 tumor targets, we found that cytokine (IFN and TNF) production and degranulation by CD56bright NK cells were still significantly enhanced
by priming, however no significant differences were observed among CD56dim NK cells as a whole
(Figure 3.6C). Degranulation and IFN- production by immature CD56dim NK cells was
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Figure 3.4: IL-15 priming selectively enhances CD56bright NK cell survival under
cytokine-starved conditions.
Purified NK cells were incubated with media alone (control) or media with 5ng/mL IL-15
(primed) for 12-16h hours. Next, cytokines were washed away and cells were cultured in media
alone for 3 or 5 additional days. After 3 or 5 days, cells were harvested and stained for NK cell
surface markers as well as Annexin V and activated caspase 3/7 expression (indicating
apoptosis). Non-apoptotic cells were Annexin V negative/activated caspase negative. The
CD56bright/CD56dim NK cell ratio (B/D) of non-apoptotic NK cells was calculated at the time
of purification, as well as at Day 3 or 5 of culture without cytokines. At the time of purification,
cells were determined to be >97% viable via AO/PI staining. (A) Flow cytometric plots from
a representative donor show CD56bright and CD56dim non-apoptotic control or primed NK cell
percentages and ratio (B/D) at baseline or after 3 or 5 days of culture without cytokines. (B)
Summary data show CD56bright/CD56dim ratio of control or IL-15-primed NK cells after 3 or 5
days of culture without cytokines, normalized to the ratio at baseline. N = 6 normal donors, 2
independent experiments. Data were compared using a 2-way repeated measures ANOVA,
with Bonferroni’s multiple comparisons testing.
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Figure 3.5: IL-15 priming does not result in robust CD56bright or CD56dim NK cell
proliferation.
Purified, CFSE-labeled (A) or unlabeled NK cells (B) were incubated with 5ng/mL IL-15
(primed) or media alone (control) for 12-16h. Next, cytokines were washed away and cells were
incubated in media alone for several days. Proliferation was assessed 3 and 5 days following
cytokine wash-out via flow cytometric analysis of CFSE dilution (A) or intracellular Ki67
staining (B). (A) Representative flow histograms of CFSE dilution at Day 3 or 5 in control or
primed NK cells. Summary data show percent of control or primed CD56bright and CD56dim NK
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2 independent experiments. (C, D) A subset of donors were used to confirm that continuous
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measures ANOVA with Bonferroni’s multiple comparisons testing of indicated groups (A, B)
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Table 3.1: NK cell mass cytometry panel design, reagents, and clustering usage.
The metal isotope tag, maker name, antibody clone, source, and clustering usage is shown for
a panel designed to deeply phenotype human NK cells. Clustering demarcates which channels
were used for analysis in the indicated figure except KIR3DL1 (*) which was not used for
donors 6-8.
Functional Panel
Tag

Antibody

Clone

Source

89 Y

CD45

HI30

DVS Sciences

141 Pr

CD14

M5E2

BD Pharmingen

142 Nd

CD19

HIB19

DVS Sciences

143 Nd

KIR3DS1/L1 (CD158e1, e2)

Z27

R&D

Clustering

Figure 3A,B

144 Nd

CD3

UCHT1

DVS Sciences

145 Nd

KIR2DS4 (CD158i)

FES172

Beckman Coulter

Figure 3A, B

146 Nd

KIR2DL1/DS1 (CD158a,h)

EB6B

Beckman Coulter

Figure 3A, B

147 Sm

NKG2D

1D11

R&D

148 Nd

KIR2DL2/2DL3 (CD158b)

CH-L

BD Pharmingen

149 Sm

MIP-1a

93342

R&D

151 Eu

CD107a

H4A3

DVS Sciences

152 Dy

TNF

Mab11

DVS Sciences

153 Eu

CD62L

DREG-56

DVS Sciences

154 Sm

KIR2DL5 (CD158f)

UP-R1

Beckman Coulter

155 Gd

CD27

L128

DVS Sciences

156 Gd

KIR3DL1 (CD158e)

DX9

R&D

158 Gd

CD137

4B4-1

DVS Sciences

159 Tb

NKG2C

134591

R&D

160 Gd

CD69

FN50

Biolegend

161 Dy

NKp30

P30-15

Biolegend

163 Er

CD94

DX22

Biolegend

165 Ho

CD16

3G8

DVS Sciences

166 Er

NKG2A

Z199

Beckman Coulter

167 Dy

NKp44

P44-8

Biolegend

168 Er

IFN-g

B27

DVS Sciences

169 Tm

CD25

2A3

DVS Sciences

170 Er

NKp80

239127

R&D

171 Yb

Granzyme B

GB11

DVS Sciences

172 Yb

CD57

HCD57

DVS Sciences

174 Yb

NKp46

557911

R&D

175 Lu

Perforin

B-D48

DVS Sciences

176 Yb

CD56

NCAM16.2

DVS Sciences

CD11b

ICRF44

209 Bi

DVS Sciences

Cisplatinum

Enzo Life Sciences

Cell-ID intercalator-Ir

Fluidigm
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Figure 3.6: Responses of IL-15-primed CD56dim NK cells were influenced by
maturity status.
Control and primed NK cells were assessed for the expression of 33 markers after stimulation
with K562 tumor targets using mass cytometry. (A) Density plots from a representative donor
in the tSNE1/2 fields of control vs. primed CD56bright (B), immature CD56dim (Imm), or mature
CD56dim (Mat) NK cells. Percentages of NK cells belonging to the different groups are
indicated in parentheses. Cell maturity state was determined according to expression of CD56,
NKG2A, KIR, and CD57. Immature CD56dim NK cells were primarily NKG2A+KIR-CD57whereas mature CD56dim NK cells were NKG2A±KIR+CD57+. (B) Median expression of the
indicated markers (CD56, NKG2A, KIR2DL2/3, CD57) is shown for the same representative
donor, demonstrating that maturity marker expression is unchanged by priming. (C) Summary
data show mean ± SEM percentage of CD107a, IFN- and TNF positive control or primed
CD56bright, CD56dim (immature + mature), immature CD56dim, and mature CD56dim NK cells
from n=8 normal donors, 3 independent experiments. (D) Summary data show mean ± SEM
fold change of primed relative to control percentage CD107a, IFN- and TNF positive
CD56bright, CD56dim (immature + mature), immature CD56dim, and mature CD56dim NK cells
from n=8 normal donors, 3 independent experiments. Data were compared using a one-way
repeated measures ANOVA with (C) Bonferroni’s multiple comparisons testing of indicated
groups or (D) Tukey’s multiple comparisons testing.
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significantly enhanced by IL-15 priming, but this increase was not seen in the mature CD56 dim
subset (Figure 3.6C). We also compared the fold increase in primed (relative to control) NK cell
subsets positive for CD107a, IFN-, or TNF upon K562 stimulation (Figure 3.6D). For all three
functional markers, the fold increase was significantly higher for CD56 bright than CD56dim NK
cells, regardless of maturity status. Thus, IL-15 appears to preferentially prime immature CD56dim
NK cells for enhanced degranulation and IFN- production in response to K562 leukemia targets,
but the magnitude of priming was less than for CD56 bright NK cells.
IL-15-primed CD56bright NK cells display increased cytotoxic effector protein levels and
enhanced cytotoxicity against tumor target cells
Since IL-15 priming markedly enhanced CD56bright NK cell degranulation in response to tumor
targets, we next evaluated cytotoxic protein expression and cytotoxicity. The perforin/granzyme
(granule exocytosis) pathway is a major mechanism used by NK cells to kill targets.1,33 At rest,
CD56bright NK cells express minimal perforin and Granzyme B protein, and thus have low
cytotoxic potential.7,34 IL-15 priming significantly increased Granzyme B and perforin protein
levels in CD56bright NK cells (Figure 3.7A). To directly assess the ability of IL-15 to augment
cytotoxic function, flow-sorted CD56bright and CD56dim NK cells were primed with IL-15 for 1216 hours, and then assessed for cytotoxicity against K562 leukemia targets. IL-15 priming led to
a substantial increase in the cytotoxicity of CD56bright NK cells at all effector:target (E:T) ratios
examined, but had a more modest impact on CD56dim NK cell killing of K562 leukemia targets.
(Figure 3.7B, C). We also assessed expression of alternate mediators of NK cell target killing,
such as the death receptor ligands TRAIL and Fas ligand. We observed a marked increase in
TRAIL following IL-15 priming of CD56bright NK cells (Figure 3.7A), but did not detect cell
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Figure 3.7: IL-15-primed CD56bright NK cells have enhanced cytotoxicity.
(A) Control or primed purified NK cells were assessed for expression of intracellular
Granzyme B and perforin and cell surface TRAIL using flow cytometry. Representative
histograms gated on CD56bright NK cells show per cell protein expression, with grey histograms
depicting unstained cells. Summary data show mean ± SEM Granzyme B and perforin MFI, or
TRAIL percent positive CD56bright NK cells. N=4-6 normal donors, 2-3 independent
experiments. (B, C) Control or primed flow-sorted CD56bright and CD56dim NK cells were
assessed for cytotoxicity against K562 leukemia cells in a 4 hour flow-based killing assay. (B)
Summary data show mean ± SEM percent specific killing by control or primed NK cell subsets
at the indicated E:T ratios. (C) Summary data show mean ± SEM specific killing at the 2.5:1
E:T ratio. N=4 normal donors, 2 independent experiments. (D) Representative confocal z-stack
images show CD107a (LAMP1) and Granzyme B (Gzm B) in flow-sorted, control or IL-15primed CD56bright NK cells. Representative images were contrast-enhanced for better
visualization. Scale bar represents 5mM. (E) Summary data show mean ± SEM LAMP1 and
Granzyme B single cell mean pixel intensity x area, quantified from focal planes in the middle
of cells (control N= 20-32, primed N =25-37) from 5 normal donors. Data were compared using
(A, E) a paired student’s t-test or (B, C) a one-way repeated measures ANOVA, with
Bonferonni’s multiple comparisons testing of indicated groups.
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surface Fas ligand (not shown). The induced TRAIL is functional and contributes to IL-15-primed
CD56bright NK cell cytotoxicity since killing of TRAIL-sensitive target cells (HL-60 AML and
RPMI 8226 myeloma) was partially abrogated in the presence of TRAIL-neutralizing antibodies
(Figure 3.8).35,36 However, for relatively TRAIL-insensitive tumor targets such as U266
myeloma,35 TRAIL blockade did not substantially impact killing by IL-15-primed CD56bright NK
cells (Figure 3.8).
To further define changes in CD56bright NK cells that may impact cytotoxicity, the granular area
and Granzyme B content of IL-15-primed CD56bright NK cells was assessed by
immunofluorescence. At rest, CD56bright NK cells are small lymphocytes that have few cytotoxic
granules. IL-15 priming of CD56bright NK cells led to markedly increased CD107a (LAMP1) and
Granzyme B mean pixel intensity as assessed by confocal immunofluorescence microscopy
(Figure 3.7D, E). This enhanced granularity of primed CD56bright NK cells was also evident as an
increase in morphologic cytoplasmic azurophilic granule content (Figure 3.9A) and side scatter
(Figure 3.9B), neither of which were changed in CD56dim NK cells. Thus, IL-15-primed CD56bright
NK cells exhibit marked enhancement of multiple anti-tumor responses, including cytotoxic
capacity and killing in vitro.
IL-15 priming promotes CD56bright NK cell conjugate formation with tumor targets
The NK cell cytotoxic response to tumor targets involves several events, including cell recognition,
conjugate formation, immune synapse formation, and directed delivery of cytotoxic granule
contents

33.

We evaluated the effect of IL-15 priming on the efficiency of tumor conjugate

formation by co-incubating control and primed NK cells with carboxyfluorescein succinimidyl
ester (CFSE)-labeled K562 cells for 5, 15, or 30 minutes (Figure 3.10A). A significantly greater
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Figure 3.8: TRAIL contributes to IL-15-primed CD56bright NK cell killing of
TRAIL-sensitive targets.
Flow-sorted, IL-15-primed CD56bright NK cells were triggered at a 5:1 E:T ratio with tumor
target cell lines of differing TRAIL sensitivity in a 18 hour flow-based killing assay. Summary
data shows mean ± SEM percent specific killing by CD56bright NK cells in the presence of a
TRAIL-neutralizing antibody or a isotype control antibody. N=4 normal donors, 2 independent
experiments. Data were compared using a paired student’s t-test.
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Figure 3.9: IL-15 priming enhances CD56bright NK cell granularity.
(A) Flow-sorted, control or primed CD56bright and CD56dim NK cells were Wright/Giemsa
stained then evaluated with a light microscope (1000x). Representative cells are shown,
demonstrating increased granularity of IL-15-primed CD56bright NK cells. (B) Summary data
show mean ± SEM side scatter (indicating cellular complexity/granularity) of control or primed
CD56bright and CD56dim NK cells. N = 10 normal donors, 5 independent experiments. Data were
compared using a paired student’s t-test.
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Figure 3.10: IL-15-primed CD56bright NK cells more effectively formed
conjugates with K562 leukemia targets.
Control or primed purified NK cells were assessed for conjugate formation via co-incubation
with CFSE-labeled K562 cells for 5, 15, or 30 minutes at a 1:1 E:T ratio. The NK/K562
conjugate percentage was assessed by the frequency of CD56bright NK cell events that were also
CFSE positive. (A) Representative bivariate flow plots show conjugate formation by control or
primed NK cells at the 15 minute time point by gating on 1) all live NK and K562 cells, 2) NK
cells (CD56+CD3-), 3) CD56bright NK cells 4) CFSE positive cells. (B) Summary data show
mean ± SEM percentage of control or primed CD56bright NK cells that formed NK/K562
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experiments. Data were compared using a paired student’s t-test.

70

percentage of IL-15-primed CD56bright NK cells formed conjugates with tumor targets at each time
point investigated compared to controls (Figure 3.10B). In contrast, there was no significant
difference in the number of tumor conjugates formed by control vs. IL-15-primed CD56dim NK
cells at 5 minutes (28.9±5.7% vs. 31.6±4.6%, P=0.053), 15 minutes (34.9±8.8% vs. 28.9±5.5%,
P=0.17) or 30 minutes (41.6±9.4% vs. 36.8%±9.2%, P=0.16) from the same donors. Thus, one
mechanism underlying the enhanced anti-tumor response of IL-15-primed CD56bright NK cells
involves more effective target recognition or target-cell synapse formation. Therefore, we next
examined expression of adhesion molecules and NK cell receptors involved in tumor target
recognition with or without IL-15 priming.
IL-15-primed CD56bright NK cells express more activating receptors and adhesion molecules than
control cells
NK cells integrate adhesion molecule, activating and inhibitory receptor, and co-stimulatory
signals, amongst others, to define their functional responses to target cells 3. We evaluated the
surface expression of numerous such signaling molecules by flow cytometry. Expression of the
following proteins (percentage positive or median fluorescent intensity [MFI]) did not differ
between control and IL-15-primed CD56bright NK cells: CD226 (DNAM-1), CD244 (2B4),
NKp80, CD94, NKG2A, NKG2C, and CD137 (41BB) (data not shown). In addition, we
confirmed no change in KIR (CD158a, CD158b1/2, CD158d, CD158e1/2 and CD158i) or CD57
expression on CD56bright NK cells following IL-15 priming.

However, we did observe

significantly increased expression of NKG2D, NKp30, NKp44, CD69, CD2 and CD11a (Figures
3.11A, 3.12) on IL-15-primed, compared to control, CD56bright NK cells, in agreement with prior
reports.37,38 Due to their role in promoting anti-tumor responses by NK cells, NKG2D, NKp44,
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Figure 3.11: IL-15-primed CD56
NK cells displayed increased expression of
co-activating and adhesion molecules as well as enhanced integrin signaling upon
tumor target engagement.
(A) Representative histograms of control or primed CD56bright NK cell CD2, CD11a, and
NKG2D surface expression (grey histograms = unstained). Summary data show mean ± SEM
CD2, CD11a, and NKG2D MFI. N=4-9 normal donors, 2-4 independent experiments. (B) IL15-primed purified NK cells were pre-incubated with isotype control or blocking anti-human
mAbs against CD11a, CD2, and/or NKG2D for 30min prior to incubation with K562 targets
for 6h (5:1 E:T ratio). Control NK responses were assessed without blocking mAbs. Summary
data show mean ± SEM percent CD107a, IFN-, and TNF+ CD56bright NK cells. N=4-6 normal
donors, 2-3 independent experiments. (C) Control or primed purified NK cells were assessed
for the expression of open conformation CD11a (mAb 24) or intracellular phosphorylated ERK
(pT202/pY204) following 15 or 3 minutes (respectively) of co-incubation with K562 targets
(grey), or in the absence of targets (baseline). Representative histogram plots show per cell
open CD11a or pERK on CD56bright NK cells. Summary data show mean ± SEM percent of
control or primed CD56bright NK cells expressing open CD11a or pERKhi (positivity cutoff set
on baseline control cells). Data were compared using (A) a paired student’s t-test, (B) a oneway ANOVA with Bonferroni’s multiple comparisons testing of indicated groups, or (C) a oneway repeated measure’s ANOVA with Tukey’s multiple comparisons testing.
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NKp30, CD2, and CD11a were thus evaluated for their contribution to IL-15-primed CD56bright
NK cell responses to tumor targets. We pre-incubated IL-15-primed NK cells with blocking mAbs
to these receptors for 30 minutes, and then triggered with K562 cells. No difference in CD56 bright
NK cell degranulation or cytokine production upon NKp44 or NKp30 blockade was observed (data
not shown). A small reduction in the priming response was observed when CD11a, CD2 or
NKG2D were blocked individually. However, priming was significantly diminished upon
simultaneous blockade of these 3 receptors (Figure 3.11B), indicating that they are collectively
involved in the enhanced anti-tumor responsiveness of IL-15-primed CD56bright NK cells.
IL-15 priming promotes integrin activation on CD56 bright NK cells
CD11a and CD18 (2) together comprise the integrin LFA-1. LFA-1 is critical for NK cell
cytotoxicity; upon binding its ligands (the intercellular adhesion molecules [ICAMs]), LFA-1
initiates immune synapse formation and tight adhesion to target cells, and provides NK cellactivating signals.33,39,40 Integrins typically exist in a bent conformation with low ligand-binding
affinity. However, signals from activating receptors promote integrin activation via inside-out
signaling, leading to high-affinity conformation changes and integrin clustering.41 NKG2D and
CD2, amongst other molecules, can activate LFA-1 on NK cells.39 Thus, in addition to measuring
overall LFA-1 (CD11a) expression, we also investigated the proportion of control or IL-15-primed
CD56bright NK cells that expressed open-conformation LFA-1 at rest or following K562 target cell
engagement. Incubation with IL-15 alone has been shown to only modestly activate LFA-1 on
bulk NK cells, however it enhances subsequent inside-out signaling following activating receptor
ligation.42 Consistent with this, we observed a modest but significant increase in activated LFA-1
expression on CD56bright NK cells as a result of IL-15 priming alone (Figure 3.11C). However,
the majority of IL-15-primed CD56bright NK cells expressed high-affinity LFA-1 after 15 minutes
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of incubation with K562 target cells, whereas K562 co-incubation induced high-affinity LFA-1 on
only a small subset of control CD56bright NK cells (Figure 3.11C). Signaling through LFA-1 has
been shown to activate ERK1/243 (outside-in signaling), and enhanced ERK1/2 phosphorylation
was observed in IL-15-primed CD56bright NK cells trigged with K562 targets compared to control
cells (Figure 3.11C). Thus, IL-15 priming promotes integrin activation on CD56bright NK cells,
potentially allowing adhesion to target cells in the absence of signals from other activating
receptors,39 and also enhances subsequent target-induced inside-out and outside-in signaling.
IL-15 primes CD56bright NK cells from normal donors and AML patients for enhanced responses
against primary AML blasts
We next examined whether IL-15 priming enhanced CD56bright NK cell responses again primary
leukemic blasts. Patient leukemia blast killing by flow-sorted, control or IL-15-primed CD56bright
and CD56dim NK cells from allogeneic normal donors was examined (Figure 3.13A, Table 3.2).
IL-15 priming resulted in a significant increase in AML blast killing by CD56 bright, as well as
CD56dim, NK cells (Figure 3.13A). In addition, since IL-15 is currently being tested in clinical
trials for cancer therapy,44,45 we investigated whether IL-15 could prime the endogenous CD56bright
NK cells of patients with AML. Control or IL-15-primed peripheral blood mononuclear cells
(PBMC) from newly-diagnosed AML patients were triggered with autologous AML blasts (Figure
3.13B) or K562 leukemia targets (Figure 3.14A) and assessed NK cell functional responses.
Indeed, we observed significant enhancement of patient CD56bright NK cell anti-tumor responses
against both target cell types following IL-15 priming, with modest enhancement of CD56dim NK
cell responses.
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Figure 3.13: IL-15 priming enhanced CD56bright NK cell anti-tumor responses
against primary AML blasts in vitro and K562 leukemia in vivo in NSG mice.
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(A) Flow-sorted control or IL-15-primed CD56bright and CD56dim NK cells were incubated with
primary AML blasts from newly-diagnosed patients in a 4h FLoKA. Summary data show
mean ± SEM percent specific killing (15:1 E:T ratio). N=7 normal donors, 4 independent
experiments. (B) Control or IL-15-primed PBMC from newly-diagnosed AML patients were
incubated with autologous BM blasts (5:1 E:T ratio) for 6h. Summary data show mean ± SEM
percent CD107a, IFN- and TNF+ NK cells. N = 7 normal donors, 3 independent experiments.
(C) On Day -1, CD56bright NK cells were flow-sorted and primed with 17.5ng/mL ALT-803.
On Day 0, NK cells were injected into NSG mice. 8 mice received 0.5-0.66x106 K562-luc
(K562 + ALT-803) and 8 received 0.5-0.66x106 K562-luc + an equal number of primed
CD56bright NK cells (K562 + Primed CD56bright NK). All mice received 5mg ALT-803 i.v. ever
2-3 days for 30 days. BLI imaging was performed on Days 2, 5, 13, 20, and 27, ± 1 day. (D)
Representative BLI images from 1 K562 + ALT-803 mouse, and 1 K562 + Primed CD56bright
NK mouse. (E) Summary data of whole body bioluminescence (photons/sec) in the different
treatment groups. N=8 mice per group, 2 independent experiments. Data were compared using
(A, B) a one-way repeated measures ANOVA with Bonferroni’s multiple comparison’s testing
of indicated groups or (E) a two-way ANOVA with Sidak’s multiple comparisons testing.
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Table 3.2: AML patient characteristics for figures where primary AML blasts
were utilized.
AML blasts from newly-diagnosed patients were used as targets (Figure 3.13A, B) and/or
AML patient PBMC were used in functional assays as effector cells (Figures 3.13B, 3.14).
APL = Acute Promyelocytic Leukemia, RARA = Retinoic Acid Receptor Alpha, FLT3 = FMSLike Tyrosine Kinase 3, ITD = Internal Tandem Duplication, NPM1 = nucleophosmin 1. ND
= Not Done. NA = Not Applicable. For FLT3, the mutation is listed if positive. For
immunophenotype, if a subset of blasts expressed the marker, partial expression is indicated
(p). If FISH was performed, the relevant positive findings are listed, or Negative if none of (5q,
7q, +8, PML-RARA, CBFB, ETO/AML) were identified. The fraction of blasts expressing
HLA-E or HLA-A/B/C is indicated.
Age WBC Blast Lymph NK
(y) (k/mL)
%
%
%

WHO

Cyto / FISH

Im m unophenotype

FLT3 /
NPM1

Figure

HLA-E
%+

HLAFigure
A/B/C
Sym bol
%+

40

2.2

<1%

78

19

APL

t(15:17) /
PML-RARA

CD3433+117+13+HLA-DR19-56-

No/No

S Fig 7A

NA

NA

60

1.1

<1%

37

11

APL

t(15:17) /
PML-RARA

CD3433+117+13+HLA-DR19p+56-

No/No

S Fig 7A

NA

NA

76

48.7

98

NA

NA AML M1 Normal / Neg CD34-33-117+13-1956+

ND/ND

Fig 6A

4

37

NA

47

65.8

70

15

NA

CD34-33+117+13HLA-DR+19-56p+

D835/No

Fig 6A

94

100

NA

71

60

NA

NA

NA AML M2

CD34+33+117+13+HL
A-DR+19-56-

No/Yes

Fig 6A

78

99

NA

47

49.8

45

13

NA AML M2 Normal / Neg

CD3433+117+13+HLADR+19-56-

D835/Yes

Fig 6A

39

92

NA

77

3.2

13

40

13 AML M6

del20(q11.2) / CD34+33+117+13+HL
ND
A-DR+19+56+

ND/ND

Fig 6B

49

91

69

6.1

22

73

2

AML M0

CD34+33117+13+HLA-DR+1956-

ND/ND

S Fig 7A,
Fig 6B

42

84

65

19.6

3

22

3

AML M4 Normal / Neg

CD3433+117+13+HLA-

ITD/Yes

S Fig 7A,
Fig 6B

67

99

62

3.3

4

30

9

AML M2

No/No

S Fig 7A,
Fig 6B

50

88

60

6.7

30

49

4

AML 5A

No/ND

S Fig 7A,
Fig 6B

41

100

49

12.6

6

38

10

AML
MDS

Trisomy 11 / CD34+33+117+13+HL
ND
A-DR+19-56-

No/ND

S Fig 7A,
Fig 6B

88

96

69

8.6

<1%

15

10

AML
M5b

Comlex / HD CD34-33-117-13+HLADR+19-56+

No/No

Fig 6B

93

99

AML
t(9;11)

t(9;11) /
11q23 abnl,
+8
ND / Neg

Trisomy 9 /
Neg

del9(q13a22) CD34+33+117+13+HL
/ ND
A-DR+19-56Complex /
11q23 abnl

CD34-33+117+13HLA-DR-19-56-
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Figure 3.14: IL-15 primes CD56bright NK cells of patients with hematologic
malignancies for enhanced functional responses to tumor cell lines .
(A) Control (c) or IL-15-primed (p) PBMC from newly diagnosed, untreated AML patients
were triggered with K562 leukemia targets for 6 hours at a 5:1 E:T ratio. Bivariate flow plots
show the percentage of control or primed CD56bright or CD56dim NK cells from a representative
AML patient positive for CD107a, IFN-, or TNF. Summary data show mean ± SEM
percentage CD107a, IFN-, or TNF positive NK cells. N=7 patients, 5 independent
experiments. (B) Control or IL-15-primed PBMC from newly-diagnosed, untreated multiple
myeloma patients were triggered with U266 myeloma targets for 6 hours at a 5:1 E:T ratio.
Summary data show mean ± SEM percentage CD107a, IFN-, or TNF positive NK cells. N=4
multiple myeloma patients, 4 independent experiments. Data were compared using a one-way
repeated measures ANOVA with Bonferroni’s multiple comparisons testing of indicated
groups.
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Next, the ability of IL-15-primed CD56bright NK cells to control leukemia in vivo was investigated
by engrafting groups of NOD-SCID-IL2R-/- (NSG) mice with either equal numbers of luciferaseexpressing K562 cells (K562-luc) cells and ALT-803-primed CD56bright NK cells, or K562-luc
cells alone, via intravenous injection. ALT-803 is an IL-15 superagonist complex exhibiting better
pharmacodynamics and pharmacokinetic properties than recombinant IL-15.46 ALT-803 is
currently in clinical trials for cancer immunotherapy.47,48 Both groups of mice received ALT-803
after cell engraftment (Figure 3.13C). We observed significantly lower tumor burden as assessed
by whole-body bioluminescence imaging (BLI) in mice treated with ALT-803-primed CD56bright
NK cells (Figure 3.13D, E), demonstrating in vivo control of tumor cell growth by adoptively
transferred, primed CD56bright NK cells.
In vitro IL-15-primed CD56bright NK cells show enhanced functional responses against multiple
myeloma (MM)
To investigate whether the enhanced anti-tumor responses conferred by IL-15 priming extended
beyond myeloid leukemia, we assessed responses of CD56 bright NK cells against MM targets.
Enhanced degranulation and cytokine production by IL-15-primed, compared to control,
CD56bright NK cells from normal donors against U266 MM cells was observed. (Figure 3.15A).
We next tested whether IL-15 was able to prime newly-diagnosed MM patient CD56bright NK cells
for enhanced responses against autologous CD138+ MM cells (Figure 3.15B, Table 3.3) or U266
MM targets (Figure 3.14B). Indeed, degranulation and cytokine production were significantly
increased compared to control CD56bright NK cells. Thus, in vitro responses against MM targets
by allogeneic and autologous CD56bright NK cells were significantly improved after IL-15 priming.
ALT-803 primes CD56bright NK cell anti-tumor responses in vivo in MM patients
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Figure 3.15: Multiple myeloma patient CD56bright NK cells are primed in vitro
by IL-15 and in vivo by ALT-803 for enhanced functional responses against
autologous myeloma cells and multiple myeloma cell lines.
(A) Control or IL-15-primed normal donor NK cells were incubated with U266 MM target
cells for 6h (5:1 E:T ratio). Summary data show mean ± SEM percent CD107a, IFN-, or TNF
positive NK cells. (B) PBMC and enriched CD138+ cells were obtained from newly-diagnosed
MM patients. Control or IL-15-primed PBMC were cultured with autologous CD138+ cells
(5:1 E:T ratio) for 6h. Summary data show mean ± SEM percentage of CD107a, IFN- and
TNF positive CD56bright or CD56dim NK cells in response to autologous MM triggering. (C)
Schematic of ALT-803 treatment regimen. Patients with rel/ref MM received 10 mg/kg ALT803 sub-q (Group A) or 3-6 mg/kg i.v. (Group B) at 0h. Peripheral blood samples were obtained
for functional analysis just prior to ALT-803 administration as well as 24h and 72h after. (D)
PBMC were isolated from multiple myeloma patient blood samples by ficoll density
centrifugation and immediately incubated with U266 myeloma targets (Group A) or K562
leukemia targets (Group B) for 6 hours. Summary data show mean ± SEM percent CD107a,
IFN- and TNF positive CD56bright NK cells. N=2 patients, 3 independent experiments (Group
A), N=3 patients, 3 independent experiments (Group B). Data were compared using one-way
repeated measures ANOVA with (A, B) Bonferroni’s multiple comparison’s testing of
indicated groups or (D, E) Tukey’s multiple comparisons testing.
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Table 3.3: In vitro multiple myeloma patient characteristics.
ASCT = autologous stem cell transplant, RVD = Revlimid, Velcade, Dexamethasone. ND, not
done.
UPN

Age
(years)

Gender

Status at
Collection

Number of Prior
Therapies

Most Recent Prior
Therapy

CD138+ HLA-E
Percent Positive

33718

67

Female

New
Diagnosis

None

None

78%

67015

86

Male

New
Diagnosis

None

None

90%

76440

74

Male

New
Diagnosis

None

None

94%

14955

84

Female

New
Diagnosis

None

None

88%

87716
(CD138+)

66

Female

New
Diagnosis

None

None

90%

87716
(PBMC)

67

Female

100 Days
Post-ASCT

1

4 cycles RVD –
Melphalan ASCT

ND
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Figure
Symbol

NA

In addition, we investigated whether IL-15 can prime NK cells in vivo utilizing PBMC from
relapsed or refractory (rel/ref) MM patients being treated with ALT-803 (NCT02099539). First,
we verified that ALT-803 primed normal donor CD56bright NK cell anti-tumor responses in vitro,
similar to IL-15 (Figure 3.16). We collected PBMC from rel/ref MM patients just prior to, 24
hours after, or 72 hours after a single injection of ALT-803, and immediately assessed NK cell
function in response to ex vivo stimulation with U266 myeloma target cells (Patient Group A) or
the traditional NK-sensitive K562 tumor target (Patient Group B) (Figure 3.15C, Table 3.4).
Twenty-four hours after ALT-803 administration, patient CD56bright NK cell degranulation and
cytokine production in response to MM and leukemia target cells were significantly increased
compared to pre-therapy values (Figure 3.15D). However, this priming effect was relatively
transitory in vivo, and responses no longer differed significantly from those observed pre-therapy
by 72 hours post-ALT-803. Thus, IL-15 primed CD56bright NK cells both in vitro and in vivo for
enhanced functional responses against MM target cells.
IL-15 more robustly activates the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK pathways in CD56bright
NK cells
Having identified elements responsible for the enhanced anti-tumor responsiveness of primed
CD56bright NK cells, we next examined signaling mechanisms that could be responsible for priming
of the CD56bright subset by IL-15. In mice, IL-15-induced activation of the PI3K/Akt/mTOR
pathway is of particular importance for promoting NK cell cytotoxicity,49,50 and mTOR activity
downstream of the IL-15R has been shown to increase Granzyme B expression in both murine and
human NK cells.50 We confirmed that CD56bright and CD56dim NK cells both robustly express the
IL-15R (Figure 3.17B). Next, the role that each pathway (JAK/STAT, PI3K/Akt/mTOR, and
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Figure 3.16: ALT-803 primes CD56bright NK cells for enhanced anti-tumor
responses in vitro.
Purified normal donor NK cells were cultured in media alone (control; con), media with
5ng/mL rhIL-15, or media with 17.5ng/mL (equimolar to 5ng/mL rhIL-15) ALT-803 for 12-16
hours. Cells were then washed and co-incubated with K562 tumor targets at a 5:1 E:T ratio and
functional responses assessed. Summary data show mean ± SEM percentage CD107a, IFN-,
or TNF positive CD56bright or CD56dim NK cells. N=4 normal donors, 2 independent
experiments. Data were compared using a one-way repeated measures ANOVA with Tukey’s
multiple comparisons testing
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Table 3.4: In vivo multiple myeloma patient characteristics.
Subject
ID

Age
(years)

Gender

Number of
Prior
Therapies

Response to Last
Prior Therapy

ALT-803 Dose

Patient
Group

027006

53

Male

7

Refractory

10mcg/kg SQ

A

027007

80

Male

2

Refractory

10mcg/kg SQ

A

027002

55

Male

4

Refractory

3 mcg/kg IV

B

027003

57

Male

4

Relapsed

3 mcg/kg IV

B

027004

70

Female

3

Refractory

6 mcg/kg IV

B
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Figure 3.17: IL-15 more robustly activates the PI3K/Akt/mTOR and
Ras/Raf/MEK/ERK pathways in CD56bright NK cells.
(A) Flow cytometry plot shows gating strategy for CD56 bright vs. CD56dim NK cells based on
relative CD56 and CD16 expression. (B) IL-15R expression was assessed via flow cytometry
on purified NK cells. Representative data show percent IL-15R positive cells and IL-15R
MFI on freshly purified CD56bright and CD56dim NK cells. N=8 normal donors, 3 independent
experiments. (C) Summary data show pAkt and pERK MFI in unstimulated CD56 bright and
CD56dim NK cells. N=7 normal donors, 3 independent experiments. (D-F) Purified NK cells
were incubated with 5ng/mL IL-15 for 30 minutes (pSTAT5) or 2 hours (pAkt and pERK) then
assessed for signaling molecule phosphorylation. Representative histograms show per cell
expression of (D) pSTAT5, (E) pAkt, and (F) pERK in IL-15-stimulated (shaded grey) vs.
unstimulated (grey line) CD56bright or CD56dim NK cells. Summary data show mean ± SEM
fold increase of phosphorylated molecule MFI in IL-15-stimulated CD56bright or CD56dim NK
cells relative to unstimulated cells. N = 7 normal donors, 3 independent experiments. Data were
compared using a paired student’s t-test.
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Ras/Raf/MEK/ERK) downstream of the IL-15R plays in CD56bright NK cell priming was
investigated. Induction of each pathway (via phosphorylation of signaling intermediates) upon
exposure to IL-15 in CD56bright and CD56dim NK cells was examined (Figure 3.17D-F). IL-15
robustly induced phosphorylation of STAT5 in both CD56bright and CD56dim NK cells (Figure
3.17D). In contrast, IL-15 more selectively induced Akt and ERK phosphorylation in CD56bright
NK cells, with a minimal fold increase over baseline observed in the CD56dim subset (Figure
3.17E, F). This was not a matter of dose responsiveness since even concentrations of IL-15 as high
as 100ng/mL did not enhance Akt and ERK phosphorylation in CD56 dim NK cells (data not
shown). Since the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK pathways were more selectively
induced by IL-15 in CD56bright NK cells, we hypothesized that they were important for priming
and investigated this through pathway blockade.
The Ras/Raf/MEK/ERK pathway is required for IL-15 primed CD56bright and CD56dim NK cell
responses, whereas the PI3K/Akt/mTOR pathway is selectively involved in CD56 bright priming
We treated NK cells with PI3K (Ly294002) or MEK (PD98059) small molecule inhibitors at
different concentrations for 1 hour before priming with IL-15 and assessed the impact of this
inhibition on functional responses to K562 targets (Figure 3.18A, B). Inhibition of PI3K
significantly impaired IL-15 priming of both degranulation and cytokine responses by CD56bright
but not CD56dim NK cells in response to K562 leukemia targets (Figure 3.18A). Notably,
impairment of IL-15 priming was not evident after mTOR inhibition by Torin1 at concentrations
that selectively inhibit mTORC1 and mTORC2. However, higher concentrations that nonspecifically inhibit PI3K were able to abrogate IL-15 priming (Figure 3.19).51 MEK inhibition
significantly impaired functional responses of both IL-15-primed CD56bright and CD56dim NK cells
(Figure 3.18B). To confirm that the functional response abrogation conferred by PI3K or MEK
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Figure 3.18: The Ras/Raf/MEK/ERK pathway is required for IL-15 priming of
CD56bright and CD56dim NK cell anti-tumor responses whereas the
PI3K/Akt/mTOR pathway is selectively required for CD56bright NK cell priming.
(A, B) Purified NK cells were cultured for 12-16 hours in media alone (control) or media +
5ng/mL IL-15 (primed). In addition, 1 hour prior to addition of IL-15, some primed NK cells
were treated with small molecule inhibitors of PI3K (Ly294002) or MEK (PD98059) at various
concentrations. Summary data show mean ± SEM CD107a, IFN-, or TNF percent positivity
in response to 6 hours of K562 stimulation (5:1 E:T). N=8 normal donors, 3 independent
experiments. (C-E) Flow-sorted CD56bright NK cells were cultured with or without (no
inhibitor; NI) Ly294002 (Pi) and PD98059 (Mi) for 1 hour prior to 12-16 hours of IL-15
priming. (C) Summary data show mean ± SEM CD107a, IFN-, or TNF percent positive cells
in response to 6 hours of K562 stimulation (5:1 E:T). N=9 normal donors, 6 independent
experiments. (D) Granzyme B and perforin MFI as assayed by intracellular flow cytometry,
with representative flow histograms (left). N=11 normal donors, 6 independent experiments.
(E) CD56bright NK cells were incubated with K562 tumor targets (E:T = 2.5:1) in a 4 hour flowbased killing assay. Summary data show mean ± SEM percent specific killing. N=12 normal
donors, 8 independent experiments. Data were compared using (A, B) paired student's t-test or
(C-E) one-way repeated measures ANOVA with Tukey’s multiple comparisons testing .
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Figure 3.19: Selective mTOR blockade does not impede IL-15 priming of
CD56bright or CD56dim NK cell anti-tumor responses.
Purified NK cells were incubated with no inhibitor (NI) or Torin1 at 10nM or 1mM for 1 hour
prior to 12-16 hours of priming with IL-15. Control (con) cells were incubated in media alone.
Next, cells were washed and (A) co-incubated with K562 tumor target cells to assess functional
responses or (B) assessed via intracellular flow cytometry for cytotoxic protein expression
levels. (A) Summary plots show mean ± SEM percent of CD56bright or CD56dim NK cells
positive for CD107a, IFN-, or TNF following co-incubation with K562 targets. (B) Summary
plots show mean ± SEM perforin or Granzyme B MFI in CD56bright and CD56dim NK cells.
N=8 normal donors, 4 independent experiments. Data were compared using a one-way
repeated measures ANOVA with Tukey’s multiple comparisons testing.
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inhibition was not an artifact of differential inhibitor affinity or E:T ratio, we repeated these
experiments with flow-sorted CD56bright or CD56dim NK cells pre-treated with both Ly294002 and
PD98059. The same pattern of response was observed (Figure 3.18C, Figure 3.20A).
Furthermore, PI3K and MEK inhibition decreased cytotoxic protein expression in CD56bright NK
cells following IL-15 priming (Figure 3.18D), and significantly reduced killing of K562 leukemia
target cells (Figure 3.18E). While the effect of PI3K and MEK inhibition on CD56 dim NK cell
cytotoxic protein expression was more modest (Figure 3.20B), K562 killing was significantly
reduced as a result of treatment with these inhibitors (Figure 3.20C). Thus, both the
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK pathways appear to be important for IL-15 priming of
CD56bright NK cells, while the PI3K/Akt/mTOR pathway was not required for the functional
response of IL-15-primed CD56dim NK cells. Interestingly, our phosphorylation studies indicated
that pAkt expression is similar between unstimulated CD56bright and CD56dim NK cells but pERK
is significantly higher in CD56dim NK cells at baseline (Figure 3.17C). Thus, it is possible that a
certain threshold of MEK/ERK pathway activation is required for significant anti-tumor responses,
which is not achieved in non-primed CD56bright NK cells or NK cells treated with PD98059.

3.4 Discussion
Numerous functional and phenotypic properties have been used to distinguish CD56 bright from
CD56dim NK cells, including the superior ability of resting CD56dim NK cells to be triggered by
tumor targets or activating receptor ligation, and to mediate cytotoxicity. Here, we identified that
brief priming through the constitutively-expressed, intermediate affinity IL-15R markedly
enhanced multiple anti-tumor functional responses (cytotoxicity, degranulation, and cytokine
production) of CD56bright NK cells. These enhanced responses were elicited in vitro from allogenic
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Figure 3.20: Combined PI3K/Akt/mTOR and Ras/Raf/MEK/ERK pathway
blockade impairs flow-sorted, IL-15-primed CD56dim NK cell anti-tumor
responses and cytotoxicity.
Flow-sorted CD56dim NK cells were cultured with or without (no inhibitor; NI) small molecule
inhibitors of PI3K (Ly294002, Pi) and MEK (PD98059, Mi) for 1 hour prior to 12-16 hours of
IL-15 priming. (A) CD56dim NK cells were then washed and incubated with K562 tumor targets
for 6 hours at a 5:1 E:T ratio. Summary data show mean ± SEM CD107a, IFN-, or TNF
percent positive cells. N=9 normal donors, 6 independent experiments. (B) CD56 dim NK cells
were assessed for Granzyme B and perforin expression via intracellular flow cytometry.
Representative histogram plots show per cell cytotoxic protein expression. Summary data show
mean ± SEM Granzyme B or perforin MFI. N=11 normal donors, 6 independent experiments.
(C) CD56dim NK cells were incubated with K562 tumor targets (E:T = 2.5:1) in a 4 hour flowbased killing assay. Summary data show mean ± SEM percent specific killing. N=12 normal
donors, 8 independent experiments. Data were compared using a one-way repeated measures
ANOVA with Tukey’s multiple comparisons testing.
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normal donor- and autologous cancer patient-derived NK cells triggered by primary AML blasts,
primary myeloma cells, or a variety of tumor cell lines. IL-15 priming was also evident in vivo in
patients with rel/ref MM treated with the IL-15 super-agonist complex ALT-803, and in a NSG
xenograft model where ALT-803-primed CD56bright NK cells significantly controlled K562 tumor
burden. Several mechanisms contributed to the enhanced anti-tumor function of IL-15-primed
CD56bright NK cells, including increased cytotoxic protein levels, tumor conjugate formation, and
CD2-, CD11a-, and NKG2D- based triggering.

Thus, exposure to IL-15 unleashes the

unexpectedly potent anti-tumor effector function of CD56bright NK cells.
Cytokine activation of NK cells to promote anti-tumor responses have been explored in many
clinical settings.52 Here, we examine short-term IL-15 activation, defined as the direct impact of
IL-15 on the NK cell, and priming, the impact of IL-15 activation on subsequent anti-tumor
responses. The effects of IL-15 priming on CD56bright NK cells were transient, persisting for less
than 72 hours after stimulation in vitro and in vivo in patients. This is distinct from combined
cytokine pre-activation with IL-12, IL-15, and IL-18 that results in a prolonged enhancement of
function (referred to as memory-like NK cell function),53–56 and suggests that clinical approaches
that utilize IL-15 priming of CD56bright NK cells will likely require repeated IL-15 dosing to
maintain primed status. Of note, our results demonstrating that IL-15 confers a selective survival
advantage to CD56bright NK cells suggest that these cells would survive preferentially over the
CD56dim subset in the setting of repeated ALT-803 administration, where drug concentrations may
fall below therapeutic levels between doses. While CD56bright NK cells constitute a minor fraction
of NK cells in the peripheral blood, they are the major subset in secondary lymphoid tissues, at
sites of inflammation, and in some malignant tumors.9–11,57,58 Furthermore, NK cells reside
predominantly in the T cell- and dendritic cell (DC)-rich parafollicular areas of secondary
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lymphoid tissues, and may normally be activated by DC-derived IL-15.9–11

Prior reports

demonstrated that CD56bright NK cells from the peripheral blood, tonsils, and spleen were activated
by mature DCs to more effectively prevent B cell transformation by EBV virus, compared to
CD56dim NK cells.59 These data support the concept that CD56bright NK cells may be primed in
humans in vivo by IL-15 on the surface of DCs or monocytes in secondary lymphoid tissue,11 and
potentially in other sites of IL-15 production such as the bone marrow and spleen,60,61 thereby
enhancing their functional competence against virally-infected or malignantly-transformed cells.
Previous work has also revealed that exposure to IL-12 or prolonged stimulation with
combinations of IL-2, IL-12, and/or IL-15 can increase CD56bright NK cell cytotoxicity.1,7,25,58,62,63
This prior work identified that CD56bright NK cells may be cultured over days to weeks into
lymphokine-activated killer (LAK) cells that have increased potency against tumor cell lines. Our
results are also consistent with a report evaluating CD56bright NK cell responses to autologous
activated CD4+ T cells, which were found to be enhanced by 4-day culture with different cytokines
including IL-15.64 Here, we report that brief cytokine priming via specific signaling pathways
transforms immunoregulatory CD56bright NK cells into robust anti-tumor effectors exhibiting
polyfunctional responses to a diverse set of cancer targets, both in vitro and in vivo. The robust
increase in TRAIL expression of IL-15-primed CD56bright NK cells furthermore suggests that these
cells may also offer a substantial therapeutic benefit for TRAIL-sensitive tumors. Collectively,
these studies highlight the plasticity of the CD56bright NK cell subset, and indicate that cytokine
cues from the NK cell microenvironment can profoundly alter their functional capacity.
The signaling mechanisms leading to IL-15 priming of CD56bright NK cells involve the
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK pathways. These pathways were robustly induced by
IL-15 in the CD56bright NK cell subset, and their blockade significantly impaired priming. This
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finding is consistent with studies investigating murine NK cell cytotoxicity,50 whereas reports
concerning human NK cell cytotoxicity have been conflicting,38,50,65 specifically with regards to
the role of mTOR. Similar to reports from another group,38 we found that pre-treatment of NK
cells with the mTOR inhibitor (Torin1) at concentrations that selectively inhibit mTORC1/2
(10nM) prior to priming did not impact effector responses (CD107a, IFN-, TNF) of CD56bright or
CD56dim NK cells again K562 targets, or impair cytotoxic protein upregulation. Priming-induced
increases in anti-tumor effector responses and cytotoxic protein levels were, however, impeded by
Torin1 at concentrations of 1mM, similar to what has been used in other studies.65 However,
micromolar concentrations result in off-target effects, including inhibition of PI3K.51 This supports
a general PI3K/Akt/mTOR requirement for IL-15 priming of CD56bright NK cells. Interestingly,
only MEK/ERK pathway inhibition impacted IL-15 priming of CD56dim NK cells. Both the more
robust PI3K/Akt/mTOR and MEK/ERK pathway activation in CD56 bright compared to CD56dim
NK cells by IL-15, and the selective involvement of the PI3K/Akt/mTOR pathway in CD56 bright
NK cell priming could then underlie the disproportionate enhancement of CD56bright NK cell
functional responsiveness by priming, in many situations to a level exceeding that of CD56 dim NK
cells. The reasons for this differential responsiveness to IL-15 are unclear and warrant further
investigation. Possibilities include SHIP1, which dephosphorylates the PI3K product PIP 3, and has
been shown to have lower expression in CD56bright than CD56dim NK cells, suggesting that this
pathway is subject to less inhibition in the CD56bright subset.66 However, CD56bright NK cells have
also been shown to express higher levels of PTEN, another inhibitor of the PI3K/Akt pathway.67
Additional studies linking IL-15 receptors signals to distinct functions are warranted.
This study has translational relevance to several cancer immunotherapy settings, including the
adoptive transfer of allogeneic NK cells.17,68 Patients that receive allogeneic NK cell infusions are
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typically prepared with lymphodepleting chemotherapy, which has been shown to induce IL-15
protein in the serum.15,68 Thus, in this situation, CD56bright NK cells that are present in the enriched
NK cell product are likely primed in vivo by IL-15. Differences in the NK cell receptor biology
of CD56bright NK cells may also influence their anti-leukemic function. Since only a small fraction
of CD56bright NK cells express inhibitory KIR, most inhibitory signals are mediated via
CD94/NKG2A.7,34 Thus, depending on their activation state, the CD56bright subset has the potential
to respond to leukemia cells regardless of donor/recipient KIR/KIR-ligand mismatch status. In our
experiments, IL-15-primed CD56bright NK cells effectively responded to primary AML blasts
without blocking CD94/NKG2A (or other inhibitory receptors). This suggests that IL-15 priming
may alter the threshold of activation for CD56bright NK cells, resulting in triggering by leukemia
targets regardless of inhibitory signals. These findings are in line with reports of in vitro
CD137L/IL-15-expanded bulk NK cells, for which activating receptor signals dominated
inhibitory KIR signaling.69 Moreover, IL-15 or IL-15/IL-15Rα complexes are being investigated
in early-stage clinical studies to support adoptively transferred NK cells 70,71 or as single agents.45
Our findings suggest that the adoptively transferred or endogenous patient CD56bright NK cells may
contribute to the therapeutic efficacy of IL-15 administration. Finally, since ALT-803, unlike
recombinant IL-15, accumulates and persists in secondary lymphoid tissues such as lymph nodes
and spleen,72 treatment with this agent may be particularly apt to provide sustained priming signals
to this lymph node-resident NK cell subset.9
Another scenario where IL-15 priming of CD56bright NK cells may be important is early (1-3
months) after allogeneic stem hematopoietic cell transplantation (HCT). Early after a HCT,
CD56bright NK cells are the major lymphocyte subset to recover in the peripheral blood.73–78
Functional CD56bright NK cell anti-leukemic responses have not been analyzed in depth in this
94

setting.57 In two reports, an ‘activated’ phenotype with an intact CD56bright response to combined
cytokine-activation was observed,76,78 although responses to leukemia or other target cells was not
assessed. In a more recent study focused on KIR+CD56dim NK cells from HCT recipients, IL-15
stimulation led to a significant enhancement of the anti-leukemia responses of CD56dim NK cells;
however, the effects of IL-15 on CD56bright NK cell responses to leukemia cells were not
reported.77 Based on our findings, elevated (or exogenous) IL-15 in the early post-allogeneic HCT
period may prime CD56bright NK cells, and thereby promote NK cell clearance of residual AML
blasts. Late after HCT, donor NK cells re-establish homeostasis after having developed from
transplanted stem cells within the host, and are no longer being primed by excessive IL-15. At
this time point, the more mature, educated KIR+CD56dim NK cells would be expected to mediate
longer-term anti-leukemia responses, consistent with well-studied associations between donor KIR
genotype and transplant outcome.14,20,21
In summary, CD56bright NK cells, traditionally considered to be minimally tumor-responsive, are
effectively primed by short-term IL-15 exposure to enable potent cytotoxicity, degranulation, and
cytokine production in response to a broad array of tumor targets and primary hematologic tumor
cells both in vivo and in vitro. This study provides a novel rationale for developing clinical
immunotherapy approaches that utilize IL-15 to prime CD56bright NK cells, and suggests that IL15-based therapeutics may act in vivo to enhance the anti-tumor capacity of this NK cell subset.

3.5 Methods
Reagents
Anti-human mAbs used in this study are included in Table 3.5. Endotoxin-free rhIL-15 was used
(Miltenyi). The following cell lines were maintained in RPMI-1640 plus 10% FCS and
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Table 3.5: List of anti-human mAbs.
The source of anti-human mAbs used is listed, with the clone indicated in parentheses.
Source

Antibody

Beckman Coulter

CD56 (N901), CD3 (UCHT1), CD45 (J.33), CD158b (CH-L), NKG2A
(Z199.1), NKp46 (BAB281), CD158i (FES172)

BD Biosciences

CD2 (RPA-2), CD11a (HI111), CD16 (3G8), IFN-γ (B27), CD107a
(H4A3), CD57(NK-1), CD69 (FN50), CD158a (HP3E4), CD158e
(DX9), CD94 (HP-3D9), CD226 (DX11), CD137 (4-1BB), Perforin
(δG9), Ki67, ERK1/2 (pT202,pY204), STAT5 (pY694), Akt (pS473)
Purified: CD2 (RPA-2.10)

Biolegend

LFA-1 (m24)
Purified: NKG2D (1D11), CD11a/LFA-1 (HI111), NKp30 (P30-15),
NKp44 (P44-8), TRAIL (RIK-2), IgG1 control (MG1-45)

Caltag

Granzyme B (GB12)

eBioscience

CD244 (eBioDM244), TNF (MAb11)

Invitrogen

Granzyme B (GB12)

R & D Systems

NKG2C (134591), NKp80 (239127), CD158d (181703), purified
TRAIL/TNSF10, goat IgG Control

96

supplements: K562 (AML), HL60 (AML), and U266 (MM), RPMI 8226 (MM). K562 were
obtained from ATCC (CCL-243) in 2008, viably cryopreserved in liquid nitrogen, thawed for use
in these studies, and maintained for < 2 months at a time in culture according to provider
instructions. K562 cells were authenticated in 2015 using SNP analysis and were found to be exact
matches to the K562 cells from the Japanese Collection of Research Bioresourses (JCRB), German
Collection of Microorganisms and Cell Cultures (DSMZ), and ATCC databases (2015, Genetic
Resources Core Facility at Johns Hopkins University). Additional cell lines were obtained from
ATCC and provided for our use by Drs. Daniel Link (HL-60), and Michael Tomasson (U266,
RPMI 8226).
NK cell purification and cell culture
Anonymous human platelet apheresis donor PBMCs were obtained by ficoll centrifugation. NK
cells were purified using RosetteSep (StemCell Technologies, ≥95% CD56 +CD3-), or by flow
cytometric cell sorting (BD FACSAriaII, ≥97% purity).53 Cells were cultured in complete RPMI1640 media containing 10% human AB serum (Sigma) for 12-16 hours (unless otherwise stated)
with or without 5ng/mL rhIL-15. ALT-803 in vitro priming of NK cells was performed at
17.5ng/mL for 12-16 hours. For assays involving IL-15 signaling pathways, NK cells were preincubated with inhibitors of PI3K (Ly294002) or MEK (PD98059; both Cayman Chemical
Company) alone or in combination for 1 hour prior to priming.
Functional assays to assess degranulation and cytokine production
Normal donor purified or flow-sorted CD56bright and CD56dim NK cells were co-incubated with
K562 or other cell line targets (E:T ratio of 5:1) for 6 hours, with brefeldin A and monensin (BD
Biosciences) added for the final 5 hours. Assessment of CD107a, IFN-γ, and TNF by flow
97

cytometry were performed as described.53 In some experiments, NK cells were pre-incubated for
30 minutes with anti-NKG2D, CD2, CD11a/LFA-1, NKp44, or NKp30 blocking mAbs (10
µg/mL) prior to K562 exposure. For ex vivo analysis of peripheral blood samples from MM
patients receiving ALT-803, fresh PBMC were isolated by ficoll centrifugation and immediately
co-incubated with U266 myeloma (E:T = 5:1) or K562 leukemia (E:T = 10:1) targets, with
functional readouts assayed as above. For assays involving in vitro priming of AML or MM patient
NK cells, PBMC were isolated by ficoll centrifugation from newly-diagnosed patients with
relatively low peripheral blood disease burden and used fresh or viably cryopreserved. Control or
primed patient PBMC were then triggered with autologous bone marrow AML (bone marrow blast
percentage ≥ 50%) or enriched CD138+ MM cells, K562 leukemia cells, or U266 multiple
myeloma cells (E:T = 5:1) with function assayed as above.
Proliferation and Viability Assays
Purified CFSE-labeled or unlabeled NK cells were incubated for 12-16 hours with media alone
(control) or media with 5ng/mL IL-15 (primed). Cytokines were then washed away and cells were
incubated in media alone for 3-5 days. To interrogate proliferation, after both 3 and 5 days, NK
cells were harvested, surface stained for NK cell markers, and CFSE dilution or intracellular Ki67
expression (BD Biosciences) was assessed via flow cytometry. To interrogate viability, after both
3 and 5 days, NK cells were surface stained for NK cell markers, then stained for activated caspase
3 and 7 (CellEvent Caspase 3/7 Red, ThermoFisher) and Annexin V (BD) per manufacturer’s
instructions. Baseline viability was determined using AO/PI (Nexcelom).
Mass cytometry

98

Mass cytometry functional assays were performed as above. Sample staining and data collection
were performed as described 56.
Flow-based killing assay (FloKA)
Flow-based killing assays were performed by co-incubating flow-sorted CD56bright or CD56dim NK
cells with CFSE-labeled K562 cells or PKH67 (Sigma)-labeled primary AML blasts for 4-5 hours
and assaying 7-AAD uptake as described.28 Background spontaneous K562 or AML blast death
(no effector control wells) was subtracted to yield percent specific killing, and in all cases this was
less than 5% (K562) or 25% (primary AML blasts). E:T ratios of 5:1, 2.5:1, and 1:1 were used for
co-incubation with K562 targets and 15:1 for primary AML blasts. For experiments investigating
the contribution of TRAIL to target cell killing, flow-sorted, IL-15-primed CD56bright NK cells
were incubated with CFSE-labeled, TRAIL-sensitive (HL-60, RPMI 8226) or insensitive (U266)
targets for 18 hours79,80 at a 5:1 E:T ratio in the present of 10mg/mL anti-TRAIL or control IgG
antibody. Background spontaneous death was less than 5% (U266, HL60) or 10% (RPMI 8226).
Light microscopy
Slides were prepared from 1-2x105 cells (via CytoSpin) and Wright-Giemsa stained. Micrographs
were obtained using Nikon Microphot SA at 1000X, with no post-image alterations except
cropping for image size. Line measure indicates 10 microns.
Confocal immunofluorescence microscopy
Flow-sorted CD56bright NK cells were cultured for 16 hours in X-vivo20 media (Lonza),
supplemented with 5% human serum with or without rhIL-15 at 5ng/mL. The cells were adhered
to CellTak (Corning) coated coverslips, fixed with 4% PFA and stained for 4 hours or overnight
with rabbit anti-human LAMP1 (Ab24170) and mouse anti-human Granzyme B-A647 (GB11),
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followed by Donkey anti-rabbit IgG Alexa568 and Hoechst33342. The stained cells were mounted
with ProLong Diamond Antifade on coverslips. Z-stacks were acquired on a LSM710 (Zeiss)
confocal microscope equipped with a Laser diode 405-30 CW (405nm), a Ar-Laser Multiline
(458/488/514nm), a DPSS-561 10 (561nm) and a HeNe-laser (633nm). A plan-Apochromat
63xNA/1.4 oil DICII (Zeiss) objective was used for the acquisition. All images were acquired
using the same confocal settings. Image processing was conducted with Zen2012 software (Zeiss).
Single cell quantification of mean fluorescence intensity x area was performed with Fiji, using the
analyze particles function for all particles > 0.001mm2. Therefore, binary images were created and
local thresholding was applied using the Bernsen-algorithm (15-pixel radius, default parameters)
and Watershed segmentation.
Tumor cell conjugation assay
Tumor conjugate formation was assessed by co-incubating purified NK cells with CFSE-labeled
K562 cells for 5, 15, or 30 minutes. The frequency of CFSE+ CD56bright NK events was used to
calculate tumor conjugate percentages.81
Integrin (LFA-1) Assays
To assess open-conformation LFA-1 expression or signaling (pERK), control or IL-15-primed
purified NK cells were co-incubated with K562 tumor targets (E:T = 5:1), spun at 1300rpm for 1
minute, then placed at 37°C for 3 minutes (pERK) or 15 minutes (open LFA-1). To stain for pERK,
cells were fixed in 1.7% paraformaldehyde, permeabilized in 100% methanol, then stained
overnight for NK cell surface markers and pERK1/2 (pT202, pY204). For open conformation
LFA-1 expression, cells were surface stained for NK cell markers and LFA-1 (clone m24, specific
for the open, high-affinity conformation of LFA-1 82).
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NSG xenograft model
CD56bright NK cells were flow-sorted from normal donor purified NK cells on Day -1 then primed
with 17.5ng/mL ALT-803 (equivalent to 5ng/mL rhIL-15) for 16 hours. Cells were harvested for
i.v. injection (200mL in PBS via tail vein) into 8-12 week old male and female NOD-SCID-IL2R/- (NSG,

Jackson Laboratories) mice on Day 0. 8 mice received an equal number (0.5-0.66x106) of

K562-luciferase (K562-luc) tumor cells and ALT-803-primed CD56bright NK cells and 8 mice
received the same amount of tumor without NK cells. In addition, 5mg of ALT-803 was
administered via tail vein at the time of, and every 2-3 days after for the first 30 days, adoptive cell
transfer. Mice were imaged by bioluminescence imaging (BLI) on Day 2, 5, 13, 20, and 27 (± 1
day). BLI imaging was performed as described83 with exposure times of 1-180 seconds.
IL-15 signaling pathway phosphorylation assays
Purified NK cells were incubated with 5ng/mL IL-15 for 2 hours (pAkt and pERK) or 30 minutes
(pSTAT5). Next, cells were fixed in 1.7% paraformaldehyde, permeabilized in 100% methanol,
then stained overnight for NK cell surface markers and phospho-signaling molecules.
Flow cytometric analysis
Cell staining was performed as described,53 and data were acquired on a Gallios flow cytometer
(Beckman Coulter) and analyzed using Kaluza (Beckman Coulter) or FlowJo (TreeStar) software.
Statistical analysis
Statistical comparisons were performed using a paired student’s t test, one-way ANOVA, one-way
repeated measures ANOVA, or two-way ANOVA with post-hoc analyses, where appropriate. (*
= p<0.05, ** = p<0.1, *** = p<0.001).
Study Approval
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Patients with newly diagnosed AML provided informed consent under the Washington University
Institutional Review Board approved protocol #2010-11766 for these studies (Table 3.2).
Five patients with newly diagnosed multiple myeloma provided informed consent under the
Washington University Institutional Review Board approved protocol #2011-02270 for these
studies (Table 3.3). For one patient, PBMC were only available after 1 round of therapy (4 cycles
RVD – Melphalan ASCT). For the above patients, PBMC or tumor cells were viably cryopreserved
and thawed for use in assays.
Five patients with relapsed/refractory multiple myeloma were treated on a phase 1 study of ALT803 and provided informed consent for sample collection under IRB approved protocol #201102270 (Table 3.4). Two of the five patients were treated with 10mg/kg ALT-803 subcutaneously
(Patient Group A) and three were treated with 3-6mg/kg ALT-803 intravenously (Patient Group
B). One patient from Group A was sampled at two independent time points. Peripheral blood
samples were drawn pre-ALT-803 and approximately 24 and 72 hours after the first dose of ALT803 and functional assays were performed on freshly isolated PBMC. All patients provided
informed consent prior to sample collection and/or treatment.
NSG mice were maintained under specific pathogen-free conditions and used in accordance with
our animal protocol approved by the Washington University Animal Studies Committee.
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Chapter 4: Stage-Specific Requirement for Eomes in Mature
NK Cell Homeostasis and Cytotoxicity
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4.1 Summary
NK cells are cytotoxic innate lymphoid cells (ILCs) that mediate anti-viral and anti-tumor
responses, and require the transcriptional regulator Eomesodermin (Eomes) for early development.
However, the role of Eomes and its molecular program in mature NK cell biology is unclear. To
address this, we developed a tamoxifen-inducible, type-1 ILC-specific (Ncr1-targeted) cre mouse,
and combined this with Eomes-floxed mice. Eomes deletion after normal NK cell ontogeny
resulted in a rapid loss of NK cells (but not ILC1s), with a particularly profound effect on
penultimately-mature stage III NK cells. Mechanisms responsible for stage III reduction included
increased apoptosis and impaired maturation from stage II precursors. Induced Eomes deletion
also decreased NK cell cytotoxicity and abrogated in vivo rejection of MHC class I-deficient cells.
However, other NK cell functional responses, and stage IV NK cells, were largely preserved. These
data indicate that mature NK cells have distinct Eomes-dependent and independent stages.

4.2 Introduction
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Natural killer (NK) cells are the founding members of a family of innate lymphoid cells (ILCs) 1
that also includes helper ILC1s, ILC2s, and ILC3s2. NK cells protect against infection and mediate
anti-tumor responses via two primary effector functions: production of immunomodulatory
cytokines and direct cytotoxicity3,4. NK cells recognize target cells based on the integration of
signals from numerous germline DNA-encoded activating and inhibitory receptors. In general,
activating receptors recognize cell stress ligands, while inhibitory receptors recognize major
histocompatibility complex (MHC) class I molecules 5. In addition, NK cells constitutively express
cytokine receptors that support their development and tune their function by ligating activating or
inhibitory signals in the surrounding environment6,7.
The developmental and transcription factor programs of NK cells are distinct from those of helper
ILCs. ILC development begins in the bone marrow (BM) from the common lymphoid progenitor
(CLP), which gives rise to both the NK and helper ILC lineages. Thereafter, most terminal NK
cell maturation takes place in peripheral tissues2,8. The NK progenitor (NKP) differentiates through
several NK cell maturation stages classically characterized based on the presence or absence of
the surface markers CD27 and CD11b9. In addition, the activating receptor NKp46, encoded by
Ncr1, is induced during stage I (CD27-CD11b-) of differentiation, followed by the integrin CD49b
(DX5), and MHC class I-recognizing Ly49 activating and inhibitory receptors8. Numerous
transcription factors are required to regulate ILC development and promote the different
lineages10,11. NK cells and ILC1s both express T-bet, but of type-1 ILCs, only NK cells express
Eomesodermin (Eomes), another T-box transcription factor critical for their development1. Recent
data have revealed that NK cells and ILC1s exhibit plasticity depending on their environment, and
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specifically that NK cells can convert to ILC1-like cells in TGF--rich tumors and tissues12–14,
which can involve downregulation of Eomes.
However, the mechanisms whereby modulation of Eomes could alter NK cellular identity and
function is unclear. Eomes, like T-bet, regulates gene expression by binding T-box DNA elements.
Eomes is generally required for early embryonic development, as evidenced by mice with global
Eomes gene deletion exhibiting embryonic lethality15. An important role for Eomes has been
demonstrated in CD8 T cell biology: it promotes the development of central memory CD8 T cells
as well as the cytotoxic T cell effector program by positively regulating IFN-, perforin, and
granzyme B16–18. Eomes is also critical for NK cell development and mice with hematopoietic- or
constitutive NK cell-specific Eomes deletion display a severe and global decrease in conventional
NK cell numbers, but preserved ILC1s19–21. Eomes is expressed by NK cells of all maturation
stages, with highest expression in the relatively immature stage II and III populations 19. NK cell
terminal maturation is thought to rely on T-bet, whose expression increases in terminally mature
(stage IV) NK cells, opposite to the decrease in Eomes 20,22. Functionally, Eomes expression
correlates with NK cell IFN- production in vivo23 and Prf1 transcription17, but T-bet has also been
shown to regulate NK cell cytotoxic protein expression22. Thus, the importance of Eomes in mature
NK cell homeostasis and function remains unclear.
Studies of Eomes in NK cell homeostasis and function have been limited by a lack of appropriate
inducible genetic models. In the constitutive Ncr1-cre models available (and similarly for Vav1cre), cre-driven Eomes deletion in immature BM NK cells results in abrogation of NK cell
development, and thus precludes the study of Eomes in mature NK cell biology19,21. Indeed, what
were thought to be Eomes-negative NK cells in such constitutive models are now better understood
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to have been type 1 ILCs19. To overcome this limitation, we developed a type 1-ILC-specific
tamoxifen-inducible cre mouse model and confirmed its properties using a Rosa26-YFP reporter
allele. Eomes-floxed mice were crossed to this model in order to elucidate the role of Eomes in
mature NK cell biology. Here, we studied the impact of induced Eomes deletion on mature NK
cell homeostasis and function. We demonstrate that there are Eomes-dependent (stage II/III) and
independent (stage IV) murine NK cell subsets, and that loss of Eomes does not reverse NK cell
maturation, as has been previously suggested19. In addition, we demonstrate a requirement of
ongoing Eomes expression for NK cell cytotoxicity and in vivo responses to MHC I-deficient
target cells.

4.3 Results
The Ncr1-iCreERT2 tamoxifen-inducible cre model specifically activates cre within type 1 ILCs
Mouse models with constitutive type 1 ILC-specific cre expression utilizing Ncr1 regulatory
elements24,25 have limitations. In these models, cre expression initiates with normal Ncr1 gene
expression in immature BM stage I NK cells26. Hence, LoxP-directed excision events occur early
in NK cell development, precluding the study of developmentally critical genes in mature NK
cells. To overcome this barrier, we developed a type 1 ILC-specific, tamoxifen-inducible cre
mouse (Figure 4.1A), generated by genetic targeting of a tamoxifen-responsive iCreERT2 cassette
into the Ncr1 locus. This cassette is linked to NKp46 C-terminal translation via a P2A ribosomal
skip site. This Ncr1-iCreERT2 model was crossed to a reporter allele consisting of a Lox-StopLox (LSL)-flanked YFP cassette genetically targeted to the Rosa26 locus in order to track cre
nuclear activity27. To test the timing of cre expression in this model, mice underwent oral gavage
with 3 mg of tamoxifen for 3 consecutive days28,29, and 3 days later YFP expression was analyzed
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Figure 4.1: Tamoxifen induces robust and type 1 ILC-specific cre activity in mice
harboring the Ncr1-iCreERT2 knock-in locus.
(A) Ncr1-iCreERT2 locus and mouse model. (B) Mean ± SEM type 1 ILC (NK1.1+CD3-) and
T cell (CD3+) percent YFP+ in the blood (Bl), spleen (Sp), bone marrow (BM), lymph node
(LN), and liver (Liv) of Ncr1-iCreERT2 x Rosa26YFPLSL mice 2 days following 3 consecutive
daily doses of 3mg tamoxifen (or no tamoxifen). Representative splenic flow cytometry data
from a tamoxifen-treated mouse shown to the right. N=2-3 mice per group, 2 independent
experiments. (C) Ncr1-iCreERT2 x Rosa26YFPLSL mice were treated with 3 consecutive daily
doses of tamoxifen. Summary data show mean ± SEM YFP+ splenic NK cells, liver NK cells
(CD49a- DX5+) and liver ILC1s (CD49a+ DX5-) for 5 weeks thereafter. N = 2 mice per group,
1 experiment. (D) Tamoxifen regimens. (E) PCR of Eomes floxed (fl – 730bp) or WT (620bp)
alleles on heterozygous Eomesfl/WT control genomic DNA (lanes 1 and 2) and YFP+ splenic
NK cells (NK1.1+ CD3-, lane 3) or T cells (CD3+, lane 4) sorted from Tam-3d ILCEomes mice. (F) Summary data show mean ± SEM percent Eomes positivity in
YFP+NKp46+ cells in tissues from Tam-6d-treated Eomes WT and ILC-Eomes mice.
Representative flow histograms show Eomes protein in Eomes WT (shaded blue) and ILCEomes NK cells (empty blue), and NK1.1- CD3- lymphocytes (background, shaded gray) in
the spleen and BM. N = 5 Eomes WT mice, 9 ILC-Eomes mice, 2 independent experiments.
114

in various tissues (Figure 4.1B). YFP expression was observed in NKp46+ cells of the blood,
spleen, and liver (>90% YFP+) as well as BM and lymph node (LN) (>80% YFP+). YFP
expression was restricted to NKp46+ cells, and not expressed by other hematopoietic lineages,
including T cells (Figure 4.1B and data not shown). Similar to other iCreERT2 models30,31, mature
(8-12 week old) Ncr1-iCreERT2 mice had small background levels of cre nuclear localization (~510%) in NKp46+ cells in the absence of tamoxifen, that increased slowly over time (Figure 4.1B,
Figure 4.2). Therefore, in this report, experiments were performed on 8-12 week old mice unless
otherwise noted.
This model is also useful to assess cellular dynamics within the NKp46+ ILC compartment. NK
cells and tissue-resident ILC1s were compared in a 3-day tamoxifen ‘pulse’, YFP ‘chase’
experiment. Here, we treated Ncr1-iCreERT2 x Rosa26YFPLSL mice with tamoxifen then assessed
splenic and liver NK cells as well as liver ILC1s for YFP positivity over the next 5 weeks. The
proportion of YFP+ liver ILC1s remained high (>90%), consistent with replenishment from
NKp46+ tissue-resident populations and/or less cellular attrition. In contrast, splenic and liver NK
cells displayed considerable turnover, and YFP positivity returned to near-baseline levels by the
end of 5 weeks (Figure 4.1C). Thus, Ncr1-iCreERT2 x Rosa26YFPLSL mice exhibited robust and
specific cre activity in NKp46+ ILCs after tamoxifen administration, which was tracked in
subsequent experiments using YFP. For the remainder of the study, experiments were performed
at 3 time points relative to tamoxifen administration: Tam-3d, Tam-6d, and Tam-9d (Figure 4.1D).
Tamoxifen rapidly eliminates Eomes in NKp46+ cells of Ncr1-iCreERT2 x Eomesfl/fl mice
We next crossed Ncr1-iCreERT2 x Rosa26YFPLSL mice to mice with floxed Eomes alleles32. Eomes
allele excision was confirmed in splenocytes of Ncr1-iCreERT2 KI/WT x Rosa26YFPLSL x Eomesfl/fl
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Figure 4.2: Background cre expression in Ncr1-iCreERT2 mice.
Ncr1-iCreERT2 x Rosa26YFPLSL mice were cheek bled every 2 weeks from 4-18 weeks of
age and splenic NK cell YFP positivity assessed by flow cytometry. N=2-5 mice per group, 1
experiment.
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(henceforth ILC-Eomes) mice after the Tam-3d regimen as PCR analysis of the Eomes locus
revealed excision in flow-sorted YFP+ NK cells but not YFP− T cells (Figure 4.1E). This was
verified at the protein level after the Tam-6d regimen using flow cytometry in ILC-Eomes
compared to control NK cells (Figure 4.1F). Thus, tamoxifen-induced cre efficiently translocated
to the nucleus and excised Eomes in mature NK cells within 2 days.
Induced Eomes deletion results in a rapid loss of NK cells, most prominently stage III
To assess the impact of induced Eomes deletion on the NK cell compartment, we treated ILCEomes and control mice with the Tam-6d regimen, then assessed for NK cell numbers and
maturation. We observed a significant decrease in global YFP + NK cell numbers in ILC-Eomes
compared to WT control mice in all tissues examined (blood, spleen, BM, LN, and liver, Figure
4.3A). Notably, induced Eomes deletion had a particularly profound effect on less mature stage II
(CD27+CD11b-) and stage III (CD27+CD11b+) NK cells. Stage III NK cells, in particular, were
significantly decreased in number and percentage in all tissues analyzed (Figure 4.3B). While
stage IV (CD27-CD11b+) NK cell numbers were reduced in the blood, BM, and LN in ILCEomes mice, their relative proportion increased in all tissues except the liver, where it was
unchanged. As expected, Eomes-dependent NK cells were decreased in both proportion of YFP +
NKp46+ cells and absolute number in the liver, while the proportion of Eomes-independent ILC1s
increased but numbers remained unchanged (Figure 4.3C)33. Despite evidence that Eomes and Tbet negatively cross-regulate one another20, we did not observe increased T-bet protein levels in
ILC-Eomes NK cells (Figure 4.3D). Thus, induced Eomes deletion negatively affects NK cell
numbers and homeostasis, particularly those of the stage III subset.
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Figure 4.3: Induced Eomes deletion results in a significant decrease in global NK
cell numbers, with a particularly profound loss of stage III NK cells.
(A) Mean ± SEM YFP+ NKp46+ cell percentage of lymphocytes and number in the blood (Bl
– per mL), spleen (Sp), bone marrow (BM – per femur), lymph node (LN – per inguinal LN),
or liver (Liv) of ILC-Eomes vs. WT mice following the Tam-6d regimen. (B) Summary data
show mean ± SEM YFP+ NK1.1+ cell stage-specific percentages and numbers in ILCEomes or Eomes WT mice in the 5 different tissues. ILC1s are included in liver gating.
Representative flow cytometry data shown for the spleen. (C) Summary data show mean ±
SEM YFP+ NK cell (CD49a- DX5+) vs. ILC1 (CD49a+ DX5-) percentage and numbers in the
liver. N=9 ILC-Eomes mice, 5 Eomes WT mice, 2 independent experiments. (D) Summary
data show mean ± SEM T-bet MFI in YFP+ ILC-Eomes and WT NKp46+ cells across the
type 1 ILC compartment, normalized to the mean T-bet MFI of ILC-Eomes NKp46+ cells in
each tissue. N = 9 ILC-Eomes mice, 5 Eomes WT mice, 2 independent experiments. Data
were compared using false discovery rate-corrected t-tests.
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Loss of stage III NK cells in ILC-Eomes mice results from apoptosis and altered cell cycling
dynamics
We hypothesized that the decrease in NK cell numbers observed following Eomes deletion could
be the result of enhanced apoptosis or altered cell cycling. This was tested at an earlier time point
after tamoxifen gavage (Tam-3d) when cells undergoing apoptosis or attempting to proliferate may
still be quantifiable. At this time point, more than 70% of splenic ILC-Eomes and control NK
cells were YFP positive, Eomes protein was nearly absent, and reductions in NK cells had started,
but were more modest compared to the Tam-6d time point (Figure 4.4A, B). A significantly
greater fraction of apoptotic (Annexin V+) stage III NK cells were present in the spleen and BM
of ILC-Eomes compared to WT mice (Figure 4.4C). This was associated with a significant
increase in caspase activation in splenic stage III NK cells of ILC-Eomes compared to control
mice (Figure 4.4D). To further understand this apoptosis phenotype, we performed unbiased
RNA-sequencing of flow-sorted stage II, III, and IV ILC-Eomes and WT splenic NK cells. Gene
set enrichment analysis (GSEA) of the RNA-Seq data revealed significant enrichment of the
Hallmark Apoptosis Pathway in ILC-Eomes, compared to WT, stage II NK cells (Figure 4.4E).
This enrichment was not observed in stage III or IV NK cell comparisons (Figure 4.5). These
data are consistent with the observed loss of stage III NK cells, as they suggest that induced Eomes
deletion activates apoptotic machinery in stage II NK cells that die at stage III.
ILC-Eomes and WT NK cells were also co-stained for Ki67 (a marker of proliferation) and
DNA content to assess cell cycle dynamics (Figure 4.6). The cell cycle distribution of bulk, stage
II, and stage IV NK cells were identical between WT and ILC-Eomes mice in the spleen and
BM (Figure 4.6C, D). However, a significantly greater percentage of stage III NK cells were in
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Figure 4.4: Induced Eomes deletion results in increased stage III NK cell
apoptosis.
ILC-Eomes and Eomes WT mice were treated with the Tam-3d regimen then apoptosis and
cell cycling dynamics were assessed. (A) YFP expression, percentage, and number of splenic
ILC-Eomes and Eomes WT NK cells. N= 5-6 mice per group, 2 independent experiments.
(B) Mean ± SEM percent Eomes+ splenic NK cells. Representative flow histogram shows
Eomes protein in splenic Eomes WT (shaded blue line) and ILC-Eomes NK cells (empty
blue line), and NK1.1- CD3- lymphocytes (background, shaded gray). N= 8 ILC-Eomes
mice, 4 Eomes WT mice, 2 independent experiments. (C) Mean ± SEM Annexin V+ ILCEomes or Eomes WT NK cells by stage in the bone marrow and spleen. N = 12-17 mice per
group, 4-7 independent experiments. (D) Mean ± SEM percent of ILC-Eomes or Eomes WT
splenic stage II or III NK cells with activated poly-caspase expression. N = 5-6 mice per group,
2 independent experiments. (E) GSEA of RNA-Seq data from ILC-Eomes and Eomes WT
Stage II NK cells. An enrichment plot for the Hallmark Apoptosis Pathway is shown to the left,
with all significantly enriched or downregulated pathways shown to the right. Data were
compared using t-tests with false discovery rate correction where appropriate.
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Figure 4.5: RNA sequencing reveals stage-specific changes in ILC-EomesΔ/Δ vs.
Eomes WT splenic NK cells.
Hallmark GSEA of ILC-EomesΔ/Δ vs. Eomes WT stage III and IV splenic NK cells.

121

Figure 4.6: Induced Eomes deletion alters stage III but not bulk, stage II, or stage
IV NK cell cycling dynamics.
(A) Mean ± SEM proportion of G0, G1, and S/G2/M Tam-3d-treated Stage III Eomes WT and
ILC-Eomes NK cells in the spleen and BM, with representative flow plots shown. N = 9-12
mice per group, 3-4 independent experiments. (B) Mean ± SEM proportion of G0, G1, and
S/G2/M Stage III ILC-Eomes and Eomes WT NK cells in the spleen and BM one day after
the Tam-3d regimen. N = 6 mice per group, 2 independent experiments. (C) Schematic of G0
vs. G1 vs. S/G2/M gating. (D) Mean ± SEM proportion of G0, G1, and S/G2/M in bulk, stage
II, and stage IV Tam-3d-treated ILC-Eomes Δ/Δ vs. Eomes WT NK cells from the spleen and
BM. Data were compared using t-tests with false discovery rate correction where appropriate.
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G1 in ILC-Eomes compared to WT mice (Figure 4.6A). No cells progressed to S/G2/M,
however, even when analyzed an additional day after the Tam-3d regimen (Figure 4.6B). This
suggests that induced Eomes deletion promotes a G0 to G1 transition in stage III NK cells, yet the
cell cycle is unable to progress beyond that point, possibly due to cell cycle arrest-related
apoptosis. Eomes-deleted NK cells are capable of cell division, however, as demonstrated via
transfer experiments into a homeostatic proliferation environment (Figure 4.7). Here, both ILCEomes and Eomes WT YFP+ splenic NK cells showed robust and comparable proliferation 14
days post-transfer into Rag2-/-c-/- recipient mice (Figure 4.7B). While restrictions on our flow
panel did not allow for stage-specific analyses, given the deleterious effect of Eomes on stage III
NK cell numbers, we hypothesize that the proliferated ILC-Eomes NK cells were largely stage
II and IV. Short-term proliferation of ILC-Eomes and WT YFP+ NK cells after 4 days in vivo
was also similar, but significantly reduced compared to cre-negative NK cells, suggesting that
induction of cre concurrent with a strong proliferation signal may alter normal cellular
proliferation (Figure 4.7A)34. Collectively, these findings suggest that Eomes loss promotes stage
III apoptosis either by directly activating apoptotic genes in precursor stage II NK cells or as a
result of cell cycle arrest.
IL-15 signaling is altered in stage II and III NK cells as a result of induced Eomes deletion but
does not account for stage III NK cell loss
IL-15 is the major cytokine involved in NK cell development, survival, and proliferation. Three
major pathways are activated downstream of the IL-15R: JAK/STAT (JAK1/3 and STAT 3/5),
MAPK, and PI3K35. STAT5, in particular, is known to be critical for NK cell survival since it
promotes the transcription of anti-apoptotic molecules like Bcl-2 and Mcl-136,37. Since Eomes is
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Figure 4.7: Ncr1-iCreERT2 mice have delayed homeostatic proliferation kinetics
that are not altered by induced Eomes deletion.
CD45.1 WT (Cre-), ILC-EomesΔ/Δ (Δ/Δ), and Ncr1-iCreERT2+ Eomes WT (WT) mice were
treated with the Tam-3d regimen. On day 3, splenocytes were CTV-labeled, NK cells
purified, and cells were sorted as NK1.1+CD3- (Cre-) or NK1.1+CD3-YFP+ (WT and Δ/Δ).
Sorted cells were transferred into CD45.2 Rag-/-gc-/- recipients, and homeostatic proliferation
(CTV dilution) was measured 4 or 14 days post-transfer. (A) Mean ± SEM percent
proliferated Cre-, WT, or Δ/Δ NK cells at the Day 4 time point. Representative flow
histograms shown to the left. (B) Mean ± SEM percent proliferated WT or Δ/Δ NK cells at
the Day 14 time point. Representative flow data shown to the left (Cre- shown at Day 4). N =
3-4 mice per group, 1-2 independent experiments. Data were compared using a one-way
ANOVA with Tukey’s multiple comparisons testing.
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known to regulate the  chain of the IL-15R (CD122)16, we hypothesized that induced Eomes
deletion resulted in decreased expression of the intermediate-affinity () IL-15R, and thus
decreased IL-15 signaling and STAT5 phosphorylation in vivo, leading to stage III NK cell
apoptosis. Indeed, a significant decrease in CD122 expression on both stage II/III and stage IV
Tam-3d-treated ILC-Eomes compared to WT NK cells was observed (Figure 4.8A). We used
Phospho-flow cytometry to interrogate activation of downstream signaling pathways in response
to low- (10 ng/mL) and high-dose (100 ng/mL) IL-15 in NK cells from WT and ILC-Eomes
mice treated with the Tam-3d regimen (Figure 4.8B). Unexpectedly, we observed no defect in
pSTAT5 activation at either IL-15 concentration tested, and accordingly, no difference in Bcl-2
protein expression between ILC-Eomes and WT NK cells (Figure 4.9A). In contrast, pERK,
and pAkt MFI were decreased in ILC-Eomes compared to WT stage II/III NK cells in response
to low-, but not high-dose, IL-15. This is consistent with higher levels of IL-15 being required to
activate these pathways, compared to STAT5, in murine NK cells 38. While they are not considered
to be the principal regulators of NK cell apoptosis, the PI3K/Akt/mTOR and MAPK pathways
have been shown to play important roles in promoting NK cell survival 37. However, stage III NK
cells were not rescued in mice that received exogenous IL-15 concomitantly with tamoxifen
(Figure 4.9B-D). Thus, the negative effect of Eomes deletion on stage III NK cell survival is likely
not the result of impaired IL-15 signaling.
Induced Eomes deletion impairs NK cell maturation in vivo
The PI3K and MAPK pathways are involved in other aspects of NK cell homeostasis, including
maturation39. We hypothesized that the stage III NK cell defect might also be due to impaired
maturation from precursor stage II cells. To test this hypothesis, we treated ILC-Eomes and WT
125

Figure 4.8: Induced Eomes deletion results in modest differences in IL-15
signaling.
(A) Mean ± SEM CD122 MFI on stage II/III (CD27+) vs. stage IV (CD27-CD11b+) splenic
NK cells from Eomes WT and ILC-Eomes mice treated with the Tam-3d regimen.
Representative flow histograms also shown. N=6 mice per group, 2 independent experiments.
(B) Mean ± SEM pSTAT5, pERK, and pAkt MFI fold change over baseline (unstimulated) in
splenic NK cells from Eomes WT and ILC-Eomes mice treated with the Tam-3d regimen.
Cells were stimulated with 10 or 100 ng/mL IL-15 for 15min (pSTAT5) or 1h (pERK, pAkt).
N=7-10 mice per group, 3-4 independent experiments. Data were compared using t-tests.
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Figure 4.9: Bcl-2 protein levels are not altered by induced Eomes deletion and
high-dose IL-15 does not rescue ILC-EomesΔ/Δ stage III NK cells.
(A) ILC-EomesΔ/Δ and WT mice were treated with the Tam-3d regimen. Summary data show
mean ± SEM splenic NK cell Bcl-2 positivity and MFI overall and by stage (stage II, III, IV).
N = 4-6 mice per group, 1 experiment. Data were compared using false discovery rate-corrected
t-tests. (B-D) ILC-EomesΔ/Δ and WT mice were treated with the Tam-3d regimen and half of
the mice received 5mg IL-15 i.p. along with each tamoxifen dose. (B) Mean ± SEM YFP+ NK
cell percent of lymphocytes. (C) Mean ± SEM NK cell percentage by stage. (D) Representative
flow data of NK cell stage distribution. N= 2 mice per group, 1 experiment.
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mice with the Tam-3d regimen then sorted YFP+ CD27+ (stage II/III) or YFP+ CD27- CD11b+
(stage IV) NK cells, transferred them into congenic recipients, and allowed them to mature for 2
weeks in vivo (Figure 4.10A)40. Stage IV NK cells from both ILC-Eomes and WT control mice
were stable and remained stage IV after 2 weeks (Figure 4.10B), contrary to previous results
utilizing ex vivo TAT-cre-induced Eomes deletion19. However, the majority of ILC-Eomes NK
cells that were stage II/III at the time of transfer were stage II after 2 weeks in vivo, with only a
small number of stage IV NK cells developing. This was in contrast to WT cells that showed
expected in vivo maturation (Figure 4.10B, C). To account for any bias introduced by sorting on
YFP+ cells, this experiment was repeated by sorting stage II/III or stage IV CTV-labeled NK cells
from ILC-Eomes or CD45.1 WT mice prior to tamoxifen, and co-transferring cells of the same
stage into CD45.2 recipients. The recipient mice were then treated with 3 days of tamoxifen, and
in vivo maturation was assessed 2 weeks later with similar results (Figure 4.11). These in vivo
maturation experiments indicate that Eomes is required for normal stage II to III NK cell
maturation. Thus, the particularly profound defect in stage III NK cells following Eomes deletion
also arises from a stage II to III maturation block.
Eomes deletion impairs NK cell cytotoxicity but not cytokine production
ILC-Eomes mice were next used to assess the impact of Eomes deletion on mature NK cell
function. To assess ex vivo cytotoxic responses, we treated ILC-Eomes and WT mice with the
Tam-3d regimen, and on the 2nd day of tamoxifen also administered poly I:C, a synthetic toll-like
receptor (TLR) 3 agonist that activates NK cells 41. Twenty-four hours later, splenocytes were
harvested and enriched NK cells were used as effectors in flow-based killing assays against MHC
class I-deficient RMA-S leukemia targets. We observed a significant decrease in RMA-S killing
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Figure 4.10: Eomes is required for normal NK cell maturation.
(A) ILC-Eomes and Eomes WT mice were treated with the Tam-3d regimen. Splenic NK
cells were sorted to YFP+CD27+ (stage II/III) or YFP+CD27-CD11b+ (stage IV) and
transferred into CD45.2 WT recipients. 2 weeks later, YFP+ cell maturation was assessed. (B)
Stage distribution of ILC-Eomes or Eomes WT sorted stage II/III or IV NK cells pre- (light
blue) or 2 weeks post-transfer (dark blue). (C) Representative flow cytometry data showing
maturation of stage II/III ILC-Eomes or Eomes WT NK cells after 2 weeks in vivo. N ≥ 3
pooled mice per group, 3 independent experiments. Data were compared using t-tests.
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Figure 4.11: Eomes is required for normal NK cell maturation in vivo.
(A) NK cells from ILC-EomesΔ/Δ (Δ/Δ) and CD45.1 WT mice were CTV-labeled and sorted to
stage II/III or IV. Δ/Δ and WT cells of the same stage were pooled and co-transferred into
CD45.2 WT recipients. Recipient mice received 3 doses of tamoxifen and maturation of
transferred cells was assessed 2 weeks later. (B) Stage distribution of Δ/Δ or WT sorted stage
II/III or IV NK cells pre- (light blue) or 2 weeks post-transfer (dark blue). (C) Representative
flow cytometry data showing maturation of stage II/III Δ/Δ or WT NK cells after 2 weeks in
vivo. A modestly increased proportion of stage IV NK cells developed when tamoxifen was
administered post- compared to pre-transfer (Figure 5), likely attributable to experimental
variability combined with the potential bias introduced by sorting on YFP+ NK cells that have
likely already initiated apoptosis. N >3 mice per group, 2-3 independent experiments. Data
were compared using t-tests.
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by ILC-Eomes NK cells at both effector-to-target ratios examined (Figure 4.12A). NK cells
were equally enriched in the two groups (Figure 4.12B), demonstrating that the killing defect was
not due to different numbers of ILC-Eomes vs. control NK cells, but rather was cell-intrinsic.
NK cell killing of target cells involves the targeted release of cytotoxic protein-containing
granules. Granzyme B protein levels were not affected by induced Eomes deletion (Figure 4.12C),
consistent with prior reports showing robust granzyme B protein levels in Eomes-deficient ILCs19.
However, RNA-Seq analysis revealed a ≥ 2-fold decrease in perforin mRNA in stage II and III
ILC-Eomes relative to WT NK cells (Figure 4.13A), consistent with prior reports of NK cell
perforin regulation by Eomes16. Indeed, we performed Eomes ChIP-Seq on primary, IL-15expanded murine NK cells, and confirmed the Prf1 transcription start site to be a direct target of
Eomes. In addition, since inducible Eomes deletion might impact the NK cell granular exocytosis
pathway more globally42, we performed GSEA of our RNA-Seq data for the KEGG Natural Killer
Cell-Mediated Cytotoxicity pathway and observed significant downregulation of this pathway in
ILC-Eomes compared to WT NK cells of all stages (Figure 4.13B). Thus, induced Eomes
deletion appears to affect several components of the NK cell cytotoxic program, including perforin.
To complement cytotoxicity assessments, we examined in vitro NK cell cytokine and
degranulation (surface CD107a) responses after stimulation. A time course of ILC-Eomes vs.
WT NK cell function following the Tam-3d, Tam-6d, or Tam-9d regimens was utilized (Figure
4.12D, E). At each time point, we observed no differences in ILC-Eomes vs. WT NK cell
degranulation or IFN− production in response to cytokine (IL-12/15) stimulation, YAC-1
lymphoma, or activating receptor NK1.1 ligation (Figure 4.12D). We also investigated stagespecific ILC-Eomes vs. WT NK cell function, and similarly, there were few substantial
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Figure 4.12: Induced Eomes deletion does not significantly alter NK cell
functional responses, but impairs ex vivo cytotoxicity.
(A, B) Tam-3d-treated ILC-Eomes or Eomes WT mice received 300g poly I:C i.p. on Day
2 of tamoxifen. 24h later, NK cells were enriched from pooled splenocytes and used in FLoKAs
against RMA-S targets. (A) Percent specific RMA-S killing at the indicated E:T ratios and (B)
mean ± SEM NK cell percentage of CD45+ cells used in the assay. N = 3 sets of mice per
group, 3 independent experiments. (C) Mean ± SEM granzyme B percent positive and MFI of
NK cells immediately pre- (blood) and 24 hours post- (spleen) poly I:C. N=7-11 mice per
group, 2-3 independent experiments. (D, E) Splenocytes from ILC-Eomes or Eomes WT
mice treated with the Tam-3d, Tam-6d, or Tam-9d regimens were stimulated with plate-bound
anti-NK1.1, IL-12 (10ng/mL) + IL-15 (10ng/mL) or YAC-1 lymphoma targets (10:1 E:T) in a
6h functional assay. Summary data show (D) overall mean ± SEM percent IFN- or CD107a
positive NK cells and (E) IFN- and CD107a positivity by stage. N= 8-9 mice per group, 3
independent experiments. Data were compared using false discovery rate-corrected t-tests.
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Figure 4.13: Inducible Eomes deletion results in global decreases in the NK cell
cytotoxic program.
(A) RNA-Seq data of Prf1 mRNA fold change in ILC-EomesΔ/Δ compared to WT stage II and
stage III splenic NK cells. (B) GSEA of the KEGG “Natural Killer Cell Mediated
Cytotoxicity” pathway performed on RNA-Seq data from ILC-EomesΔ/Δ vs. Eomes WT NK
cells of different stages
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differences. The most consistent was a modest deficit in ILC-Eomes stage II NK cell functional
responses to anti-NK1.1 ligation (Figure 4.12E). Thus, in vitro NK cell cytokine and
degranulation responses were largely preserved upon induced Eomes deletion, despite reduced ex
vivo cytotoxicity.
Induced Eomes deletion impairs rejection of MHC class I-deficient splenocytes in vivo
To investigate the importance of induced Eomes deletion on NK cell function in vivo, we assessed
the ability of NK cells to reject MHC class I-deficient targets43. ILC-Eomes and WT mice were
treated with the Tam-3d regimen, and on day 3 were injected i.v. with a 50:50 mix of WT and
2m-/- (MHC class I-deficient) splenocytes. 18-20 hours later, mice were sacrificed and the
WT:2m-/- ratio of transferred cells in the spleen assessed (Figure 4.14). 2m−− cells were
efficiently rejected in WT mice, but no rejection occurred in ILC-Eomes mice (Figure 4.14AC). Indeed, the WT:2m-/- ratio of transferred cells in the spleen after 18-20 hours was the same
for ILC-Eomes mice as it was for negative control mice that had been NK cell-depleted.
Alterations in the NK cell Ly49 repertoire could underlie this finding, and prior publications have
demonstrated that Eomes is required for the generation of a diverse Ly49 repertoire, but not its
maintenance19. However, there were no substantial differences in Ly49 receptor expression
between ILC-Eomes and WT NK cells (Figure 4.14D), suggesting that Ly49 alterations were
unlikely to account for the impaired in vivo rejection phenotype. Thus, the impaired ex vivo
cytotoxicity of ILC-Eomes  cells was manifest in vivo, as the cells showed no ability to reject
MHC class I-deficient targets.
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Figure 4.14: Inducible Eomes deletion impairs in vivo NK cell rejection of 2m/splenocytes.
(A-C) Eomes WT and ILC-Eomes mice were treated with the Tam-3d regimen. On Day 3,
mice received tamoxifen as well as 2 x 106 WT and 2 x 106 2m-/- splenocytes via tail vein
injection. Transferred splenocytes were CFSE+ and differentially labeled with CTV. 18-20
hours later, mice were sacrificed and the WT vs. 2m-/- content of CFSE+ splenocyte events
was assessed. As a control for NK-independent killing, some mice received 200g of antiNK1.1 antibody i.p. 2 days before splenocyte transfer. (A) 2m-/- vs. WT composition of
transferred (CFSE+) splenocytes 18-20h post-transfer with representative flow in (B). (C)
Mean ± SEM percent rejection by ILC-Eomes vs. WT mice. Percent Rejection = (1-[(Ratio
WT:2m -/-)experimental/(Ratio WT:2m-/-)NK depleted])*100. N=10 Eomes WT mice, 10 ILCEomes KO mice, 6 NK-depleted mice, 2 independent experiments. (D) Ly49 repertoire of
Eomes WT and ILC-Eomes YFP+ NK cells following the Tam-3d regimen. N = 8-11 mice,
3-4 independent experiments. Data were compared using t-tests with false discovery rate
correction where appropriate.
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4.4 Discussion
The role of Eomes in mature NK cell homeostasis and function has been incompletely understood,
in large part due to a lack of inducible, conditional genetic models. Constitutive Ncr1-cre and Vavcre models have conclusively demonstrated that DX5+ NK cells fail to develop in the absence of
Eomes19,21. While some studies attempted to investigate the functional and phenotypic properties
of cells that did develop in these models, particularly in the liver, these results are challenging to
interpret in light of our current understanding that these were ILC1s and not Eomes-deficient NK
cells. Since constitutive Ncr1-cre and Vav-cre models delete genes early in NK cell development
(stage I or earlier), they preclude the study of genes required for normal NK cell ontogeny (like
Eomes). In addition, global inducible models are complicated by cell-extrinsic effects and the
requirement for adoptive transfer experiments44. To overcome these limitations, we developed a
highly-penetrant, tamoxifen-inducible type 1 ILC-specific cre mouse. A transgenic inducible
model that expressed cre in a small minority of NKp46+ cells was previously reported, but lacked
highly-penetrant type 1 ILC-specific gene targeting45. The Ncr1-iCreERT2 reported here results in
near-complete Eomes protein loss throughout the NK cell compartment in 2 days, and permitted
the demonstration of a persistent requirement for Eomes in mature NK cell homeostasis and
function. Like most cre-LoxP systems, our Ncr1-iCreERT2 model has limitations that must be
considered during experimental design, including small background levels of cre expression in
older mice and potentially altered proliferation kinetics. These limitations reinforce the importance
of having a reporter for cre activity in experimental mice.
Eomes deletion negatively affected NK cell homeostasis, with a particularly profound effect on
stage III NK cells. We determined that the stage III deficit arose from several mechanisms,
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including increased apoptosis (likely caspase-dependent), altered cell cycling, and impaired
maturation from stage II NK cells. IL-15-induced activation of PI3K/Akt/mTOR and MAPK was
impaired in response to low-dose IL-15 in ILC-Eomes  cells yet exogenous IL-15 failed to
rescue stage III NK cells in vivo. Thus, Eomes appears to regulate NK cell survival via mechanisms
that are not rescued by exogenous IL-15. Indeed, we observed enrichment of apoptosis-related
genes specifically in ILC-Eomes compared to WT stage II NK cells, which likely undergo cell
death as they transition to stage III. These data reveal a role for Eomes in regulating hematopoietic
cell apoptosis, a greater understanding of which could potentially lead to novel ways of supporting
NK cells in the setting of adoptive transfer. The deficit in PI3K and MAPK activation by IL-15 at
physiologic cytokine levels could, however, contribute to the maturation defect observed in stage
II ILC-Eomes  cells39. Importantly, and in contrast to prior models that induced Eomes
deletion ex vivo in mature NK cells19, we demonstrate that mature (stage IV) NK cells are largely
Eomes-independent, and do not revert to an immature state if Eomes is lost. In addition, although
we saw no overall deficits in NK cell homeostatic proliferation upon induced Eomes deletion,
stage specific-analyses as well as investigations of activation or inflammation-driven proliferation
were not performed, and will be important to fully appreciate the impact of Eomes deletion on NK
cell proliferation. For the last decade, NK cell maturation has largely been classified based on
CD27 and CD11b expression9. Our findings suggest that an alternate way of characterizing NK
cell maturation is based on Eomes-dependence. As such, stage II/III NK cells are Eomesdependent, while stage IV NK cells are predominantly Eomes-independent. Terminally mature
NK cells downregulate Eomes and upregulate T-bet, and so we hypothesize that stage IV NK cell
homeostasis is T-bet-dependent. Additional studies utilizing the inducible cre model with both Tbet and Eomes floxed alleles will clarify these T-box transcription factor requirements.
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Functionally, we observed that induced Eomes deletion impaired NK cell killing - both in vivo
rejection of MHC class I-deficient splenocytes and ex vivo killing of tumor target cells. While the
decreased NK cell number arising from induced Eomes deletion could be a contributing factor, the
killing defect in vivo was disproportionate to the NK cell deficit, and the ex vivo killing assay was
performed with equal NK cell numbers. Thus, Eomes deletion impairs NK cell killing in vivo and
ex vivo via NK cell-intrinsic mechanisms. NK cells kill via exocytosis of cytotoxic proteincontaining granules and via the ligation of death receptors on target cells. Ongoing Eomesregulated transcription is not required for short-term granzyme B protein expression, as we
observed no reduction in granzyme B protein levels in ILC-Eomes compared to WT NK cells.
In contrast, RNA-Seq revealed a significant reduction in perforin mRNA in ILC-Eomes stage II
and III NK cells compared to WT, and Eomes ChIP-seq confirmed Prf1 to be an NK cell target of
Eomes. While we were unable to quantify perforin protein due to technical limitations of available
flow-based antibodies, decreases in perforin protein are likely to have occurred given the perforinsensitivity of RMA-S cells46 . However, perforin mRNA was unchanged by induced Eomes
deletion in stage IV NK cells, and since these cells are major NK cytotoxic mediators, this
suggested that other components of the NK cell cytotoxic machinery may have been altered by
induced Eomes deletion. Indeed, we observed downregulation of the KEGG NK Cell-Mediated
Cytotoxicity pathway in ILC-Eomes NK cells of all stages, demonstrating a broader role for
Eomes in regulating NK cell cytotoxicity. It is also possible that alterations in death receptor ligand
expression contributed to the killing defects observed. TRAIL, in particular, is expressed on tissueresident, Eomes-negative ILC1s, so it is possible that it is upregulated upon Eomes deletion.
However, RMA-S cells are relatively TRAIL- and FasL-resistant in short-term killing assays46,47.
Thus, while it will be important to investigate death receptor ligand expression and function on
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ILC-Eomes NK cells in the future, they likely did not contribute substantially to our cytotoxicity
phenotype.
Unlike the cytotoxicity results, short-term NK cell degranulation and IFN- production were
largely unaltered by induced Eomes deletion. It has been suggested that Eomes may be important
for sustained NK cell functional responses and that Eomes downregulation, for example in cells
infiltrating a tumor, might be a sign of NK cell exhaustion 23. As such, it will be informative to
perform studies of sustained NK cell function (such as infection with murine cytomegalovirus
[MCMV] or tumors) using our inducible cre system to assess the role of Eomes in these types of
NK cell responses. Intriguingly, our ChIP-Seq data, performed on IL-15-expanded NK cells,
revealed a weak binding peak near the granzyme B promoter. We speculate that in settings of
sustained activation, Eomes may play a role in regulating the expression of this cytotoxic protein
as well, and that this may be a mechanism through which Eomes loss contributes to NK cell
exhaustion. A greater understanding of how Eomes deletion affects the entire NK cell activating
(e.g., NKG2D, NKp30) and inhibitory (e.g., NKG2A) repertoire will also be important to fully
understand virus and tumor model findings.
This conditional, inducible cre model has many potential applications beyond the study of
developmentally-critical genes, which will make it important for addressing other outstanding
questions in the type 1 ILC field. For example, it could be used to study NK cell populations that
arise only after specific physiologic triggers, such as MCMV-specific innate memory or cytokineinduced memory-like NK cells. In addition, since we demonstrated that ILC1s regenerate at a
much slower rate than NK cells, or from NKp46+ precursors, this model may be useful to
selectively ablate genes within ILC1s, thereby permitting studies of the in vivo functions of these
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distinct but related cell types. Thus, this study provides a critical tool for the field to address new
questions and avenues of investigation in type 1 ILC biology.
Limitations
Submission of this manuscript occurred during the SARS-CoV-2 pandemic, limiting our ability to
perform experiments to address all issues raised during peer review. Some experiments, while of
great interest, were beyond the feasible scope of the manuscript in light of restrictions imposed to
contain the pandemic. These issues will be addressed in future studies, including (1) whether death
receptor ligands (TRAIL, FasL) are differentially expressed on ILC-Eomes vs. control NK cells,
and whether they contribute significantly to ILC-Eomes NK cell cytotoxicity, (2) whether
induced Eomes deletion alters sustained NK cell function, as determined by an in vivo virus or
tumor model, (3) if the expression of other activating and inhibitory receptors (ex: NKG2D,
NKp30, NKG2A) differs between ILC-Eomes and control NK cells, (4) evaluation of perforin
protein in addition to decreased mRNA in stage II and III ILC-Eomes NK cells, and (5) a
comprehensive assessment of the impact of Eomes deletion on NK cell proliferation.
In summary, we developed a type 1 ILC-specific inducible cre mouse to identify a stage-specific
requirement for Eomes in regulating NK cell homeostasis and cytotoxicity. In addition to
elucidating the role of Eomes in mature NK cell biology, this study highlights the importance of
complementing studies of constitutive cre with inducible models in order to elucidate the
biological roles of genes at all stages of cellular development. As such, we anticipate that the Ncr1iCreERT2 model will provide important insights into the nascent field of type 1 ILC biology.

4.5 Methods
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Experimental Model and Subject Details

Mice
Ncr1-iCreERT2 mice were developed in the Fehniger lab on the C57BL/6J background. Mice were
bred to Rosa26 YFPLSL knock-in mice (The Jackson Laboratory, stock no. 006148) as well as
Eomesfl/fl mice (The Jackson Laboratory, stock no. 017293). For all experiments, ILC-Eomes
refers to Ncr1-iCreERT2

KI/WT

x Rosa26YFPLSL x Eomesfl/fl mice. Ncr1-iCreERT2

KI/WT

x

Rosa26YFPLSL x EomesWT/WT mice were used as WT controls in Figures 4.1E, 4.2, 4.3, 4.4A-B
& D, 4.6, 4.7, 4.9, 4.10, and 4.12A-B. In the remaining figures, if these mice were limiting, Ncr1iCreERT2 WT/WT x Rosa26YFPLSL x Eomesfl/fl mice as well as CD45.1 and CD45.2 C57BL/6J mice
(The Jackson Laboratory, nos. 002014 and 000664) were also utilized. CD45.1 C57BL/6J mice
were utilized as WT controls in Figure 4.11 and as cre-negative controls in Figure 4.7. Rag2-/-c/-

mice (Taconic, no. 4111) were used as recipients for in vivo homeostatic proliferation assays

(Figure 4.7). All mice (Eomes WT and ILC-Eomes) were treated with identical tamoxifen
regimens for all experiments. Mice were orally gavaged with 3mg tamoxifen (Sigma) in corn oil
(Sigma) for 2-3 days as described. Mice were bred and maintained in specific pathogen-free
housing, and experiments were conducted in accordance with the guidelines of and with the
approval of the Washington University Animal Studies Committee. Experiments were performed
on 8-12 week old male and female mice.
Cell Lines
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RMA-S and YAC-1 cell lines were maintained at 37 oC in 5% CO2 in RPMI-1640 plus 10% FBS
and supplements (10mM HEPES, 1% NEAA, 1% sodium pyruvate, 1% L-glutamine, 1X penicillin
and streptomycin) following ATCC guidelines and kept in continuous culture for < 2 months.
Method Details
Organ isolation and processing
Mice were sacrificed by CO2 asphyxiation and organs harvested immediately. Blood was harvested
by cardiac puncture prior to removal of other organs. Spleens and inguinal nodes were isolated
and crushed through a 70m filter to generate a single cell suspension. Bone marrow was harvested
by flushing femurs with a 23-gauge needle. Whole livers were desiccated with a tissue grinder
then lymphocytes were isolated using a Percoll gradient. All tissues were ammonium-chloridepotassium lysed. Cell counts were obtained using propium iodide exclusion with a Cellometer
counter (Nexcelcom).
Flow cytometry and cell sorting
Surface antibody staining was performed for 15 minutes at 4ºC. Intracellular staining was
performed in permeabilization buffer following fixation/permeabilization with kits from BD
Biosciences (for IFN- staining) or Invitrogen (for Eomes, Granzyme B, Bcl2, and Ki67 staining).
Eomes NK cells (and cre-positive WT cells) were gated on YFP+ events whenever possible.
Since Invitrogen fixation/permeabilization quenches YFP, cells were pre-fixed in 1% PFA for 2
minutes at room temperature prior to fixation/permeabilization in order to preserve YFP when
intracellular proteins were assessed after the Tam-6d regimen (Figures 4.1E, 4.3). However, prefixation was unable to preserve YFP after the Tam-3d regimen, so intracellular analyses were
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performed on bulk NK cells (which were nearly 80% YFP+, Figure 4.4) at this time point. For
phosphoflow cytometry assays, splenocytes were stimulated with recombinant mouse IL-15
(Peprotech) at 10ng/mL or 100ng/mL for 15 minutes (pSTAT5) or 1 hour (pERK, pAkt). Cells
were then fixed with 1% PFA for 10 minutes at room temperature. Next, cells were permeabilized
in ice cold methanol for 30 minutes at 4ºC, then washed and stained overnight with phosphoflow
antibodies. Flow cytometry data were collected on a Gallios flow cytometer (Beckman Coulter)
and analyzed using FlowJo (Treestar) software. Cell sorting was performed on a BD FACS Aria
II to greater than 95% purity.
Cell cycle and viability assays
Cell cycle was assessed using Ki67 and FxCycle Violet (Invitrogen) staining following Invitrogen
Fixation/Permeabilization. For viability assays, freshly-isolated splenocytes were incubated at
37ºC for 2-3 hours then assayed for poly-caspase activation (Immunochemistry Technologies) or
surface Annexin V (performed in Annexin V buffer, both BD Biosciences).
In vivo maturation experiments
In Figure 4.10, ILC-Eomes and Eomes WT mice were treated with the Tam-3d regimen. Next,
NK cells were purified via negative selection (Stemcell Technologies) from pooled ILC-Eomes
or Eomes WT spleens and sorted to YFP+ stage II/III (CD27+) or stage IV (CD27- CD11b+).
Cells were injected into separate male CD45.2 WT recipients. 2 weeks later, mice were sacrificed
and the stage distribution of YFP+ splenocytes analyzed via flow cytometry. In Figure 4.11, NK
cells were purified from pooled ILC-Eomes or CD45.1 WT spleens, labelled with CTV
(Invitrogen) and sorted to stage II/III (CD27+) or stage IV (CD27- CD11b+) prior to tamoxifen
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administration. ILC-Eomes and Eomes WT cells of the same stage were pooled and injected
into male CD45.2 WT mice, who then received 3 daily doses of 3mg tamoxifen in corn oil via oral
gavage. 2 weeks later, recipient mice were sacrificed and the stage of CTV+YFP+ (ILC-Eomes)
and CTV+CD45.1+ (WT) cells analyzed by flow cytometry.
In vivo homeostatic proliferation
ILC-Eomes and Eomes WT mice along with Cre- CD45.1 WT controls were treated with the
Tam-3d regimen. Splenocytes were CTV-labeled, then NK cells were purified from pooled
splenocytes via negative selection (Stemcell Technologies) and sorted to NK1.1+CD3-YFP+
(ILC-Eomes and WT) or NK1.1+CD3- (CD45.1WT). Sorted cells were injected in CD45.2
Rag2-/-c-/- recipients and CTV dilution of YFP+ (ILC-Eomes and WT) or CD45.1+ cells
(CD45.1 WT) was assessed 4 or 14 days post-transfer via flow cytometry.
ChIP sequencing
In 3 separate experiments, purified NK cells from pooled CD45.2 Eomes WT splenocytes were
expanded in vitro for 4 days with 100ng/mL IL-15. Cells were then harvested and approximately
10 x 106 cells were used per ChIP experiment. Chromatin immunoprecipiation was performed
using the MAGnify Chromatin Immunoprecipitation System (Thermo Fisher) as per
manufacturer’s instructions with a ChIP-grade anti-Eomes antibody from Abcam (ab23345). Nonimmunoprecipitated DNA was used as an input control. ChIP DNA was blunt ended, had addition
of “A” base to 3’ end, and had sequencing adapters ligated to the ends. The fragments were size
selected to 200-600 base pairs, and underwent amplification for 15 cycles with primers
incorporating p5 and p7 sequences and a unique index tag for multiplexing. The resulting libraries
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were sequenced using the Illumina HiSeq3000 as single reads extending 50 bases. The raw data
was demultiplexed and aligned to the reference genome using Novoalign. MACS was used to call
peaks. For downstream analysis, gene-associated peaks that had > 5-fold enrichment over input
and were present in all three replicates (± 500 base pairs from each other) were identified.
RNA sequencing and Gene Set Enrichment Analysis
In 3 separate experiments, ILC-Eomes or CD45.2 Eomes WT mice were treated with the Tam3d regimen. Next, NK cells were purified from pooled ILC-Eomes or Eomes WT splenocytes
and sorted to stage II (CD27+CD11b-), stage III (CD27+CD11b+), or stage IV (CD27-CD11b+).
KO cells were also YFP+. Cells were stored in Trizol at -80ºC until RNA isolation using the Directzol RNA MicroPrep kit (Zymo Research). NextGen RNA sequencing was performed using an
Illumina HiSeq 2500 sequencer. RNA-Seq reads were aligned to the Ensembl release 76 top-level
assembly with STAR version 2.0.4b. Gene counts were derived from the number of uniquely
aligned unambiguous reads by Subread:featureCount version 1.4.5. Differential expression
analysis was performed to analyze for differences between conditions and the results were filtered
for only those genes with Benjamini-Hochberg false-discovery rate adjusted p-values less than or
equal to 0.05.
We utilized Gene Set Enrichment Analysis (GSEA) with the Molecular Signatures Database
(MSigDB)48,49 developed by the Broad Institute and UC San Diego on the RNA sequencing results
of sorted stage II, III, and IV ILC-Eomes and Eomes WT NK cells to identify biological
pathways that were enriched or downregulated in ILC-Eomes vs Eomes WT NK cells in
respective maturation stages. Pathways were considered significantly enriched or downregulated
if p < 0.05 and FDR < 0.25.
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In vivo 2m-/- rejection
ILC-Eomes and WT mice were orally gavaged with 3mg tamoxifen in corn oil for 3 consecutive
days. On the third day, mice also received 4e6 splenocytes that were a 50/50 mix of CD45.2 WT
and 2m-/- (a gift from Wayne Yokoyama). Transferred splenocytes were differentially labelled
with CTV for discrimination. In addition, on the first day of tamoxifen administration, some
control mice received 200g anti-NK1.1 intraperitoneally (i.p.) to control for non NK-specific
killing. 18-20 hours after splenocyte transfer, mice were sacrificed and the ratio of CTVhi (WT) to
CTVlow (2m-/-) splenocytes was assessed. Percent rejection was calculated as: (1-[(Ratio
WT:2m-/-)experimental/(Ratio WT:2m-/-)NK depleted])*10050.
In vitro cytotoxicity (FLoKA) assays
ILC-Eomes and WT mice were administered 3mg tamoxifen in corn oil via oral gavage for 2
consecutive days. On the second day, mice were also administered 300g of poly I:C (Invivogen)
i.p. 20-24 hours post-poly I:C, splenocytes were pooled from 2-3 mice per group and NK cells
were enriched via negative selection (Stem Cell Technologies). NK-enriched splenocytes were
used in killing assays against CTV-labelled RMA-S targets at the indicated E:T ratios for 4 hours.
Dead cells were identified via 7-AAD staining and specific killing calculated as: % 7AAD+effector+target - % 7-AAD+target

alone.

Mice were cheek bled immediately prior to poly I:C

administration for a baseline NK cell granzyme B readout, and splenic NK cell granzyme B was
also assessed at the time of the killing assay.
In vitro functional assays
ILC-Eomes and Eomes WT mice were treated with the Tam-3d, Tam-6d, and Tam-9d regimens.
At each time point, functional assays were performed on splenocytes. Splenocytes were either
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unstimulated (media alone) or stimulated with cytokines (10ng/mL IL-12 + 10ng/mL IL-15, both
Peprotech), YAC-1 lymphoma targets (E:T = 10:1), or plate-bound purified anti-NK1.1 for 6
hours. Anti-CD107a (LAMP-1) antibody was added at the start of the assay to detect
degranulation, and brefeldin A and monensin (BD Biosciences) were added for the final 5 hours.
Cells were then surface stained, fixed/permeabilized (BD Biosciences), and intracellularly stained
for IFN-, follow by flow cytometry analysis.
Quantification and Statistical Analysis
Statistical analyses were performed using GraphPad Prism 7 software. Tests utilized are indicated
in figure legends. * = p<0.05, ** = p<0.01, *** = p<0.001.
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Chapter 5: Concluding Remarks & Future Directions
5.1 NK Cells and Cancer Therapy
The field of NK cell cancer immunotherapy is rapidly expanding. Numerous methods of
activating and expanding NK cells, along with ensuring their in vivo persistence and effective
homing to/recognition of cancerous cells, are currently under investigation. Our group has
focused primarily on cytokine-activating NK cells, with the possibility of then utilizing these
effectors alone or in combination with other therapeutic agents.1–4 In particular, we have focused
on two types of cytokine activation: combined cytokine pre-activation leading to the
differentiation of long-lived memory-like NK cells with enhanced functional responsiveness, as
well as shorter-term IL-15 activation, or priming, of CD56bright NK cells. Both approaches have
unique advantages as well as important considerations for clinical translation.

5.1.1 Cytokine-Induced Memory-Like NK Cells
The enhanced cytokine production and cytotoxicity of memory-like NK cells both in vitro and in
vivo is well-established,1,2,5 and results from phase I clinical studies have shown that these cells
are safe and capable of inducing complete responses in patients with cancer. 2 However, not all
patients showed clinical responses to these cells, and in the ones that did, responses were of
limited duration, suggesting that the NK cells were not capable of completely eliminating
cancerous cells. This might have occurred for several reasons. First, memory-like NK cells were
transferred into an allogeneic environment.2 Once the patient’s immune system (namely T cells)
started to recover from the conditioning chemotherapy, adoptively transferred memory-like NK
cells were rapidly rejected. Thus, these cells have a limited “window of opportunity” in which to
eliminate cancer. Our group has another study underway in which patients first receive a
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hematopoietic cell transplantation from the NK cell donor prior to NK cell adoptive transfer
(NCT02782546). In such a scenario, NK cells are transferred into a syngeneic environment and
we have evidence that they can persist for months, thus prolonging the window for cancer
elimination. Second, it is likely that tumor cells evolve to evade NK cell rejection. One way to do
so would be via the upregulation of ligands for inhibitory checkpoints on NK cells (ex: PD-1),
which have been shown to impair NK cell function.6 NK cell/checkpoint blockade combination
therapy is an approach currently under investigation. While the impact of PD-1 and other wellestablished checkpoint molecules like CTLA-4 on memory-like NK cell function is not yet wellcharacterized, we have evidence that memory-like NK cells are particularly sensitive to
CD94/NKG2A-based inhibition. Additional studies of NKG2A blockade or genetic deletion will
be needed to see whether this can improve therapeutic outcomes. In addition, studies of the
tumor microenvironment more generally before and after memory-like NK cell therapy will be
important to discover novel mechanisms of NK cell resistance. Finally, if tumor cells do not
express NK-activating ligands, it is possible they could evade NK cell detection. Thus,
mechanisms of better targeting NK cells to tumors are important. One method, adapted from T
cells, involves the insertion of chimeric antigen receptors (CARs) onto NK cells.7 The CAR-NK
cell field is still nascent and has focused primarily on cord blood-expanded NK cells or NK cell
lines, but it will be exciting to see how it develops. Our group is currently generating CAR
memory-like NK cells, with promising preliminary results. In addition, since we demonstrated
that memory-like NK cells show enhanced triggering via FcRIIIa,8 it will be interesting to see
whether pre-clinical studies of memory-like NK cells combined with monoclonal antibodies
recapitulate these findings, and if such an approach could be used clinically.
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Despite the rapid and successful translation of memory-like NK cells into the clinic, many of the
molecular mechanisms underlying their differentiation and function remain unresolved. We
hypothesized that signaling downstream of activating receptors may be enhanced in memory-like
NK cells, and tested this using FcRIIIa, an activating receptor with a well-defined signaling
cascade. However, we observed no major differences in proximal or distal signaling downstream
of the receptor in memory-like vs. control NK cells, demonstrating that their biology is unique
from HCMV-adaptive NK cells. The mechanisms responsible for the enhanced function of
memory-like NK cells are being actively investigated. Unpublished data from the lab has
demonstrated modest dephosphorylation of an important regulatory region upstream of the IFNG
locus in human memory-like NK cells,9,10 suggesting that the gene may be poised for
transcription. Basal IFNG mRNA expression in control vs. memory-like NK cells, as well as
kinetics of mRNA induction upon stimulation, will need to be interrogated in greater detail. In
addition, it is possible that memory-like NK cells can more rapidly translate pre-existing mRNAs
for effector proteins like IFN-, perforin and Granzyme B. A greater understanding of these
molecular mechanisms will be important to harness memory-like NK cells most effectively in
the clinical setting.

5.1.2 IL-15-Primed CD56bright NK cells
While two major subsets of human NK cells can be identified in the peripheral blood and
secondary lymphoid tissue, CD56bright NK cells have long been overlooked with regards to NK
cell-based immunotherapy since they traditionally have not been considered to be cytotoxic.
However, we demonstrated that CD56bright NK cells have the potential for robust cytotoxicity,
which can be unleashed via brief priming with IL-15.4 IL-15-primed normal donor CD56bright NK
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cells showed enhanced degranulation, cytokine production, and cytotoxicity in response to tumor
cell lines as well as primary myeloma and AML blasts, and were able to control an AML cell
line in vivo. In addition, we demonstrated that IL-15 priming enhanced cancer patient CD56bright
NK cell functional responses to their autologous tumor cells, and that patient CD56bright NK cells
could be primed in vivo via IL-15 receptor super-agonists. These results demonstrate, first and
foremost, that CD56bright NK cells should no longer be overlooked in NK cell therapy, and may
actually prove to have several therapeutic advantages. For instance, while CD56bright NK cells are
the minor NK cell population in the peripheral blood, they predominate in secondary lymphoid
tissues and outnumber CD56dim NK cells overall.11,12 Indeed, CD56bright NK cells express unique
chemokine and tissue-homing receptors that localize them to different physiologic compartments
than CD56dim NK cells.13 Thus, CD56bright NK cells may be particularly useful for treating
cancers of secondary lymphoid tissues, such as lymphomas, or even solid tumors if they are
better-penetrated by this NK cell subset. Furthermore, while CD56bright NK cells are present in
small numbers in the peripheral blood, they are more highly proliferative in response to IL-15,14
suggesting that they could be expanded ex vivo prior to transfer into patients. The IL-15 dosing
in studies of CD56bright NK cell therapy will be important to consider. In our experiments, IL-15
priming of CD56bright NK cells was evident for about 48-72 hours, meaning that repeated IL-15
administration would be necessary. However, recent studies have shown that continuous
exposure of NK cells to IL-15 can lead to functional impairment and reduced survival,15 so an
optimal IL-15 regiment would need to be experimentally defined.
We demonstrated that IL-15 priming involves upregulation of different activating and adhesion
receptors, integrin (LFA-1) activation, and induction of the PI3K and MAPK pathways. In
keeping with the observed upregulation of activating and adhesion receptors as well as open155

confirmation LFA-1 following IL-15 priming, IL-15-primed CD56bright NK cells more readily
formed conjugates with tumor cells than their unprimed counterparts. It would be informative to
investigate whether the nature of the lytic synapses that form between IL-15-primed vs control
CD56bright NK cells and tumor targets are different. Confocal microscopy permits visualization of
synaptic components such as actin, tubulin, and cytotoxic granules, and could be employed to
answer this question. In addition, it is currently unknown whether IL-15 priming enhances
CD56bright NK cell serial killing, or the ability to kill multiple targets back-to-back. Novel cellular
visualization techniques could also be utilized to address this as well.
Finally, the molecular mechanisms underlying IL-15 priming of CD56bright NK cells remain
incompletely characterized. Given the rapidity with which priming occurs, it is doubtful that
transcriptional changes occur, and instead it seems likely that priming relies on translation of
pre-existing mRNA. However, interestingly, our time course of IL-15 priming suggested that
there were two “waves” that brought about maximal CD56bright functional responses: one peaked
after approximately 12 hours, and another after 24-48 hours of IL-15 exposure. Thus, it is
possible that more prolonged priming does rely on transcriptional changes. Performing RNA-Seq
on short-term- (12-16 hour) vs. long-term- (24-48 hour) primed CD56bright and CD56dim NK cells
would help to define transcriptome changes associated with delayed priming. Lastly, it is not
understood why PI3K and MAPK are more robustly induced by IL-15 in CD56bright compared to
CD56dim NK cells. The data that exist regarding this issue are conflicting: one study showed
lower expression of the negative regulator of PI3K signaling SHIP1 in CD56bright vs CD56dim NK
cells, however another negative regulator of this pathway, PTEN, has been shown to be higher in
CD56bright NK cells.16,17 Furthermore, in our study, CD56bright NK cells showed lower basal ERK
activation than CD56dim NK cells, and we hypothesize that this might underlie their lower basal
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level of cytotoxicity. Additional studies better-characterizing IL-15 signaling in CD56bright and
CD56dim NK cells are needed to answer these questions, and will undoubtedly have important
therapeutic implications. Overall, this study highlights the unique biology of CD56bright NK cells
and provides a rationale for the development of treatment approaches that tap into their
immunotherapeutic potential.

5.2 Eomes and NK Cell Homeostasis & Function
Inducible Cre systems are necessary for the study of developmentally-critical genes, yet an NK
cell-specific model was previously unavailable in the field. To meet this important need, our lab
developed a novel NK cell-specific, Tamoxifen-inducible Cre mouse. We also included a YFP
reporter in order to track Cre expression, and determined that in our model, Tamoxifen induced
robust Cre expression in an NK-restricted manner. We crossed our mouse to mice harboring
floxed alleles of Eomes, an NK cell vs. ILC1 lineage-defining transcription factor critical for NK
cell development. Using our model, we demonstrated that Eomes deletion in mature NK cells
negatively impacted their homeostasis, particularly that of Stage III NK cells. Stage III NK cells
showed enhanced caspase-dependent apoptosis, impaired maturation from Stage II precursors,
and altered cell cycling dynamics upon inducible Eomes deletion. In addition, in vivo rejection
of 2m-/- splenocytes by Eomes KO NK cells was impaired, along with ex vivo killing of tumor
targets. However, in vitro functional responses were largely preserved.
While Eomes was known to be more highly expressed by Stage II and III NK cells compared to
Stage IV,18,19 its function in these cells was unclear. Here we show that Eomes regulates NK cell
apoptosis, maturation, and cell cycling, but the precise molecular mechanisms and Eomes targets
remain to be determined. Our ChiP-Seq, RNA-Seq, and IL-15 signaling studies identified the
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pro-apoptotic molecule Bim as a potential mediator of Eomes-dependent NK cell apoptosis.
Specifically, we found that Eomes directly binds the Foxo3 locus, a known activator of Bim, and
that in Eomes KO Stage II and III NK cells, Foxo3 mRNA is expressed at a higher level that in
WT cells. Thus, Eomes appears to suppress Foxo3 transcription. In addition, Eomes KO Stage II
and III NK cells are less sensitive to IL-15 signaling, and defects in PI3K and MAPK activation
could lead to further Bim dysregulation. We are testing this hypothesis using CRISPR/Cas9 to
delete Bim in Eomes KO bone marrow, transfer it into recipients and allow for reconstitution,
then treat recipients with Tamoxifen. We hypothesize that the NK cell defect will be at least
partially rescued when Eomes is deleted in mature NK cells already lacking Bim. With regards to
the maturation defect observed, additional studies will be necessary to conclusively determine
that maturation is indeed blocked, and not that the Eomes-deficient Stage III NK cells are simply
dying as soon as they differentiate. Interestingly, Eomes is more highly expressed in CD56bright
than CD56dim human NK cells, similar to its higher level of expression in relatively immature
murine NK cells. Studies of Eomes deletion in human NK cells will be important to see if Eomes
also plays a role in regulating CD56bright NK cell homeostasis, and potentially maturation to
CD56dim NK cells.
Our data also revealed some interesting inconsistencies with regards to the role of Eomes in NK
cell function. Eomes deletion had a negative impact on NK cell killing, but Eomes KO NK cells
were able to upregulate Granzyme B protein upon poly I:C stimulation. These data suggest that a
lack of Granzyme B was not responsible for the impaired killing. However, we observed lower
perforin mRNA in Stage II and III Eomes KO compared to WT NK cells. Assaying perforin
protein is difficult due to a lack of robust flow cytometry antibodies, however doing so will
provide important mechanistic insight into the killing defect. Indeed, the mechanism via which
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NK cells reject 2m-/- splenocytes is still unknown, but knowing that this function is defective in
Eomes KO NK cells could open up new pathways for investigation. Despite the killing deficit,
however, Eomes KO NK cells showed little to no change in their ability to degranulate and
produce IFN- in vitro in response to a variety of different stimuli. The mechanism for this
discrepancy is currently unknown. One study has shown that Eomes downregulation marks
exhausted NK cells, for instance those in tumor microenvironments.20 This same group found
that overexpression of Eomes in adoptively transferred NK cells could actually result in better
tumor control. Thus, it is possible that defects in Eomes KO NK cell cytokine production or
degranulation are only evident upon prolonged activation. It will be important to test this in vivo
using viral and tumor models.
Investigating the role of Eomes in mature NK cell homeostasis and function is just one of many
important uses for our model. Several other genes are critical for NK cell development, and our
model could be used to investigate their function in mature NK cells, as well. Another important
question is the exact physiologic role of NK cells vs ILC1s, both in health and during infection
or malignant transformation. Both subsets express NKp46, and so would induce Cre upon
Tamoxifen administration in our model. It would be interesting to selectively deplete NK cells
(via Eomes) or ILC1s (potentially via the transcription factor Hobit21) to ask these types of
questions. Finally, certain types of NK cells, like MCMV-specific innate memory NK cells,
develop from mature NK cells in response to certain physiologic stimuli. Our model could also
be used to gain further insight into the biology of these NK cell types. We are distributing our
mouse model to the NK cell community as a resource that can be used to address these and other
important outstanding questions in the field.
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